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Abstract 
 
Oncolytic viruses can be genetically modified to limit their replication in normal cells 
rendering them a cancer specific treatment. In addition, they can induce a “danger 
signal” in the form of pathogen- and damage-associated molecular patterns leading to 
anti-tumour immunity. Furthermore, they can be armed with various immunomodulatory 
molecules to further enhance anti-tumour immunity. In this project I aim to exploit these 
qualities to develop a translatable cancer vaccine. Virus-infected cancer cells were 
injected subcutaneously in a prime/boost regimen. Dying cancer cells will release the 
required danger signal leading to dendritic cell activation and cross-presentation of 
tumour associated antigens to T cells to elicit an anti-tumour immune response. 
 
Our results in the murine pancreatic cancer model showed that vaccination with virus-
infected DT6606 cells induced tumour specific immunity capable of protecting 
vaccinated animals against re-challenge with tumour cells. The highest level of 
interferon gamma production, a surrogate marker of anti-tumour immunity, was 
achieved when animals were primed with adenovirus-infected cells. There was no 
significant difference between various boost groups. To enhance the safety of the 
proposed protocol a secondary treatment was introduced to arrest the proliferation of 
tumour cells prior to injection. Our results confirmed that secondary treatment with 
mitomycin does not affect the induction of tumour specific immunity and it does not 
affect the release of pathogen-associated molecular patterns in the form of viral 
proteins and DNA. 
 
To test our vaccination regimen in head and neck squamous cell carcinoma (HNSCC) 
we develop a clinically relevant mouse model using SCC7, B4B8 and LY2 cells to 
replicate various clinical scenarios including locally advancing disease and post 
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excision locoregional recurrence. Vaccinating mice with HNSCC cells pre-infected with 
our recently developed tumour-targeted triple-deleted adenovirus (AdTD) resulted in a 
cell-specific antitumour immune response. In addition, it resulted in an increase in 
effector memory T-cells of both CD4+ and CD8+ phenotypes. Efficacy studies showed 
our vaccination can significantly slow down the growth rate of tumours in locally 
advancing disease. This led to increase survival of the vaccinated mice although it did 
not reach statistical significance.  
 
To further enhance the efficacy of our vaccination regimen, we aimed to increase T cell 
trafficking to the tumour site.  CCL25 is a gut homing chemokine. Priming T cells in the 
presence of CCL25 will lead to upregulation of the surface expression of α4β7 integrin. 
The latter is a ligand of MAdCAM-1, a cell adhesion molecule highly expressed in the 
gut and pancreatic tumours. The α4β7/MAdCAM-1 interaction results in preferential 
homing of activated T cells to these organs. We hypothesised that vaccinating mice 
with pancreatic tumour cells pre-infected with a CCL25-armed adenovirus will lead to 
increased T cell trafficking to pancreatic tumours leading to enhanced efficacy. 
Although we achieved encouraging results in our pilot experiment, we did not detect 
any significant increase in α4β7 expression once we added a secondary treatment to 
the vaccination protocol. Similarly, efficacy experiments in the pancreatic cancer 
transgenic KPC mice did not show any difference in survival between AdTD-CCL25 
and the control virus although both groups showed a trend towards increased survival 
compared to naïve mice.  
 
In conclusion, Virus-infected cancer cell vaccine is a potentially promising 
immunotherapeutic strategy that can be combined with traditional cancer therapies to 
increase survival of HNSCC and pancreatic cancer patients.  
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HGF  Hepatocyte growth factor 
HMGB1 High-mobility group box 1 
HNSCC Head and Neck Squamous Cell Carcinoma 
HPV  Human Papilloma Virus 
HSV  Herpes Simplex Virus 
ICD  Immunogenic Cell Death 
IFN  Interferon 
IM  Intramuscular 
IT  Intratumoural  
kbp  kilo base pair 
LB  Lysogeny Broth 
mAb  Monoclonal antibody 
MAdCAM-1 Mucosal addressin cell-adhesion molecule-1 
MDSC  Myeloid Derived Suppressor Cells 
MHC  Major Histocompatibility Complex 
MMC  Mitomycin C 
MOA  Modes of Action 
MOI  Multiplicity of Infection 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium 
MTX  Mitoxantrone 
NDV  Newcastle Disease Virus 
NK  Natural Killer Cells 
OV  Oncolytic Virus 
PCR  Polymerase Chain Reaction 
PD-1  Programmed Cell Death Protein 1 
PDAC   Pancreatic Ductal adenocarcinoma  
PAMPs Pathogen Associated Molecular Patterns 
PBS  Phosphate Buffered Saline 
PD-L1  Programmed Cell Death Ligand 1 
pfu  Plaque forming unit 
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PRR  Pattern Recognition Receptors 
qPCR  Quantitative Polymerase Chain Reaction 
RFP  Red Fluorescent Protein 
RGD  Arginylglycylaspartic acid 
rSAP  Recombinant Shrimp Alkaline Phosphatase 
RT  Room temperature 
Rx  Irradiation 
SC  Subcutaneous  
SCC  Squamous Cell Carcinoma 
TAA  Tumour associated antigen 
TCM  T-cell media 
TCM  Central memory T cell 
TEFF  Effector T cell 
TEM  Effector memory T cell 
TGF-β  Transforming Growth Factor Beta 
TSA  Tumour specific antigen 
Th  T Helper cell 
TK  Thymidine kinase  
Tregs  Regulatory T cells 
VICCV  Virus Infected Cancer Cell Vaccine 
VLTF-1 Vaccinia late transcription factor 1 
vp  Virus particle 
VV  Vaccinia Virus  
VVL15  Lister strain vaccinia virus with thymidine kinase gene-deletion 
WR  Western Reserve strain vaccinia virus 
WRDD Western Reserve vaccinia virus with double gene deletion (TK and 
VGF) 
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Chapter one: Introduction 
 
Despite advances in cancer treatment over the last few decades, cancer remains a 
major cause of morbidity and mortality in the UK and worldwide. More than 331,000 
people a year are diagnosed with cancer in the UK with an estimated 14.1 million new 
cases a year worldwide. Mortality figures are 162,000 and 8.2 million a year in the UK 
and worldwide, respectively [2]. Despite significant progress in traditional cancer 
treatments of surgery, chemotherapy and radiotherapy, survival of patients, with 
pancreas, lung and head and neck cancers has not improved over the last few 
decades. In addition, these treatments are often associated with severe morbidity due 
to poor tumour selectivity. The search for the “Holy Grail” treatment that can target and 
kill cancer cells sparing normal tissues remains as relevant today as it has always 
been. 
 
1.1 Oncolytic virotherapy  
1.1.1 Oncolytic viruses 
An oncolytic virus (OV) is a virus capable of killing cancer cells, which can be utilised 
as a cancer therapy.  The first such use dates back to the late 19th century concurrently 
with the discovery of viruses. Scientists noticed a temporary regression of malignant 
disease in cancer patients during viral infections [3, 4]. These were often temporary 
regressions in leukaemia and lymphoma patients. Nevertheless, this observation led to 
early attempts to treat cancer with viruses with minimal clinical success. The second 
wave of virotherapy came in the 1960s with the advancement of tissue culture 
techniques and the improved understanding of virus biology. The persistent limited 
clinical success of that era led to the abandonment of virotherapy in the next decade. 
Only in the early nineties did virotherapy re-emerge with the advancement of 
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recombinant DNA technology allowing scientists to genetically modify viruses to 
improve efficacy and selectivity [5]. 
 
Oncolytic virotherapy is based on the ability of OVs to specifically target and replicate 
in tumour cells (Fig. 1.1). To facilitate such a process, the injected virus needs to reach 
tumour cells, infect them and start the lytic process. It needs to replicate within these 
cells producing more viral particles leading to tumour cell lysis, which releases viable 
virions capable of infecting neighbouring tumour cells. This process would continue 
until all tumour cells are lysed sparing normal cells. In reality this process would be 
short lived as the immune system will clear the virus limiting its clinical benefit. In fact, 
clinical trials have not shown that direct tumour lysis to be an important antitumour 
mechanism [3]. However the ability of the virus to alter the immune composition of the, 
ordinarily, immune-suppressive tumour microenvironment led to a new line of thinking 
Fig 1.1 Tumour selectivity of oncolytic viruses.  
Tumour-targeted oncolytic viruses can exploit defective cellular pathways in cancer cells 
(top). OVs can infect and replicate in cancer cells leading to cell lysis and release of viral 
particles.  These in turn infect neighboring tumour cells and so forth. In normal cells (bottom) 
cellular defense mechanisms prevents viral replications 
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of the role of OVs (Fig. 1.2). Current evidence suggests that anti-tumour immunity, 
where the virus is acting as an oncotropic immunomodulator, is the key determinant of 
a successful oncolytic virotherapy [6-9]. This will form the basis of this study and will be 
discussed in detail later. In addition, OVs can target multiple cellular pathways [10-12] 
minimising the risk of tumour resistance and induce different modes of cell death [13-
16]. Furthermore, OVs can function in synergy with conventional cancer treatments of 
chemoradiotherapy [17-20].  Finally, OVs as a treatment platform are amenable to 
adjustment and development following our ever-increasing understanding of cancer 
cells, the virus and host immune responses to both tumour and virus.  
 
Tumour selectivity is the main feature of OVs. It is related to the ability of OVs to exploit 
the altered cellular pathways and deregulated metabolic activity to their advantage [6]. 
In fact, many of the hallmarks of cancer [21] make tumour cells susceptible to viral 
replication including immune escape, sustained cell proliferation and resistance to cell 
death [22]. OVs fall broadly into two categories: viruses that have natural preferential 
replication in tumour cells such as Newcastle disease virus, myxoma virus and 
reovirus; and viruses that are genetically engineered to be tumour selective such as 
vaccinia virus, measles virus and adenovirus [23, 24].  
 
OVs can additionally be utilised as a vector system to deliver genetic material to cancer 
cells or the tumour microenvironment. They can be armed to express a variety of 
immunomodulatory proteins such as granulocyte-macrophage colony-stimulating factor 
(GM-CSF) [25, 26], interleukin-12 [27] and interleukin-10  [28]. These expressed 
cytokines can change the immune profile of the tumour microenvironment and enhance 
the anti-tumour response. 
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Fig 1.2 Multiple modes of action (MOA) of tumour-targeted oncolytic viruses.  
OVs can kill cancer cells via a variety of mechanisms. First, they directly infect, replicate 
and lyse tumour cells sparing normal cells. Released virions can infect neighbouring 
tumour cells and so forth. Second, OVs can induce immunogenic cell death associated 
with the release of PAMPs and DAMPs. In addition viral infection results in the release of 
cytokine and chemokines deviating the immune response towards a cytotoxic profile. 
Dendritic cells can pick TAAs released from lysed tumour cells and prime CD8+ T cells to 
induce a tumour-specific immune response. Third, OV infection can result in vascular 
shutdown caused by direct viral infection of endothelial cells and thrombosis caused by 
cytokine-mediated neutrophil accumulation. Key: (TC) tumour cells, (DC) dendritic cells, 
(N) neutrophils, (CD8) Cytotoxic T cells, (EC) endothelial cells, (TAAs) tumour associated 
antigens and (VV) vaccinia virus. 
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1.1.2 Vaccinia virus 
Vaccinia virus (VV) has played a prominent role in one of the greatest achievements in 
medical history: the eradication of smallpox.  Since then, VV has been developed as a 
vector for vaccines against infectious diseases such HIV, influenza, malaria and 
tuberculosis, as well as in immunotherapies [29] and oncolytic therapies for cancer [30, 
31]. 
 
1.1.3.1 Positive features of Vaccinia virus as an oncolytic virotherapy agent 
Vaccinia virus is a member of the poxvirus family. It is a double stranded DNA virus 
approximately 192kbp in size, carrying approximately 200 genes [32] with the free ends 
connected via a hairpin loop [33]. It can stably accommodate up to 25kbp of cloned 
exogenous DNA [34]. Structurally it consists of a core region composed of viral DNA 
and various viral enzymes including RNA polymerase and polyA polymerase encased 
in a lipoprotein core membrane. The outer layer of the virus consists of double lipid 
membrane envelope [35, 36]. VV has two major forms of infectious virions; the intra 
cellular mature virions (IMV), as described above, which is released upon cell lysis and 
the extra cellular enveloped virion (EEV) released from the cells via cell membrane 
fusion. The latter has an additional lipid bilayer membrane wrapped around the IMV 
particle. 
 
Vaccinia virus has many inherent characteristics that make it an ideal choice for 
oncolytic virotherapy. Unlike other OVs, VV does not have a specific surface receptor 
for cell entry allowing it to infect a wide range of cells unhindered by the lack of 
expression of that specific receptor. It depends on a number of membrane fusion 
pathways for cell entry which are not fully characterised  [37, 38].  
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VV has a short life cycle of eight hours that take place in its entirety in the cytoplasm 
eliminating the risk of genome integration. Following viral core entry into the cell, 
packaged viral proteins are released into the cytoplasm. Within 20 minutes this core 
produces a set of early mRNAs encoding the required proteins for the cytoplasmic 
DNA replication [39]. This usually starts two hours after infection, at which time the host 
cell nucleic acid synthesis shuts down as all cellular resources are directed towards 
viral replication, and takes place in structures called viral factories or virosomes. DNA 
replication initiate the transcription of late genes encoding for the late proteins that are 
necessary for viral assembly and viral enzymes which are packaged within the viral 
particle cores [40-42]. VV independence from host mechanisms for mRNA transcription 
makes it less susceptible to biological changes of the host cell. Cell lyses takes place 
between 12-48 hours releasing packaged viral particles. 
 
The existence of various antigenically-distinct forms of the mature virus allows it to 
evade host immune system. EEV form of the virus is encapsulated in a host-derived 
envelope, with incorporated viral proteins, that contains several host complement 
control proteins [43-45]. In addition, VV infected cells secretes Vaccinia compliment 
control protein (VCP) which binds an inactivate C4b and C3B inhibiting the classic and 
alternative complement activation pathways [46-48]. VV therefore can be disseminated 
relatively unharmed in the blood stream to reach distant tumours allowing systemic 
delivery of the virus [49], which is more suitable for the treatment of the advanced 
cancers. Recent clinical trial evidence has demonstrated the feasibility of intravenous 
injection for VV oncolytic therapy [50].  
 
Hypoxia is a feature of many cancers that contributes to treatment resistance. In 
contrast to adenovirus [51], our group has found that hypoxic conditions did not affect 
replication, viral proteins production, cytotoxicity and transgene expression of the Lister 
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strain of vaccinia virus [52]. To the contrary, recent evidence from our group and others 
suggests that hypoxic condition can actually enhance the oncolytic effect of VV due the 
enhanced internalization of the virus. This is due to the hypoxic induction of vascular 
endothelial growth factor A (VEGF-A) expression [53]. In addition, VEGF signaling 
sensitises endothelial cells to vaccinia virus infection facilitating viral spread to tumour 
cells following IV viral delivery [54]. 
 
Finally, VV has a good safety track record following its use as a vaccine for over a 
century. Minor and less severe side effects include fever, rash and inadvertent 
inoculation. Moderate to severe side effects include eczema vaccinatum, generalized 
vaccinia, progressive vaccinia, and postvaccinial encephalitis [55]. Sides effects are 
rare with an incident of less than 1:10,000 and severe side effects in particular are 
extremely rare [56]. Genetically modified recombinant VV could be potentially safer due 
to their tumour selectivity. Recent clinical trial of JX-594 virus in hepatocellular 
carcinoma showed the treatment to be well tolerated with mainly flu-like symptoms in 
all patients and a single severe side effect [31]. 
 
1.1.3.2 Cancer selectivity and modes of action of vaccinia virus  
Vaccinia virus has a natural tropism to cancer cells [57, 58]. The virus can utilise 
activated molecular pathways in tumour cells to aid its replication [59-61]. In fact, many 
of the hallmarks of cancer [21] make tumour cells susceptible to viral replication 
including immune escape, sustained cell proliferation and resisting cell death. In the 
case of vaccinia virus, the epidermal growth factor receptor (EGFR) family [62], 
potentially plays an important role in tumour selectivity. The viral smallpox growth 
factor (SPGF), an EGF-like growth factor carried by vaccinia virus, can activate host 
cellular pathways leading to increased viral replication [63]. In addition, Ras-GTP-
activating protein S3H domain-binding protein (G3BP), over-expressed in most human 
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cancers [64], plays a role in VV replication by complementing the activity of the viral 
intermediate transcription factor-2 (VITF-2) [65].  
  
Various techniques can be utilised to enhance tumour selectivity of VV. The virus 
depends for its replication in normal cells on a set of genes that prepare the cell 
resources for viral replication and block apoptotic pathways. Deleting these genes will 
limit the virus ability to replicate in normal cells. However, these pathways are often 
disrupted in cancer cells allowing the virus to replicate despite the defective genes. 
One such example is the disruption of the vaccinia thymidine kinase gene affecting the 
virus ability to synthesise deoxyribonucleotides [66, 67]. Normal cells have a much 
smaller reserve of deoxyribonucleotides, compared to tumour cells, limiting the ability 
of VV to replicate. Another example is the deletion of the B18R gene encoding the 
secreted IFN-binding protein that blocks IFN-α signaling [68]. In normal cells this gene 
deletion attenuates viral replication due to IFN antiviral effect while cancer cells remain 
permissive to VV replication as IFN signaling is often disrupted [69, 70]. In addition, 
altering the expression of crucial vaccinia viral gene by microRNA (miRNA) also 
enables tumour-specific viral replication, which is a potentially novel and versatile 
platform for engineering vaccinia viruses for cancer virotherapy [71].  
 
Vaccinia virus kills cancer cells via a combination of necrosis and immunogenic 
apoptosis resulting in the release of damage associated molecular patterns (DAMPs) 
[72-75] and pathogen associated molecular patterns (PAMPs) [76-78] as well as the 
release of viral antigens into the tumour. This process leads to a strong inflammatory 
response that can overcome the immune suppression within the tumour 
microenvironment. In addition, tumour cell lysis releases tumour-associated antigens 
(TAAs) into this inflammatory environment. Dendritic cells can in turn pick up these 
exposed TAAs and cross-prime CD8+ T cells resulting in a potent anti-tumour adaptive 
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immune response.  It has been demonstrated that an oncolytic VV (JX549) could 
induce tumour-specific immunity in human cancer patients [79] and pre-clinical study 
[80]. Therefore, oncolytic virotherapy with VV may be considered as a method of 
vaccination in situ, enabling the adaptive immune response to clear residual disease 
and provide long-term surveillance against relapse. 
 
Finally, VV can utilise vascular shut down to kill non-infected tumour cells [25, 49, 81]. 
This is believed to be caused by accumulation of neutrophils in blood vessels, 
mediated by cytokines and chemokines, leading to intravascular thrombosis [81]. In 
addition, VV can infect and destroy tumour-associated endothelial cells further 
contributing to vascular collapse [69]. 
 
1.1.3.3. Strain selection and gene deletions 
Selecting the “right” strain of VV could be of significant importance to the safety and 
efficacy of the oncolytic viral treatment. The non-vaccine strain Western Reserve (WR) 
VV is widely used in experimental preclinical trials. JX-963, a GM-CSF armed mutant of 
WR VV with deletion of both the Thymidine Kinase and the Viral Growth Factor gene 
(vvDD-GM-CSF), has been reported as the most potent tumour-targeted oncolytic VV 
[60]. Other strains, such as the European vaccine Lister strain, are largely untested. 
Our group recently evaluated the anti-tumour potency and bio-distribution of different 
vaccinia virus strains using in vitro and in vivo models of cancer including pancreatic, 
head and neck and colorectal cancer models. The Lister strain virus with a Thymidine 
Kinase gene deletion (VVL15) demonstrated superior anti-tumour potency and cancer-
selective replication in vitro and in vivo, compared to WRDD, especially in human 
cancer cell lines and immune-competent hosts [82]. Further investigation of functional 
mechanisms revealed that Lister VVΔTK presented favorable viral bio-distribution 
within the tumours, with lower levels of pro-inflammatory cytokines compared to 
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WRDD, suggesting that Lister strain may induce a diminished host inflammatory 
response [82]. This comprehensive study indicates that the Lister strain vaccinia virus 
with TK deletion, used in my work, is a particularly promising vaccinia virus strain for 
the development of the next generation of tumour-targeted oncolytic therapeutics.   
 
1.1.3 Adenovirus 
Adenovirus (AdV) is the most commonly used viral vector for cancer gene therapy. It is 
a member of the Adenoviridae family. The name is derived from its initial isolation from 
adenoid tissue in 1953 [83]. They have broad range of vertebrate hosts. There are 59 
serotypes of human adenovirus divided into seven subgroups, A to G according to their 
clinical manifestations [84, 85]. Ad5, the adenovirus used in this study, belongs to 
group C.  
 
1.1.2.1 Positive features of adenovirus as an oncolytic virotherapy agent 
Adenovirus is a non-enveloped, icosahedral-shaped, double stranded DNA virus. The 
icosahedral capsid has 20 faces composed of hexon proteins and 12 vertices of penton 
proteins. A fibre protein ending with a globular knob domain extends outward from 
each of the penton bases. The latter is responsible for attachment to the host cell 
receptors [86, 87].  
 
Adenovirus has many favourable characteristics making it an attractive oncolytic virus. 
The genomic structure of adenovirus is well characterised and their modes of 
replication, infection and pathogenesis is known. Its linear DNA core is approximately 
35-40kbp in size encoding for approximately 35 proteins. These genes are expressed 
in two phases; early which occurs in the first few hours after infection prior to DNA 
replication, and late which occurs afterwards. The early genes are regulatory genes 
that allow the virus to divert host cell resources and initiate viral DNA replication. They 
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are arranged into five transcription units; E1A, E1B, E2A, E3A and E4A.  Late genes 
encode for viral structural proteins are arranged into; L1, L2, L3, L4, L5 and ADP [88, 
89]. The latter is a gene encoding for Adenovirus Death Protein which mediates cell 
lysis to release assembled viral particles [90].  
 
Adenoviruses are non-integrating DNA viruses with extensively studied life cycle. AdV 
attaches to the host cells through binding of the knob domain of the fibre protein to the 
cell receptor. The most studied adenovirus receptor is the coxsackievirus and 
adenovirus receptor (CAR) [91],  however there are a number of other receptors 
including CD46 [92], heparan sulfate glycosaminoglycans [93], CD80 and CD86 [94] to 
name a few. This is followed by attachment between an exposed arginylglycylaspartic 
acid (RGD) motifs on the penton base to cell surface integrin molecule. Integrins 
known to facilitate adenovirus attachment and entry include αvβ1 [95], αvβ3 and αvβ5 
[96]. This attachment induces cellular signals, including activation of PI3 kinase, which 
leads to actin cytoskeleton rearrangement and initiation of viral internalistion [97]. The 
virus then enters the cell in a clathrin-coated pit that forms into an endosome. 
Acidification leads to partial disassembly of the capsid and virion escapes into the 
cytoplasm [98]. The capsid is then transported to the nucleus where its DNA is injected 
via the nucleic membrane pores where early gene transcription starts utilising cellular 
enzymes. Early mRNA is then transported to the cytoplasm for translation. DNA 
replication starts after the late phase. In addition viral structural proteins are produced 
at high levels during the late phase and translocated to the nucleus to be assembled 
into viral particles. 
 
Adenoviruses can be safely used as vaccine vector and oncolytic virotherapy agents 
with limited morbidity. In fact millions of US army personnel have received live AdV 
vaccination of serotypes 4 and 7 with excellent safety track record [99]. They only 
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cause mild self-limiting diseases in human mainly in the form of respiratory tract 
infection. They can however lead to severe infections, or even mortality, in 
immunodeficient  patients [100]. Further genetic modifications (section 1.1.2.2) can 
enhance AdV safety. In fact, such modified AdVs (serotype 5) have been used in 
various clinical trials with excellent safety track record [101, 102].  
 
Finally, AdV is amenable to genetic modifications, deletion and transgene cloning. 
They can be produced to Good Manufacturing Practice (GMP) with high-level titration 
and purity. 
 
1.1.2.2 Cancer selectivity and gene deletions of adenovirus 
Earliest anticancer clinical trials in the fifties used non-attenuated wild type adenovirus 
to treat a variety of cancers. Various AdV serotypes delivered systematically or 
intratumourally resulted in initial tumour necrosis but failed to achieve significant 
sustained therapeutic results [103-105], however they demonstrated the safety of AdV-
based therapies and highlighted the need for better tumour-targeted viruses. 
 
Wild-type AdV has wide tropism and can infect proliferating and non-proliferating cells.  
This wide tropism could be a useful tool for gene therapy applications in somatic 
diseases and cancer; however it can lead to toxicity when administered in high doses 
[106, 107]. Replication-deficient AdV vectors were developed in the early nineties to 
overcome this potential off-target effect. This can be achieved by deleting the E1A or 
E2A gene, both essential genes for viral replication, and replacing them with a 
promoter from a different organism, such as the cytomegalovirus (CMV) promoter, to 
drive the expression of the therapeutic gene. Advexin and Gendicine are first 
generation replication-defective adenovirus vectors with double gene deletions of E1A 
and E3B. Both viruses have been armed with p53 gene driven by CMV promoter and 
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Rouse Sarcoma Virus promoter respectively [108, 109]. The rationale is that 
expression of the p53 gene in tumour cells will lead to cell cycle arrest. These two 
viruses have been used extensively in clinical trials over the years with excellent safety 
but modest clinical outcome when used as monotherapeutic agents [109-112]. 
Numerous other replication-defective AdV with various therapeutic genes have entered 
clinical trials [113]. These replication defective vectors can be made tumour selective 
by using tissue specific promotor to drive transgene expression selectively in tumour 
cells [114, 115]. 
 
The focus of scientific research then moved to tumour-targeted replication-competent 
AdV. The shift was encouraged by safety of replication-defective AdV in clinical trials 
and better understanding of the genomic structure and life cycle of adenovirus and its 
relation to the host cell cycles. Various approaches could be adopted to achieve 
tumour selectivity.  Using a tumour or tissue-specific promoters, such as PSA promoter 
[116], allows AdV to selectively replicate and lyse tumour cells expressing that specific 
gene.  
 
However the most common strategy, as with vaccinia virus, is viral gene deletions. 
dl1520 (also known as Onyx-015) is an E1B55K and E3B gene-deleted AdV designed 
to selectively replicate and lyse cancer cells carrying the mutant p53 gene but causes 
limited damage to normal tissue [117-119]. p53 is a pro-apoptotic protein that is 
activated by viral infection leading to further activation of apoptotic genes leading to cell 
apoptosis. E1B55k protein is a p53 inhibitor allowing wild-type adenovirus to continue 
replication in normal cells and avoid apoptosis. Deleting this protein will render the 
adenovirus to be replication-dependent on the presence of a mutant p53 gene as is the 
case in many cancer cells [120]. However, later studies showed that dl1520 is also 
cytopathic in p53-intact tumour cells [121]. It is now believed that dl1520 tumour 
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selectivity is mainly due to late viral gene mRNA export [122, 123]. dl1520 has been 
used in many clinical trials for various types of cancer with limited clinical success but 
excellent safety record [102, 124-132]. Such limited efficacy was reported to be due to 
attenuated replication and reduced viral progeny production limiting its anti-tumoural 
effect. The E1B55K gene was found to be essential to viral life cycle through its 
interaction with E4orf1 protein [133]. In addition, deletion of gene products encoded by 
the E3B region could further weaken its oncolytic effect due to increased macrophage 
infiltration and higher TNF and IFN-γ secretion leading to rapid viral clearance [134]. 
Our group has found recently that E3B can supress transcription factor STAT1 in 
monocytes leading to inhibition of chemokine expression [135]. dl1520, and other E3B-
delted viruses, lack this inhibitory function leading to high chemokine expression and 
macrophage infiltration. Despite its shortcoming, H101 (an adenovirus similar to 
dl1520) remains the only licensed oncolytic virus for treatment of Head and Neck 
cancers in China [136]. 
 
In order to improve on the limited clinical success of dl1520 and to create a potent yet 
safe oncolytic virus, our group and others have targeted other AdV genes for deletions 
(Fig 1.3). E1A conserved region 2 (E1ACR2) viral protein binds to retinoblastoma 
Fig 1.3 A schematic diagram of viruses used in this study in comparison with wild-
type adenovirus (Ad5).  
dl1520 virus contains a deletion in the E1b55K and E3B regions. Our triple deleted virus 
(Ad-TD-C) contains three deletions in the E1A conserved region 2, E1B19K and E3gp19K. 
CCL25 gene was inserted in the latter region to create the Ad-TD-CCL25 virus.  
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protein (pRB) releasing the E2F transcription factor to drive the cell cycle from G1 to S 
phase. Deleting this region will reduce viral replication in normal quiescent cells while 
maintaining its ability to replicate in cancer cells with altered cell cycle control.  One 
such virus, dl922-947, was shown to be more potent when compared to dl1520 [137]. 
 
E1B19K viral protein inhibits both extrinsic and intrinsic apoptosis induction pathways. 
It acts as a homologue for Bcl2 capable of binding to Bax and Bak preventing the 
downstream process of apoptosis, allowing the cell to survive while viral replication 
takes place [138]. In addition, E1B19K can inhibit Fas-mediated extrinsic apoptosis 
pathway by inhibiting FADD oligomerisation [139]. Deleting this gene will therefore 
reduce the ability of AdV to survive and replicate in normal cells. On the other hand 
these pathways are often inhibited in cancer cells which allows the virus to replicate 
[140]. In addition, deleting this antiapoptotic gene will sensitise tumour cells to DNA-
damaging cytotoxic drugs [141].  
 
E3gp19K is an endoplasmic reticulum (ER) membrane glycoprotein. It can bind to 
major histocompatibility complex (MHC) class I and inhibits its transport to cell surface 
allowing the virus to evade cytotoxic T cells (CTL) recognition [142]. In addition, it can 
inhibit recognition by natural killer (NK) by intracellular sequestration of NK ligands 
MICA and MICB [143]. Deleting the E3gp19K gene can enhance CTL recognition and 
killing of infected tumour cells enhancing the antitumour efficacy of the virus [134]. In 
addition cloning transgenes at this site, as the case with the adenovirus mutant cloned 
for this study, allows high level expression under the control of the endogenous E3 
promoter [144]. 
 
In this study, we will use our latest generation of adenovirus with triple deletions of E1A 
conserved region 2, E1B19K and E3gp19K genes (AdTD), the resultant virus is 
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replication-competent selectively in cancer cells. It promotes apoptosis of tumour cells 
and sensitise them to chemotherapy cytotoxic drugs and it recruits the immune system 
to aid tumour clearance.  
 
1.2. Cancer immunity 
1.2.1 Cancer immune escape 
The process of “immunoediting”, as described by Dunn and colleagues suggests a dual 
capacity of the immune system to both promote and suppress tumour growth [145]. At 
early stages of tumour development the immune system can eliminate the most 
immunogenic tumour cells. The process reaches equilibrium where tumour cells with 
less immunogenic phenotypes can continue to divide until it reaches a stage where it 
can escape immune surveillance and develop into overt cancer [146]. 
 
Various mechanisms contribute to tumour immune escape. Tumour cells can down 
regulate expression of tumour antigen via down regulation of MHC I [147-149], or down 
regulate the transporter for antigen presentation proteins (TAP) [150] reducing 
expression of tumour associated antigen on the cell surface, which in turn reduce the 
ability of CTLs to recognise tumour cells. In addition, tumour cells often lack co-
stimulatory molecules leading to anergy of T cells [151].  
 
Regulatory T cells (Tregs), and tumour-derived Tregs in particular, play major role in 
immune suppression [152, 153]. These cells are recruited into the tumour 
microenvironment via tumour-mediated chemokine production [154, 155]. In addition, 
transforming growth factor beta (TGF-β) can aid the conversion of T helper cells to 
Tregs in situ [156]. Myeloid derived suppressor cells (MSDCs) can suppress CTL 
mediated antitumour immune response and play a role in tumour initiation, 
angiogenesis and metastasis [157, 158]. Furthermore, immature dendritic cells (DCs) 
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present in the tumour microenvironment can contribute to CTL suppression. 
Gangliosides expressed on some tumour cells can alter the phenotype of DCs to 
express lower levels of CD80, CD86 and CD40 [159].  
 
Cancer cells and other non-cancerous cells in the tumour microenvironment can 
produce a variety of immuno-suppressive cytokines. TGF-β is believed to play a major 
role in this process [160-162]. In addition TGF-β combined with IL-10 expression can 
shift T helper cell profile from Th1 to Th2 leading to reduced CTL activation [162].  
Various mediators such as vascular endothelial growth factor (VEGF), IL-10, TGF-β 
can inhibit differentiation of progenitors to DCs and prevent the maturation of DCs 
resulting in immune tolerance as antigens are presented to T cells without the 
appropriate co-stimulatory factors [163, 164].  
 
Immune checkpoints have emerged in recent years as an essential mechanism to 
regulate the function of the immune system and maintain self-tolerance. Cytotoxic T 
lymphocyte-associated antigen 4 (CTLA-4) was the first immune check point to be 
discovered. In normal tissue CTLA-4 is progressively expressed on the surface of 
CTLs following their TCR binding to its cognate antigen. CTLA-4 counteracts the 
activity of T cell co-stimulatory receptor CD28 by competitively binding to its ligands 
CD80 and CD86 (also known as B7.1 and B7.2 respectively) [165, 166]. In normal 
tissue CTLA-4 down-modulates immune response to chronic antigen stimulation 
preventing autoimmunity, while in cancer it promotes tolerance and immune escape 
[167, 168].  Programmed cell death protein 1 (PD1) is expressed on the surface of T 
cells. Its main function is to limit the activity of T cells in peripheral tissues during 
inflammatory response [169-171]. Tumour cells can express immune inhibitory 
molecules such as programmed cell death ligand 1 (PD-L1) which can negatively 
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regulate T cell responses [172, 173]. This expression can be upregulated as a 
response to an antitumour immune response [174]. 
 
Finally, tumour cells have been shown to induce apoptosis in T cells leading to 
peripheral immune tolerance [175, 176].  
 
1.2.2 The “Danger” model in immunity 
The original “Self vs. Non-Self” model of immunity was first suggested by Burnet [177]. 
It proposes that the immune system distinguishes between tolerated self and attacked 
non-self. This theory was further reinforced with the work of Medawar et al on clonal 
selection [178, 179]. Despite changes to this model over the years and the addition of 
the helper cell [180] and the second costimulatory signal generated by antigen-
presenting cells [181] the model still failed to explain a number of immunological 
phenomena mainly the failure of antigen-presenting cells (APC) to present self-antigen 
despite being non-antigen-specific cells. To address this point an “Infectious non-self” 
model was proposed [182] where APCs have the capacity to distinguish and be 
activated by non-self evolutionary-conserved pathogen associated molecular patterns 
(PAMPs) via their pattern recognition receptors (PRR). However, this model fell short 
when it came to anti-tumour immunity, graft rejection and non-cytopathic viral 
infections. 
 
Matzinger proposed the “danger” model of immunity where the main function of the 
immune system is to recognise and protect against danger [183]. This model suggests 
that APCs not only recognise PAMPs but also can recognise, and be activated as a 
result, of stimulation from damaged distressed cells. This damage could be the result 
of infection, trauma, oncogenic transformation, toxins and so on. These distressed cells 
would release or express what was collectively termed damage associated molecular 
  
41
patterns (DAMPs). These were later discovered to include, among others, lipoproteins, 
uric acid, serum amyloid A protein, lipopolysaccharides, tumour necrosis factor-4, 
adenosine triphosphate (ATP) and so forth [184].     
 
1.2.3 Oncolytic viruses and anti-tumour immunity 
Oncolytic viruses have a number of advantages as cancer immunotherapy agents. 
They kill cancer cells through a variety of immunogenic and non-immunogenic 
mechanisms including apoptosis, necrosis, autophagy and pyroptosis [185, 186]. The 
most dominant form of cell death varies depending on the individual OV.  This oncolytic 
process provides the necessary “danger signal” to dendritic cells to initiate a potent 
anti-tumour immune response. These signals include DAMP from dying tumour and 
stroma cells and PAMP from the OV itself [182, 183, 187]. In turn, activated DCs can 
take up released tumour associated antigens (TAA) and induce an adaptive immune 
response that can target the tumour [22].  
 
Table 1.1 List of PAMPS and DAMPS associated with Adenovirus and Vaccina Virus 
 PAMPs DAMPs 
Adenovirus Adenovirus DNA [188-190] ATP [16] 
Ectopic Calreticulin [16] 
HGMB1 [16] 
Uric Acid [191] 
 
Vaccinia Virus 
 
Unknown ligand of TLR2 [76-
78] 
Viral RNA [192] 
 
ATP [74] 
HGMB1 [72, 73, 75] 
 
 
Immunogenic cell death (ICD) is a type of cell death, induced by certain 
chemotherapeutic agents, characterised by the expression of calreticulin on the 
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surface of dying tumour cells with the active release of DAMPs such as ATP and high-
mobility group box 1 (HMGB1) [193, 194]. However, other types of cell death such as 
necrosis, pyroptosis and autophagy share many of the immunogenic features of ICD 
including the release of DAMPs and pro-inflammatory cytokines from dying cells [8, 
195, 196]. OVs including AdV [16, 197], herpes simplex virus (HSV) [198], measles 
[15] and pox viruses [74] can kill tumour cells via a variety of mechanisms leading to 
the induction of ICD features resulting in a potent anti-tumour immunity.  
 
Autophagy is another important mechanism of OV-induced anti-tumour immunity. It 
mediates the sequestration, degradation and recycling of cellular components and 
intra-cellular pathogens. It plays an important role in the activation of both innate and 
adaptive immunity [199, 200]. OV such as AdV [201, 202], HSV [203], and Newcastle 
Disease virus (NDV) [204] can induce autophagy in tumour cells. Autophagy has been 
shown to stimulate antigen processing and cross-presentation by DC cells to naïve T 
cells [205, 206] resulting in the cross-priming of TAAs and viral antigen to generate 
tumour and virus specific CD8+ T cells [207-209].  
 
1.3 Cancer vaccination 
1.3.1 The concept of therapeutic cancer vaccination 
Prophylactic vaccination in the field of infectious disease has been one of modern 
medicine biggest success stories resulting in the eradication of smallpox and the near-
eradication of polio. It was a major contributor to the increase in life expectancy over 
the last two centuries [210]. This success has extended to cancers of an infectious 
pathogen origin. Vaccines against human papilloma virus [211, 212] and hepatitis B 
virus [213, 214], the leading causes of cervical cancer and hepatocellular carcinoma 
respectively, are now in routine medical practice.  
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Following in the footsteps of such a success, a huge effort and interest in the medical 
and scientific community has been directed towards developing a therapeutic cancer 
vaccine. The prospect of harnessing the power of the immune system to fight cancer is 
a highly attractive approach. It aims to generate an anti-tumour immune response that 
can be effective, safe and long-lasting. Such a treatment can clear any residual 
disease or microscopic metastasis that remains after conventional treatments. It can 
even provide an immune memory that can protect against tumour recurrence or a 
second primary.   
 
An effective cancer vaccine can, in theory, be achieved if it can combine the “right” 
antigen, the “right” adjuvant and the “right” immune response [215]. 
 
Tumour antigens that can be recognised by the immune system were first discovered 
in human melanoma [216-218]. Normal proteins are ignored by the immune system 
due to self-tolerance. Tumour protein that can be recognised by the immune system 
can be generally categorised into three categories: cancer testis antigens (CTAs), 
tumour specific antigens (TSAs) and tumour associated antigens (TTA). CTAs are 
proteins that are expressed in testis and foetal ovaries but can also be expressed by 
tumour cells such as oncofoetal proteins [219-221]. TSAs are antigens not normally 
encoded in the normal host genome. They represent proteins of oncogenic viruses or 
arise from somatic mutations form of normal proteins (neoantigens) [222-224]. TTAs 
are normal proteins that are expressed in tumours in a quantitatively (abnormally high 
expression levels) or qualitatively (post-transcriptional modifications) different form 
[225-227]. 
 
However, tumour antigens by their very nature are weakly immunogenic. In addition, 
they represent a small minority of the total molecules released from the dying vaccine 
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cells, while the vast majority are non-immunogenic normal cellular components further 
dampening the immune response [228]. To overcome these factors, and other immune 
escape mechanisms discussed above, the immune system requires an adjuvant 
molecule that can activate APCs leading to T cell-mediated immune response as 
discussed previously.  
 
1.3.2 Cancer vaccine approaches 
Various different approaches to cancer vaccination have been trialled in the last few 
decades. These include peptides, naked DNA, ex vivo antigen presenting cells, viral 
vectors and whole cell vaccines.  
 
TAA peptide epitopes that contain the specific major histocompatibility complex (MHC)-
restricted amino acid sequence can be used as a cancer vaccine. Following injection 
they can be picked up by host APCs and cross-presented to T cells for the generation 
of an immune response. This process will often require an immune adjuvant molecule 
that can be injected simultaneously to stimulate APCs [229, 230]. This approach has a 
number of advantages that include safety, ease of production and the ability to 
generate high levels of T cell response [231, 232]. However they have a number of 
limitations including high level degradation in-vivo, low immunogenicity due to poor 
MHC affinity and the restriction of a certain peptide to a specific HLA type limiting its 
applicability across patients [230].  
 
Naked DNA vaccines are used to deliver a gene encoding the specific peptide of the 
relevant TAA in an expression vector. This can be injected directly subcutaneously 
(SC) or intra-muscularly (IM) where it can transfect host cells and express the protein 
of interest, which in turn can be picked by APC and presented to T cells. Naked DNA 
vaccines have a number of advantages including low cost, ease of production, safety 
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and the possibility to co-express immunostimulatory molecules [233]. While naked 
DNA vaccines have shown a great potential to generate immune responses against 
exogenous pathogen-derived antigens [234, 235], while they have low immunogenicity 
when expressing self-antigens due to central and peripheral immune tolerance limiting 
their clinical applications [236]. 
 
Dendritic cell vaccines exploit the ability of these cells to capture released TAAs and 
present them to T cells. Ex vivo DCs generated from haematopoietic progenitor cells 
can be loaded with TAA peptides or whole proteins then re-injected in the patient to 
generate an antigen specific immune response [237, 238]. Other approaches have 
been utilised to generate antigen-specific DCs include transfection with tumour DNA, 
transduction with viral vectors containing the gene of interest, pulsing DC with dying 
tumour cells or cell lysate and fusing DCs with tumour cells [215, 239]. These are not 
without their challenges. It requires the selection of the correct DC population capable 
of activating the right subset of T cells. In addition DC cells need to undergo a 
maturation process to enhance their T cell-activation properties [215]. Although DC 
vaccination has been shown to induce an antigen-specific response [240, 241] it has 
yet to be translated into a successful vaccine in day to day medical practice [239]. 
 
Whole cancer cell vaccine has an advantage over antigen-specific vaccines in that it 
can target multiple or even undefined antigens simultaneously. This approach allows 
the immune system to select the most immunogenic antigen to target. However when 
whole cells are used as vaccine they release, in addition to tumour-specific cell-surface 
protein, a proportionately vast amount of intra cellular proteins and non-specific 
molecules [242] potentially dampening the immune response [228]. To overcome weak 
immunogenicity, tumour cells can be gene-modified to express an immunostimulatory 
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molecules such as GM-CSF [243] or a combination of cytokine and co-stimulatory 
molecule such as B7.1 (CD80) [244, 245]. 
 
Another approach (adopted in this study) to enhance the immunogenicity of a whole 
cell vaccine is the addition of a pathogen or a pathogen-derived product to act as an 
immune adjuvant and provide the necessary “danger signal” to stimulate APCs. This 
will be discussed in more detail in the following section. 
 
1.3.3 Pathogen-based cancer vaccines, what has been achieved to date? 
The idea of using pathogens to treat cancer goes back to the late 1800s when William 
Coley injected a mixture of various dead bacteria into his patients’ tumours leading to 
tumour regression [246, 247]. 
 
The tuberculosis vaccine, Bacillus Calmette-Guerin (BCG), was the first successful 
pathogen-based immunotherapeutic agent to enter routine clinical practice. Early 
clinical trials in the 1970s using irradiated non-modified allogeneic melanoma cells 
mixed with BCG showed some encouraging results [248, 249]. However, two phase III 
trials using the same strategy showed no significant benefit to patients and was 
subsequently discontinued. Other phase III trials targeting renal cell carcinoma and 
colorectal cancer showed promising results [250-252]. However, a subsequent large 
multi-centre trial targeting colorectal cancer failed to show significant difference 
between the treatment groups [253]. The inconsistent results, according to the author, 
of this trial could be related to the variability of the quality of vaccine produced locally at 
various trial centres and the failure to develop delayed type hypersensitivity (DHT) to 
tumour cells. Encouragingly, survival analysis showed a correlation between survival 
and DHT reactivity. 
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The discovery of hypomethylated CpG sequence from bacterial DNA as the 
immunogenic component of BCG [254, 255] led to its use in clinical trials. PF-3512676 
(CpG 7909, a Toll-like receptor 9 agonist) has been used as an adjuvant to autologous 
cell vaccine in renal cell carcinoma in combination with IFN-α and GM-CSF and led to 
a reported 20% clinical response. In keeping with BCG trials, clinical response 
correlated to DHT reactivity [256]. 
 
Melacine is another whole cell vaccine that entered clinical trials and was subsequently 
licensed for clinical use in some countries. The vaccine is a lysate of two melanoma 
cell lines given with DETOX adjuvant (altered mycobacterium cell wall skeleton and 
monophosphorilyl lipid A). An early phase II trial confirmed the safety of the vaccine 
and showed a 10% response rate. However, phase III trial comparing Melacine to 
chemotherapy showed no significant difference between the two groups however 
quality of life was strongly in favour of Melacine [257, 258].  
 
Newcastle disease virus is an enveloped avian RNA paramyxovirus. It has been used 
as an immune adjuvant, where tumour cells are pre-infected with the virus then 
irradiated before injection subcutaneously as a vaccine. Animal trials showed 50% 
protection from metastasis in a lymphoma model [259]. This vaccine model was used 
in phase I and II clinical trials in breast, colorectal, renal cell carcinoma leading to an 
increased survival rate between 24 – 36% [260]. A small phase II/III trial on melanoma 
showed no statistical difference in survival [261]. A phase III trial in patients with 
colorectal cancer showed no overall survival improvement however subgroup analysis 
showed an improved disease free survival and metastasis free survival in patients with 
colon cancer but not rectal disease [262]. A much larger clinical trial involving 592 
colorectal cancer patients showed an average survival of 5.13 years in the vaccination 
plus surgery group compared to 4.46 in the surgery alone group (p<0.01) [263]. 
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1.4 Immunotherapy in head and neck cancers 
1.4.1 Introduction to head and neck cancer 
Head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer with 
severe impact on the quality of life of patients and significant morbidity and mortality 
rates. It is the sixth most common form of cancer affecting more than 50,000 in the 
United States and half a million people worldwide [264, 265]. HNSCC is a set of 
malignancies arising from the epithelium of the upper aerodigestive tract including 
oropharynx, nasopharynx, oral cavity, nasal cavity, sinuses and larynx. In the United 
Kingdom oral cavity tumours affects 6,800 people every year with a 2,100 deaths in 
2012. Incidence levels and mortality rates have increased by approximately 33% and 
10% respectively in the last decade [266]. While laryngeal SCC affected 2,360 people 
with 78 deaths in 2012 [267]. Male-to-female ratio of HNSCC incidence could be as 
high as 2:1, however this ratio is declining due to increased incidence in women due to 
higher use of tobacco [267, 268].   
 
HNSCC incidence and mortality are higher in disadvantaged population groups [269]. 
Tobacco and alcohol use remains the main risk factor for the development of these 
cancers, however oncogenic viruses could play a major role in tumour development 
such as Epstien-Bar virus in nasopharyngeal carcinoma and human papilloma virus in 
oral or oropharyngeal cancers. In fact, developed countries have seen an epidemic of 
oropharyngeal cancers due to HPV infection possibly contracted during sexual activity 
[265].  
 
Surgery, radiation and chemotherapy remain the mainstay treatments for HNSCC. 
However, changes to their delivery timing and combinational approach have led to 
improved clinical outcome especially in advanced disease. In such cases all three 
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modalities should be used with chemotherapy delivered as a combination 
chemoradiotherapy. The latter has been shown to be more beneficial compared to 
radiation alone. Induction chemotherapy could shrink primary tumour prior to surgical 
excision. It has been shown to increase local control and reduce metastasis with an 
overall survival increase of about 5% [270, 271]. Radiotherapy treatment has 
witnessed similar advancement with the introduction of hyper-fractionated 
radiotherapy, accelerated radiotherapy and intensity modified radiotherapy [270].  
 
Despite the advances in traditional treatments, research in new treatment modalities is 
required to improve the lives of our patients. Survival rates of HNSCC patients has not 
improved over the last few decades [272]. In addition these treatments continue to 
have high morbidity rate and significant impact on quality of life. Surgery is often 
invasive with high complication rate. Major head and neck surgery is associated with 
temporary or permanent loss of voice, taste and swallowing functions. In addition, it 
has a significant aesthetic, social and psychological impact on patients [273]. Similarly 
chemoradiotherapy has a high morbidity and complications rates and significant impact 
on quality of life [274, 275]. Furthermore, although the advances in traditional 
treatments has improved the rate of locoregional control it has made little impact on 
metastatic disease [276].  
 
1.4.2 HNSCC and the immune system 
HNSCC is an immunosuppressive disease. These tumours can induce deficiency in 
quantity [277] and quality of T cells [278, 279] and anergy in NK cells  [280, 281]. They 
express a tumour-permissive cytokine profile leading to a proinflammatory immune 
response and increased angiogenesis [282-285]. In addition, these tumours often show 
defective antigen processing and presentation further contributing to their immune 
escape [286, 287]. On the contrary, developing an effective host immune response 
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correlates with a better outcome in HNSCC. Immunosuppressed patients have a higher 
risk developing HNSCC with worse clinical outcome [288, 289]. Higher levels of 
tumour-infiltrating lymphocytes (TIL) seem to be associated with better outcome in 
HPV positive oropharyngeal cancer patients [290, 291]. In oral squamous cell 
carcinoma the density of CD8+ TILs correlates with tumour size, clinical stage and 
metastasis [292]. Higher levels of CD8+ T cells and CD20+ B cells in metastatic lymph 
nodes has been reported to correlate with favourable outcome in pharyngeal cancers 
[293].  
 
As previously discussed, immune check points plays a major role of tumour 
development and evasion of the immune system. PD-L1/PD-1 interaction in particular 
seems to play an important role in HNSCC. PD-L1 is expressed in 66% of these 
tumours [294]. Premalignant lesion in the head and neck are reported to express high 
levels of PD-L1 [295, 296] which could be a target area for immunotherapy.  The role of 
PD-L1 is most studied in HPV associated oropharyngeal carcinoma where the 
increased expression of PD-L1 due to chronic viral infection can contribute to T cell 
dysfunction [297]. Similarly, Tobacco and alcohol related HNSCC shows increased 
expression of PD-L1 [298]. And although PD-L1 expression doesn’t correlate with 
overall survival [292, 299] it appears to correlate with distant metastasis [299].  
 
The success of immunotherapy in any cancer depends of the expression of tumour 
associated antigen that are either uniquely expressed by tumour cells or expressed in 
increased levels compared to normal cells and the ability of the immune system to 
detect these antigens. HNSCC can express a variety of TAAs with clinical importance 
such as MUC-1, RAGE and CAGE tumour antigens and the cancer-testis antigen (NY-
ESO-1) [300, 301]. Patients with advanced disease can express higher serum levels of 
MUC-1 and anti MUC-1 antibodies [302]. Antibodies to p53 have also been reported to 
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be expressed in higher levels in HNSCC undergoing surgical treatment which 
correlated with the presence of distal metastasis [303]. In addition to humoral immunity, 
CD4+ and CD8+ T cells isolated from HNSCC patients can be activated with synthetic 
MUC-1 protein fragments [304].  
 
1.4.3 Current Immunotherapy approaches to HNSCC 
Immunotherapy in HNSCC has been an area of great interest in the last decade. While 
prophylactic vaccines targeting EBV or HPV viruses carry a great potential they are 
beyond the scope of this study. Therapeutic immunotherapy approaches in HNSCC 
aim to stimulate a generalised immune response, target cell surface receptors using 
monoclonal antibodies (mAb), reverse HNSCC-induced immunosuppression, or 
generate an antitumour immune response via vaccination.  
 
Cytokines can be powerful stimulators of the immune system. Earlier studies of peri-
tumour and peri-lymphatic administration IL-2 in HNSCC can lead to increased levels 
of NK cells and TILs [305, 306] with evidence of improved survival in certain patient 
groups [307]. A phase III clinical trial (NCT00002702) aiming to study the effect of IL-2 
when administered in conjunction with surgery and radiotherapy is currently in 
progress. IRX-2 is a biological product that contains cell-derived multiple cytokines 
including IL-1, IL-2, IL-6, IL-8, TNF-α, IFN-γ and GM-CSF [308]. A phase II trial 
(NCT00210470) showed promising results including increased lymphocytes infiltration 
and minimal toxicity. Two year survival and disease free survival were increased 
compared to matched control group [309, 310]. A phase III trial is currently being 
planned according to the manufacturing company website.  
 
EGFR is expressed by 90% of HNSCC and is associated with radioresistance, 
locoregional recurrence and inferior survival rates [311, 312]. It is involved in most 
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aspects of HNSCC tumourigenesis. Cetuximab is a chimeric mAb which targets the 
extra cellular domain of EGFR. It was the first FDA approved molecularly targeted 
agent for the management of HNSCC. Cetuximab main action mechanism is 
interference with the binding of natural ligands such as EGF, disrupting its signalling 
pathway [313]. In addition, cetuximab can activate the antibody-binding receptor FcγR 
IIIa on NK cells leading to antibody-dependant cellular cytotoxicity (ADCC). These 
activated NK cells can secrete higher levels of IFN-γ leading to maturation of dendritic 
cells. This NK-DC cross-priming increases the antigen presenting capacity of DC cells 
leading to the induction of TAA-specific antitumour immunity [314]. When combined 
with radiotherapy or platinum-based chemotherapy it can increase overall survival in 
advanced HNSCC patients [315, 316]. Another approach to target EGFR using 
chimeric antigen receptor (CAR) T cell transfer is currently undergoing phase I clinical 
trial (NCT01818323) [317]. 
 
HNSCC induces a tumour-permissive cytokines profile including VEGF and hepatocyte 
growth factor (HGF) [282, 283, 318]. These cytokines can be targeted by monoclonal 
antibodies to neutralise their function. Bevacizumab is an anti-VEGF mAb. It is 
currently being tested in combination with chemotherapy in a phase III trial 
(NCT0058870) despite modest success in a phase II trial when combined with 
cetuximab [319]. Ficlatuzumab is a mAb that binds and neutralises HGF. It is currently 
undergoing phase I trials in combination with cetuximab or chemoradiotherapy 
(NCT02277197 and NCT02277184 respectively).  
 
Another approach to reverse the immune suppression induced by HNSCC is to target 
the immune check points. Both CTLA-4 and PD-1 are highly expressed in tumour 
infiltrating lymphocytes in HNSCC [320, 321]. Ipilimumab, an anti-CTLA-4 mAb, is 
currently being tested in a phase I trials in combination with cetuximab and 
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radiotherapy in HNSCC (NCT01860430). Similarly, anti-PD-1 mAb, nivolumab, is 
currently undergoing a phase III trial in recurrent HNSCC (NCT02105636). 
 
HNSCC express a variety of TAAs making these tumours suitable for therapeutic 
vaccine approaches. Melanoma antigen E (MAGE)-A3 is a cancer testis antigen 
originally found in melanomas but later identified in HNSCC [322, 323]. A recent phase 
I trial targeting MAGE-A3 and HPV-16 using a Trojan peptide vaccination technique, 
where the peptide contain a “penetrin” sequence that allows the entire peptide to 
translocate through the cell membrane and penetrate directly into the endoplasmic 
reticulum where they can form peptide-HLA complexes [324], was found to be safe and 
well tolerated. It generated an immune response to HLA-II peptides but not HLA-I. 
There was no demonstrable clinical benefit and one patient suffered severe 
neurological events post vaccination [325]. Vaccination with lethally irradiated semi-
allogeneic human fibroblasts (MRC-5) transfected with tumour DNA is currently in 
phase I trial (NCT02211027). Another cellular vaccine in phase I trial is AlloVax(TM), a 
personalized anti-cancer vaccine combining Chaperone Rich Cell Lysate as a source 
of tumour antigen prepared from patient's tumour and AlloStim(TM) activated CD4+ cells 
[326] as an adjuvant (NCT01998542).  
 
Although not currently in clinical trials, but relevant to our treatment model, is the 
vaccination with HNSCC autologous tumour cells pre-infected with Newcastle disease 
virus to act as vaccination adjuvant. In a phase II trial, 20 patients with HNSCC of 
various anatomical locations were recruited. They all received surgical treatment +/- 
radiotherapy to be followed after three months with vaccination. Autologous tumour 
cells were isolated, expanded, infected with NDV then irradiated before being injected 
subcutaneously. The treatment was well tolerated with only flu-like symptoms, fatigue 
and induration at injection site recorded. Of the advanced disease patients (stage III 
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and IV, n=18) 11 survived over 5 years (61%) [327], remarkably higher than the 38% 5-
year survival reported at that time [328]. Despite the study shortcomings of small 
patient cohort and poorly reported functional immunological response data, the overall 
survival rate is impressive and further validates our own approach of virus-infected 
cancer cell vaccine. 
 
1.5 T cell homing role in pancreatic adenocarcinoma therapeutic vaccines 
The success of any vaccination protocol relies on the ability of memory T cells to 
localise to peripheral tissue were they are required. This is achieved by expression of 
homing receptors on these lymphocytes during activation. Vaccination efficacy can be 
improved by inducing a specific homing receptors pattern relevant to the targeted 
organ on the resultant memory cells. In human pancreatic adenocarcinoma prognosis 
correlates with the level of tumour infiltrating CD8+ cells [329]. However, evidence from 
human disease and animal models show that the desmoplastic stroma of this disease 
forms a barrier to immune cell infiltration, especially CD8+ [330, 331]. We hypothesised 
that a vaccination strategy that can induce a pancreas-specific homing capacity in 
CD8+ cells can overcome this barrier and improve the prognosis of these patients.  
 
1.5.1 Introduction to pancreatic cancer 
Pancreatic cancer remains one of the most difficult cancers to diagnose and treat. It is 
the fifth most common cause of cancer death in the UK with one and five-years survival 
of 20.8% and 3.3% respectively. These figures have hardly improved since the early 
1970s [332]. Complete surgical resection remains the only curative treatment. 
Unfortunately less than 20% of pancreatic tumours are amenable to surgical excision 
at the time of diagnosis. However, even with complete surgical resection prognoses 
remains poor with five years survival around 20% [333, 334]. Gemcitabine is the main 
chemotherapeutic agent approved for advanced pancreatic cancer. Despite being 
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shown to improve life expectancy compared to 5-flurouracil, effect remains modest with 
median survival around 6 months [335]. Combining gemcitabin therapy with erlotinib 
led to minimal increase in life expectancy from 5.9 to 6.2 months [336].  
 
Immunotherapy is a promising new avenue in the management of pancreatic cancer. 
Early clinical trials of peptide-based [337, 338] and dendritic cells vaccines [339, 340] 
have demonstrated the ability of these treatments to induce an antitumour immune 
response and a promising clinical potential. However the most successful vaccine to 
enter clinical trials is a whole cell vaccine, similar to our approach. G-Vax is a GM-CSF 
expressing allogeneic whole cell vaccine that was shown to induce an antitumour 
immune response involving CD4+ and CD8+ cells [341]. Importantly, patient 
vaccinated with G-Vax developed mesothelin-specific IFN-γ-producing CD8+ T cells, 
which provided evidence of in vivo cross-priming by antigen-presenting cells of this 
tumour-associated antigen [342]. This led to the introduction of CRS-207, a live-
attenuated Listeria monocytogenes-expressing mesothelin to the vaccination regimen. 
A recent phase III clinical trial using G-Vax prime and CRS-207 boost resulted in an 
increase of overall survival compared to G-Vax alone [343]. 
 
Other vaccination approaches utilising the immunogenic abilities of oncolytic viruses, 
and vaccinia virus in particular has been reviewed by the author recently [1] (appendix 
IV). 
 
1.5.2 T-cells homing 
Leukocytes adhesion to the vascular endothelium and the subsequent migration into 
adjacent tissue is an integral part of the immune system function. It allows 
lymphocytes, and other white blood cells, to reach the site of the body where their 
services are required. This is a multistep process involving; tethering and rolling where 
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lymphocytes are loosely attached to an adhesion molecule on the surface of 
endothelial cells, activation by exposure of the lymphocyte G-protein-coupled receptor 
to a chemoattractant chemokine and arrest where lymphocytes are firmly attached via 
their activated integrin to the endothelial cells. Transmigration follows were 
lymphocytes cross the endothelium into surrounding tissue via the junctions between 
endothelial cells [344, 345]. Each of these steps is mediated by specific interaction 
between adhesion molecules and surface receptors. In order to extravasate a 
lymphocyte needs to engage all these receptors in a sequential manner. The various 
different combination of these receptors and ligands give each tissue type a specific 
molecular “post code” that allows specific T cells to target a specific area [345].  
 
Chemokines play an essential role in all steps of the adhesion and migration process. 
They increase the affinity of integrin for their adhesion molecule ligands, provide the 
necessary signal at the activation stage via interaction with their cognate receptor, and 
provide the chemotactic gradient to direct lymphocytes migration into the relevant 
tissue compartment following extravasation [346]. More than 50 chemokines and 20 
receptors have been identified. Chemokines are divided into four groups depending on 
the arrangement of the first two cytosine residue; CC, CX, C and CX3C. They are 
further divided into inflammatory and homeostatic based on their function [346, 347]. 
Chemokine receptors are composed of seven transmembrane domain coupled with G-
protein that are expressed on the surface of lymphocytes. Each receptor can interact 
with several chemokines and vice versa [348].  
 
Naïve T cells circulate between blood and lymph nodes (and other secondary lymphoid 
organs) constantly. This migration to lymph nodes depends on the expression of L-
Selectin (CD62L) and the chemokine receptor CCR7 on lymphocytes and interaction 
with their prospective ligands peripheral lymph node addressin (PNad), and 
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chemokines CCL19 and CCL21 [349]. In the guts, migration to Payer’s patch requires 
the engagement of α4β7 integrin in addition to L-Seletin [350]. This interaction takes 
place in post-capillary high endothelial venules where shear forces of the blood flow 
are reduced and accumulation of lymphocytes doesn’t interfere with gas and fluid 
exchange [351].  
 
Upon activation of T cells in the lymph nodes by dendritic cells, they proliferate and 
became either effector or memory cells and they leave the lymphoid compartment. 
Some activated T cells maintain expression of CD62L and CCR7 and can migrate to 
lymph nodes. These cells are referred to as central memory T cells (TCM), while effector 
T cells (TEFF) and effector memory T cells (TEM) lose their expression and the ability to 
migrate to lymph nodes but they migrate peripheral and non-lymphoid tissue [352, 
353]. However, the difference between these subsets can be subtle. TCM can be as 
efficient as TEM in providing effector function when faced with antigen challenge [354]. 
In addition, TEM can convert back to TCM and localise to lymphoid tissue [355].  
 
1.5.3 Gut and non-lymphod T cell homing 
TEFF and TEM cells show migratory selectivity to various organs, including the gut, based 
on expression of various selectin ligands and chemokines receptors as discussed 
earlier. Gut-tropic T cells express high levels of α4β7 integrin and the chemokine 
receptor CCR9 [356-358]. These cells migrate preferentially to the small intestine 
lamina propria venules where mucosal addressin cell adhesion molecule 1 (MAdCAM-
1), α4β7 ligand, and CCL25, the main ligand of CCR9, are highly expressed [359, 360]. 
 
The site of antigen entry into the body influences the traffic qualities of TEFF. Pathogen 
entering through the skin primes lymphocytes with skin homing receptors [361]. 
Similarly, oral vaccination induces higher level of α4β7 compared to intramuscular or 
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subcutaneous vaccination allowing the primed T cells to home to the guts [362]. In 
addition, the homing potential of lymphocytes depends on the lymphoid 
microenvironment where these cells are primed. T cells primed in mesenteric lymph 
nodes express higher levels of α4β7 and CCR9 compared to those primed in skin 
draining lymph nodes [363, 364].  
 
Dendritic cells play an essential role in inducing a tissue-specific homing potential into 
T cells. Intestinal DCs from Peyer’s patch and mesenteric lymph nodes induces gut 
homing capacity while those derived from peripheral lymph nodes induces a skin 
homing pattern [365-367]. The capacity of DCs to induce tissue specific homing 
capacity in T cells is believed to depend on the ability of the DCs to produce active 
metabolites from tissue-derived factors such as retinoic acid by gut-derived DCs [368] 
and vitamin D3 by skin DCs [369].  
 
MAdCAM-1/α4β7 and CCR9/CCL25 mediated T cell homing plays a role in the 
pathogenesis of various diseases outside the guts.  In normal circumstances 
MAdCAM-1 expression is confined to the blood vessels of the small intestines [370]. 
MAdCAM-1 is not detected in normal liver while it can be expressed in chronic 
inflammatory liver disease [371] and liver cirrhosis [372]. Similarly, the mucosal 
immune composition in Barrett's oesophagus including high level expression of 
MAdCAM-1 resembles that of the small intestine suggesting that the disease process 
is caused by intestinal homing signals rather than to an active local inflammatory 
response [373].  
 
In the pancreas, MAdCAM-1 is highly expressed in normal and diabetic neonate mice 
and plays a critical role in the pathogenesis of type 1 diabetes [374]. This expression is 
down regulated in normal adult mice [374] but remains high in diabetic animals 
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although restricted to inflamed islets [375]. In human pancreatic cancer, tumour-
derived endothelial cells express higher levels of addressins including MAdCAM-1 
compared to those derived from normal tissue, allowing selective transmigration of 
Treg cells from peripheral blood to tumour tissue [376].  
 
1.5.4 Induction of homing capacity via vaccination 
The induction of T cells with specific homing capacity requires tissue-derived DCs as 
discussed above. This can be achieved by enteral vaccination to generate gut-homing 
phenotype [362] or via intranasal route to target the head and neck region [377]. 
However this approach has some practical disadvantages in a clinical setting. This will 
be especially relevant to our vaccination approach that depends on delivering viable 
tumour cells infected with an oncolytic virus, neither of which is resistant to gastric 
enzymes.   
 
One approach to overcome that would be to recreate the tissue-specific 
microenvironment in the lymph nodes via the delivery of tissue specific chemokines. 
Unpublished work of our collaborator showed that priming of T cells in the presence of 
CCL25 in vivo and in vitro would induce higher expression of α4β7 integrin on CD4+ 
and CD8+ cells, in consequence a gut homing phonotype [F Marelli-Berg, unpublished 
data]. We speculated that a similar approach can be utilised to generate an anti-tumour 
immune response with a pancreas-targeting phenotype.  
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1.6 Hypothesis, aims and objectives   
1.6.1 Hypothesis 
Based on the work of our group and others demonstrating the induction of antitumour 
immunity following infection of tumour cells with oncolytic viruses, we hypothesised that 
prime/boost vaccination with virus-infected tumour cells would induce a therapeutic T 
cell-mediated antitumour immune response. In addition, arming these oncolytic viruses 
with CCL25 chemokine would generate tumour-targeting T cells with higher expression 
of α4β7 integrin preferentially homing to the MAdCAM-1-rich pancreatic tumour. 
  
1.6.2 Major aim: 
• To develop a virus-infected cancer cell vaccine (VICCV) that can be translated 
into the clinic (Fig 1.4). 
 
1.6.3 Objectives 
• To optimise the viral dose and the best prime/boost combination to induce a 
tumour specific immunity. 
• To optimise the safety of the vaccination regimen with a secondary treatment of 
irradiation or cytotoxic drugs to arrest cell proliferation. 
• To evaluate the effect of the secondary treatment on viral life cycle and anti-
tumour immunity. 
• To investigate the immunological functions involved in VICCV. 
• To test the efficacy of the vaccination regimen in therapeutic and prophylactic 
Head and Neck and pancreatic tumour models. 
• To generate a T cell immune response with pancreatic-homing phenotype to 
enhance the therapeutic efficacy of the VICCV in pancreatic cancers. 
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Fig 1.4 A schematic diagram of the virus-infected cancer cell vaccine (VICCV). 
Tumour cells collected during tumour excision are isolated and expanded, infected with an 
oncolytic virus, replication-arrested and injected subcutaneously. The same is repeated 
after 4 – 6 weeks using virus 2. The resultant tumour specific immunity could in theory clear 
any minimal residual disease or micro metastasis and prevents tumour recurrence. 
Replication 
arrest 
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Chapter two: Materials and Methods 
 
2.1 Cell lines 
Murine pancreatic ductal adenocarcinoma (PDAC) cell lines DT6606 and TB11381 
cells were kindly provided by Professor David Tuveson (Cold Spring Harbour 
Laboratory & John Hopkins University, NY, USA). They were obtained from pancreatic 
tumours of the transgenic mouse strains KC (K-rasLSL.G12D/+; PdxCre) and KPC ( K-
rasLSL.G12D/+; p53R172H/+; PdxCre) [378, 379] respectively. 32Dp210 is a leukaemia cell 
line derived from C3H/HeN mice [380]. It was kindly provided by Professor Farzin 
Farzaneh (Kings College London, London, UK). Lewis Lung cancer (LLC), CT26, 
CMT93, 4T1, SUIT2 and Mia PaCa cell lines were all obtained from the Cancer 
Research UK cell bank. SCC7 is a head and neck derived squamous carcinoma, from 
C3H/HeN mice and was kindly provided by Dr Osam Mazda, (Department of 
Microbiology, Kyoto Prefectural University of Medicine, Japan). B4B8 is murine SCC 
cells derived from oral keratinocytes treated with chemical carcinogene 4NQO [381]. 
LY-2 cell line was isolated from lymph node metastasis after inoculation with PAM212 
squamous cell carcinoma cells [382, 383]. They were kindly provided by Dr Carter Van 
Waes (National Institute of Health, Bethesda, MD, USA). Pkpa130200 is a pancreatic 
cancer cell line isolated from tumours developed in progenies of KPC mice crossed 
with Atg7fl/fl [384]. They were kindly provided by Professor Kevin Ryan (Beatson 
Institute, Glasgow, UK). CV1, HEK-293 and JH293 cell lines were all obtained from 
ATCC (VA, USA) and were used for virus production and titration. All other cell lines 
were obtained from Cancer Research UK cell bank. All cell lines are listed in Table 2.1. 
 
All cell lines, except 32Dp210, were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM) high glucose (Sigma-Aldrich, MO, USA) supplemented with 5-10% foetal calf 
serum (Gibco®, Life Technologies, CA, USA) and 1% penicillin-streptomycin (Sigma-
  
63
Aldrich, MO, USA) at 37°C in a humidified atmospher e containing 5%CO2. 32Dp210 
cells were grown in RPMI-1640 (Sigma-Aldrich, MO, USA) supplemented with 10% 
FCS and 1% penicillin-streptomycin. 
 
Table 2.1 List of all cell lines used in this study 
Cell line Organism Strain Disease 
DT6606 Mouse KC Pancreatic Ductal Adenocarcinoma 
TB11381 Mouse KPC Pancreatic Ductal Adenocarcinoma 
Pkpa130200 Mouse KPC Atg7fl/fl Pancreatic Ductal Adenocarcinoma 
LLC Mouse C57BL/6 Lewis Lung Carcinoma 
32Dp210 Mouse C3H/HeN Leukaemia 
SCC7 Mouse C3H/HeN Head and Neck SCC  
B4B8 Mouse BALB/c Head and Neck SCC 
LY-2 Mouse BALB/c Head and Neck SCC 
CT26 Mouse BALB/c Colon Carcinoma 
CMT93 Mouse C57BL/Icrf Colorectal Carcinoma 
4T1 Mouse BALB/c Breast Adenocarcinoma 
JC Mouse BALB/c Breast Adenocarcinoma 
SUIT2 Human - Pancreatic Carcinoma 
Mia PaCa Human - Pancreatic Carcinoma 
CV1 Green Monkey - Normal Kidney Fibroblasts 
HEK293 Human embryonic - Epithelial kidney transfected with E1A 
JH293 Human embryonic - Slow growing subclone of HEK293 
 
2.2 Generation of Renilla Luciferase stable cell lines 
2.2.1 Puromycin killing curve  
Cells were plated in 6-wells plates at 1x105 cell/well, one plate per cell line, and 
incubated at 37°C in a humidified atmosphere contai ning 5% CO2 overnight. Puromycin 
serial dilutions were made in DMEM medium supplemented with 5% FCS as described 
(section2.1) starting with 10µg/ml then 5, 2, 1, 0.5 and negative control of medium only. 
Puromycin dilutions were added to each well and incubate for 7 days. Cell death was 
monitored and 2µg/ml dilution was chosen as it resulted in 100% cell killing. 
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2.2.2 Lentivirus transduction 
B4B8, LY-2 and SCC7 cells were plated at 2x104 cells/well in two wells of a 24-wells 
plate and incubate at 37°C in a humidified atmosphe re containing 5% CO2 overnight. 
On day two, medium was replaced with fresh medium containing hexadimetherine 
bromide (Sigma-Aldrich, MO, USA) to a final concentration of 4 µg/ml. RediFect Green 
Renilla-Puromycin Lentivirus vector (#CLS960004, PerkinElmer, MA, USA) was  added 
directly to the cells at MOI=15 units/cell and incubated for 24 hours. One well was left 
un-infected as negative control for puromycin selection. On day three, virus-containing 
medium was replaced with fresh pre-warmed medium. Day four, medium was replaced 
with fresh medium with puromycin at the required concentration (2µg/ml) Renilla 
Luciferase positive cells were selected in puromycin for 5-7 days. Luciferase 
expression was confirmed using Renilla luciferase expression assay from Promega 
(#E2810, Madison, WI, USA) following kit instructions. Stable cells were expanded and 
frozen 10% DMEM medium supplemented with 10% DMSO. 
 
2.3 Animals 
5-7 weeks old male C57BL/6, 5-7 weeks old female C3H/HeN and 5-7 weeks old 
female BALB/c mice were purchased from Charles River Laboratories (UK) and 
housed at the BSU, Charterhouse Square.  
 
KPC (K-rasLSL.G12D/+; p53R172H/+; PdxCre) mice were bread and genotyped in-house by 
the author by cross-breading KP (K-rasLSL.G12D/+; p53R172H/+) mice with PDX-Cre mice 
[379]. Parental mice were kindly provided by Professor David Tuveson (Cold Spring 
Harbour Laboratory & John Hopkins University, NY, USA).  
 
All animals were housed and all experiments were conducted in accordance with 
Home Office regulations [385]. 
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2.4 Radiation and chemotherapeutic agents 
Cells were irradiated using a RS2000 Biological Irradiator (Rad Source Technology 
Inc., GA, USA) with a total dose of 30Gy, unless otherwise indicated. 
 
Chemotherapeutic agents used in this study were mitomycin C (Roche Applied 
Science) used at 50 µg/ml and mitoxantrone (Onkotrene, Baxter, Norfolk, UK) used at 
2µM/ml. 
 
2.5 Viruses 
2.5.1 Vaccinia virus  
VVL15 (VVΔTK) is a thymidine kinase-deleted Lister strain vaccinia virus with E. coli 
LacZ and firefly luciferase reporter genes inserted in its locus [386]. VVL15-RFP was 
constructed by Dr L Chard from our group and is equivalent to VVL15 but contains an 
RFP transgene replacing LacZ.  
 
All Vaccinia viruses used in this study were mass produced by Miss M El-Khouri or Dr 
L Chard. The virus was grown in 40 T175 flasks of CV-1 cells and purified by ultra-
centrifuge sucrose gradient banding. All viruses were re-titrated by the author (section 
2.8) prior to use. 
 
2.5.2 Adenovirus  
Ad5 is a wild type class C Human adenovirus serotype 5. dl1520 has an 827 base 
deletion in the region encoding the E1B 55-kDA protein. Ad5-GFP-PL11 is a wild type 
Ad5 with the GFP gene inserted in the E4 untranslated region [387]. It was kindly 
provided by Dr G Hallden (Queen Mary University of London, London, UK).  
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All adenoviruses used in this study were mass produced by the author with the 
exception of dl1520 which came from our lab stock. HEK-293 cells were expanded and 
plated in a Cell Factory-10 system (equivalent to 36 T175 flasks) (Thermo Fisher 
Scientific, MA, USA) and infected with viral primary expansion. Cells were harvested 
two days later and spun down before three cycles of freeze/thaw to release viral 
particles.  Adenovirus was purified by sequential ultra-centrifuge CsCl banding. Purified 
virus was aliquoted and stored at -80°C.  
 
2.6 Plasmids and AdTD-CCL25 virus construction 
AdTD plasmid was constructed by Dr Pengju Wang of Sino-British Research Centre for 
Molecular Oncology, Zhengzhou University of China. This vector contains the full 
genome of Ad5 with triple gene deletions; E1ACR2, E1B19K and E3gp19K. The latter 
was replaced with chloramphenicol resistance gene flanked by two SwaI restriction 
enzyme sites. In addition, the AdTD vector contains a kanamycin resistance gene 
located outside the Ad5 genome, flanked by two PacI restriction enzyme sites. 
 
AdTD vector was digested with SwaI (New England Biolabs, Ipswich, MA, USA) at 25° 
for four hours. Blunt digested ends were then dephosphorylated using Shrimp Alkaline 
Phosphatase (New England Biolabs, Ipswich, MA, USA) at 37° for 60 minutes. 
Enzymes were deactivated at 65° for 20 minutes. DNA  was purified using 
Phenol:Chloroform:Isoamyl Alcohol 25:24:1 (Sigma-Aldrich, MO, USA) followed by 
DNA precipitation using sodium acetate and ethanol 96-99% at -80° overnight. DNA 
suspension was centrifuged at 13,000 rpm for five minutes. DNA pellet was washed 
with Ethanol 70% and centrifuged again and left to air-dry. DNA was eluted in distilled 
water and concentration measured using NanoDrop 1000 Spectrophotometer (Thermo 
Fisher Scientific, MA, USA). 
  
67
 
PCMV6-Entry-mCCL25-MycDDK plasmid was purchased from Origene (#PS100001, 
Rockville, MD, USA). It contains a full murine CCL25 cDNA with MycDDK expression 
tag at the C-terminal. Plasmid was digested using EcoRI (New England Biolabs, 
Ipswich, MA, USA) at 37° for two hours followed by blunting of the DNA free ends 
using Quick Blunting™ Kit (New England Biolabs, Ipswich, MA, USA) supplemented 
with Deoxynucleotide (dNTP) (New England Biolabs, Ipswich, MA, USA) and 
dithiothreitol (DTT) (Sigma-Aldrich, MO, USA). A second digestion with SmaI (New 
England Biolabs, Ipswich, MA, USA) at 25° for four hours followed. DNA bands were 
separated via electrophoresis in 1% UltraPure™ Low Melting Point Agarose gel 
(Invitrogen, Thermo Fisher Scientific, MA, USA). CCL25 band was cut from the gel and 
DNA was extracted using illustra GFX PCR DNA and Gel Band Purification Kit (GE 
Healthcare Life Sciences, Buckinghamshire, England) following the manufacturer 
instruction.  
 
T4 DNA ligase (New England Biolabs, Ipswich, MA, USA) was used to ligate mCCL25 
fragment into AdTD vector. Insert and vector were mixed with enzyme and buffer at a 
free-ends ratio of 20:1 insert to vector. Reaction tube was incubated at 16° overnight. 
Vector-only ligation reaction was used as a control for dephosphorylation efficacy. Both 
ligation products were transformed into One Shot® TOP10 Electrocomp™ competent 
E.coli using electroporation. Transformed E.Coli were plated and grown over night on 
kanamycin agar dishes at 37°. Ten colonies were pic ked from AdTD-CCL25 plate and 
each was grown in kanamycin liquid lysogeny broth (LB) for 15 hours with shaking at 
37°. The following day DNA was extracted using QIAp rep Spin Miniprep kit (Qiagen, 
Venlo, Netherland) following manufacturer instruction. Insertion and direction were 
confirmed by Polymerase Chain Reaction (PCR) (Section 2.7).  
 
  
68
Positive clone DNA was digested using PacI digestion enzyme (New England Biolabs, 
Ipswich, MA, USA) to linearise the plasmid and remove the kanamycin resistance 
gene. DNA was purified as described above. In addition, AdTD backbone plasmid was 
digested with PacI to create AdTD-C control virus.  
 
HEK293 cells were plated in 6-wells plate at 1x105 cells/well and incubated overnight at 
37° and 5% CO 2. The following day, linearised AdTD and AdTD-CCL25 plasmids were 
transformed into the cells using Effectene Transfection Reagent (Qiagen, Venlo, 
Netherland) following the manufacturer instructions (Fig 2.1). Plates were incubated for 
7 days and observed for cytopathic effect (CPE). Once most cells showed signs of 
infection, supernatant was collected for confirmation of CCL25 expression. Cells and 
remaining culture media were harvested by scrapping the wells and underwent three 
cycles of freeze/thaw to release viral particles. 100 µl of the virus suspension was used 
to infect a T25 flask of HEK293 cells which in turn used to infect a T175 flask to make 
the viral primary expansion. DNA was extracted from the remaining viral suspension 
using Blood DNA extraction kit (Qiagen, Venlo, Netherland) and used for construct 
validation by PCR. 
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2.7 PCR validation of adenovirus constructs 
AdTD-CCL25 plasmid constructs were validated for transgene insertion and direction 
by PCR. E3gp19K external primers were used to screen colonies for successful 
ligation. The expected size of the amplified segment using these primers is 733 bp in 
an AdTD-CCL25 plasmid compared to 1019 bp in the AdTD vector. CCL25 gene 
Fig 2.1 Schematic diagram of AdTD-CCL25 construction.  
AdTD plasmid and PCMV6-Entry-mCCL25-MycDDK were digested with SwaI and 
EcoRI+SmaI respectively. Isolated DNA fragments were then ligated and transformed into 
competent E.Coli. The correct clone was then linearised using PacI before transfection 
into HEK293 cells to be packaged into AdTD-CCL25 virus. Key: Kanamycin resistance 
gene (Kan), Chloramphenicol resistance gene (Chlo) 
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insertion was further validated using CCL25 internal primers. Direction of the insert was 
confirmed using an E3gp19K forward primer and CCL25 reverse primer. Successful 
amplification of DNA using these primers indicates the insert is in the right direction 
(section 6.1). 
 
Standard Ad5 primer sets [388] (Table 2.2) were used to validate the triple gene 
deletions of both AdTD-C and AdTD-CCL25 viruses prior to viral mass production 
(Section 6.1).  
 
All PCR reactions contained 1-2 µl DNA (approximately 100ng), 0.5 µl forward primer, 
0.5 µl reverse primer, 10 µl distilled water and 12.5 µl ReddyMix PCR Master Mix 
(Thermo Fisher Scientific, MA, USA). PCR reactions were run for 25-30 cycles each 
consisting of 94°C for 30 seconds, 62°C for 30 seco nds and 72°C for one minute. 
Cycles were proceeded by a single incubation at 95°C for one minute and followed by 
a single incubation step at 72°C for seven minutes,  to be followed by a hold step at 
4°C. 
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Table 2.2 List of all PCR primers used for this study 
Primer Primer Sequence 
Ad5 set 1 
Forward CCCGGTGAGATTCCTCAAGAGGCCAC 
Reverse CCGGACCCAAGGCTCTCTGCTCTCCGGCTGCTCGGGC 
Ad5 set 2 
Forward GTAATGTTGGCGGTGCAGGAAGGGATTG 
Reverse GGGTCCCCCGTATTCCTCCGGTGATAATGAC 
Ad5 set 3 
Forward GTGTTCGCTTTGCTATATGAGGACCTGTGGC 
Reverse CCTCGATACATTCCACAGCCTGGCGACGCCCACC 
Ad5 set 4 
Forward CCTGTGATTGCGTGTGTGG 
Reverse GACAACAGTAGCAGGCGATTC 
Ad5 set 5 
Forward GCATCTGTGGAGAGCGGTTGTGAGACAC 
Reverse GCGCCAAGCAGATCAAGCTCATTAGCGC 
Ad5 set 6 
Forward GCTTAATGACCAGACACCGTCCTGAGTG 
Reverse GCACCAAGTGATCGGGCCTCAGCTCC 
Ad5 set 7 
Forward CACCCTCACGCTCATCTGCAGCCTCATCACTGTGG 
Reverse CTTCAGACGGTCTTGCGCGCTTCATCTGC 
Ad5 set 8 
Forward CGCTGGGGTCGCCACCCAAGATGATTAGG 
Reverse GAGTAGGGTACAGACCAAAGCGAGCACTG 
E3gp19k ext 
Forward CTCTGCCTAAGGCTCGCCG 
Reverse GCAAGCAGCGAGTAAAGCAGTT 
CCL25 int 
Forward TCGCCATGAAACTGTGGCTT 
Reverse GCGTACGCGTATTGTTGGTC 
 
2.8 Virus titration 
Purified virus titre was determined using the 50% tissue culture infective dose 
(TCID50) method. 8,000 cells/well of CV1 or JH293 cells, for vaccinia virus and 
adenovirus respectively, were plated in 96-well plates in 200µl DMEM supplemented 
with 5% FCS as described (section2.1) and incubated at 37°C in a humidified 
atmosphere containing 5% CO2 overnight. The purified virus was diluted 1:105 in 
DMEM 5%CSF. 20µl of the diluted virus were used to infect each well of the top row of 
the plate. Serial 1:10 dilutions were made to the next six rows. The last row was left 
uninfected as a negative control. Plates were incubated as above and the number of 
infected wells was counted on day 7 days for vaccinia virus and day 10 for adenovirus. 
The titre (pfu/ml) was calculated using the Reed Muench method [386, 389]. 
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Table 2.3 List of all viruses used for this study. 
Virus Batch No. Titre (pfu/ml) 
VVL15 010612 6.34X1010 
VVL15 010814 8.14X109 
VVL15-RFP 060509 2.1X109 
Ad5 221013 1x109 
Ad5 141113 1.95x1010 
dl1520 111105 7.13x109 
Ad5-GFP-PL11 010313 2.47x109 
AdTD-C 290514 1x1010 
AdTD-CCL25 020714 2.59x109 
 
2.9 Picogreen assay 
Adenovirus particle count was determined using a Quant-iT™PicoGreen®dsDNA 
Assay Kit (Invitrogen, Eugene, OR, USA). Stock virus was diluted 1:2 in TE (Tris-
ethylenediaminetetraacetic acid (EDTA)) and inactivated at 56°C for 15 minutes. The 
viruses were then diluted 1:6 and 1:10, and incubated at room temperature for 10 
minutes to allow equal distribution. Lambda DNA was diluted in TE to a concentration 
of 1 µg/ml. This was serially diluted to generate a standard curve 0-750 ng/ml. The viral 
dilutions and DNA standard samples were further diluted 1:20 and added in triplicate to 
a photosensitive 96-well plate (100 µl/well). 1x picogreen reagent was added to each 
well (100 µl/well) and the plate was left to incubate for two minutes at room 
temperature. The plate was read at 485 nm/535 nm on a Dynex Opsys MR 96 Well 
Microplate Reader and the samples were quantified from the standard curve. The virus 
particle (vp)/ml concentration was then determined using costumised GraphPad Prism 
5.0 and Excel spreadsheet. 
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2.10 Virus replication assay 
Cells were plated at 2x105 cell/well in a total of 2ml MDEM 5%FCS in a 6-wells plate to 
a total of 51 plates per cell line and incubated overnight. The next day cell count per 
well was obtained by averaging the cell count of three of the wells. The remaining 48 
wells were infected with 1pfu/cell for VVL15 and 50pfu/cell for Ad5. Cells were 
incubated for two or four hours for VVL15 and Ad5 respectively.  
 
Cells were then treated with irradiation (Rx), mitomycin C (MMC), mitoxantrone (MTX) 
or left untreated as negative control. After two hours of treatment, medium was 
aspirated and the cells were washed with phosphate buffered saline (PBS) twice. 
Following this 2ml of fresh medium was added to each well and incubated at 37°C.  
 
Twenty-four hours later cells of each well were scraped and transferred with medium to 
a cryotube and placed into -80°C freezer. The proce dure was repeated at 48, 72 and 
96 hours. The cells were then lysed by two rapid freeze/thaw cycles to release viral 
particles. 
 
TCID50 assay with top dilution of 1:1,000 was used to determine virus titre for each 
sample, as described above (section 2.8).  
 
2.11 Cell viability assay, MTS 
2.11.1 Dose-response cell kill assay 
Cells were plated at 1,000 cell/well in 96-wells plate in 90µl DMEM 5%FCS. 6 hours 
later, triplicate plates were infected per tested virus. The first column was infected at 
100pfu/cell for vaccinia virus and 1x104pfu/cell for adenovirus diluted in 10µl DMEM 
5%FCS. Virus was serially diluted at 1:10 a further 8 times through the other columns. 
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Uninfected cells acted as the negative control and media only wells as the positive 
control. Plates were incubated at 37°C. Six days af ter infection 20µl of MTS reagent 
(Cell titer 96AQueous MTS Reagent, Promega, Madison, WI, USA) supplemented with 
5 % PMS (Sigma-Aldrich, MO, USA) was added to each well and plates were 
incubated at 37°C for 2 hours. Optical density was measured at 490 nm using a 96-well 
plate reader. Dose response curve and EC50 values were calculated using customised 
Excel spreadsheet and Graphpad Prism 5.0 software. 
 
2.11.2 Time course cell kill assay 
Cells were plated in triplicate at 2x104 cell/well in 96-wells plate in 200µl DMEM 
5%FCS. Six hours later cell were infected with AdTD or AdTD-CCL25 virus at an 
MOI=10 pfu/cell. One plate was used per time point. Triplicate wells of un-infected cells 
and media only were used as negative and positive controls respectively. Plates were 
incubated at 37°C. 24 hours later MTS reagent was a dded and cell kill percentage was 
calculated as above. The same procedure was repeated at 48, 72 and 96 hours.  
 
2.12 Cell proliferation assay 
This assay was used to determine irradiation, MMC or MTX dose and incubation period 
required to arrest the proliferation of tested cells over a period of 96 hours. 
 
Cells were plated at 2x105 cell/well in a total of 2ml MDEM 5%FCS in a 6-wells plate 
and incubated overnight. The next day cell count per well was obtained by averaging 
the cell count of three of the wells. Triplicate wells were then treated with either MMC 
and incubated for 2 hours, or MTX and incubated for 2, 4 or 24 hours. Additionally 
triplicate wells were irradiated at increasing irradiation dose from 15 to 120 Gy. 24 
hours later triplicate wells were trypsinised for each treatment group and live cell count 
was determined using the Trypan blue exclusion test [390]. 
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2.13 Virus infectivity assay using fluorescence  
32Dp210 cells were plated at 2x105 cell/well in a total of 2ml RPMI 10%FCS in 6-well 
plates and incubated overnight. The next day cell count per well was obtained by 
averaging the cell count of three of the wells. Cells were infected at MOI=10 or 20 
pfu/cell for VVL15-RFP, and 50 or 100 pf/cell for Ad5-GFP-PL11. After 24 hours 
incubation at 37°C, florescent cells percentage (as  a marker of infected cells) was 
measured using BD LSRFortessa™ cell analyzer (BD Biosciences, CA, USA). 
 
2.14 Western blot 
2x105 cells in 6-well plates were lysed for 5 min on ice with 100 µl of lysis buffer 
containing 50 mM Tris pH7.4, 150 mM NaCl, 10 mM CaCl2, 1% NP40 and 1 protease 
inhibitor tablet for each 50 ml of buffer (Roche Applied Science, Mannheim, Germany). 
Protein concentration in samples was determined by using a Bradford assay (BioRad, 
CA, USA) and measuring optical density at 595nm using a 96-well plate reader. 
Proteins were resuspended in 5 µl of Laemmli sample buffer 5X (50 mM Tris, 4% SDS, 
10% glycerol, 5% Mercaptoethanol, 0.01 % Bromophenol Blue) and distilled water to 
give a final concentration of 30µg in 25µl. Samples were heated to 95°C for 5 min. 
Samples were separated according to molecular weight on 10% SDS-polyacrylamide 
gels and transferred onto a polyvinylidene difluoride membrane (GE Healthcare, Little 
Chalfont, Buckinghamshire, UK) using a wet transfer system. Membranes were 
blocked in 0.1% Tween 20 in PBS supplemented with 5% fat-free powdered milk for 40 
minutes. They were then incubated with primary antibodies overnight at 4°C specific to 
the following proteins: E1A (MS-587-P1, NeoMarkers, CA, USA), Hexon (LF-PA0099, 
Seoul, Korea), vaccine virus proteins (9503-2057, Biogenesis Ltd, Poole, UK). Alpha 
tubulin was used as a loading control (ab52866, Abcam, Cambridge, UK). Antibodies 
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were diluted 1:1,000 – 1:2,000 in 0.1% Tween 20 in PBS supplemented with 5% 
bovine serum albumin (BSA). 
 
Membranes were then transferred to the appropriate horseradish peroxidase-labelled 
secondary antibodies (Santa-Cruz Technology, Santa Cruz, CA, USA). Secondary 
antibodies were then detected using ECL Western Blotting Detection System (GE 
Healthcare, Little Chalfont, Buckinghamshire, UK). 
 
2.15 Quantitative PCR 
DT6606 cells were plated, infected and secondary treatment with Rx, MMC or MTX 
was performed as with the viral replication experiment (Section 2.10). 24 hours later, 
cells were scrapped, transferred to 15mls conical tubes and spun down at 1500rpm for 
5 minutes. Supernatant was discarded. Viral DNA was extracted from cell pellets using 
the Blood DNA extraction kit (Qiagen, Venlo, Netherland). DNA samples were diluted 
in Nuclease-free water to 20ng/µl (100ng/reaction). Quantitative PCR (qPCR) was 
performed using SYBR® Green PCR Master Mix (Applied BioSystems, Thermo Fisher 
Scientific, MA, USA). Primers sets used for this assay are shown in table 2.4. Data 
were interpreted as either viral copy numbers using a standard curve of serially diluted 
viral DNA. 
Table 2.4 List of primers used for qPCR 
Gene Primer Sequence 
Ad5 E1A 
Forward TGCCAAACCTTGTACCGGA 
Reverse CGTCGTCACTGGGTGGAAA 
Ad5 Penton 
Forward GATCGGAAAACCTCTCGAGAAA 
Reverse CGTAGGAGGGAGGAGGACCTT 
VVL15 VLTF-1 
Forward AACCATAGAAGCCAACGAATCC 
Reverse TGAGACATACAAGGGTGGTGAAGT 
18s 
Forward ATCCCTGAAAAGTTCCAGCA 
Reverse CCCTCTTGGTGAGGTCAATG 
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2.16 CCL25 ELISA 
Supernatant samples harvested from viral construction, virus replication assay and cell 
killing assay were diluted 1:5 in 1x Reagent Diluent Concentrate (R&D Systems, 
Minneapolis, MN, USA).  CCL25 levels were measured using Mouse CCL25/TECK 
DuoSet ELISA (R&D Systems, Minneapolis, MN, USA) following the manufacturer 
instructions. Data was analysed using GraphPad Prism 5.0. 
 
2.17 CCR9 expression 
Cells were trypsinised and washed twice with FACS buffer (PBS + 1% BSA). A 
triplicate of 1x106 cells of each cell line were spun down and resuspended in Anti-
mouse CCR9 APC (eBioscience, San Diego, CA, USA) diluted 1:100 in FACS buffer 
and incubated on ice away from light for 45 minutes. Stained cells were washed twice 
in FACS buffer. Unstained samples of each cell line were used as negative control. 
Data was acquired on BD LSRFortessa (BD Biosciences, San Jose, CA, USA).  
 
2.17 Cancer vaccination (Prime/Boost) 
Cells were grown in T-175 flasks to a 70% confluence. The next day cell count per 
flask was obtained by averaging the cell count of two flasks. The flasks were infected 
with MOI= 1pfu/cell for VVL15 and 50pfu/cell for Ad5 (or as otherwise indicated in the 
individual experiment). Cells were incubated for two or four hours for VVL15 and Ad5 
respectively.  
 
Cells were then treated with irradiation (Rx), mitomycin C (MMC), mitoxantrone (MTX) 
or left untreated as control. After two hours of treatment, medium was aspirated and 
the cells were washed with phosphate buffered saline (PBS) twice. Other control 
groups are: PBS, cell lysate obtained by three freeze/thaw cycles, Rx-treated cells, 
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MMC-treated cells or MTX-treated cells. The cells were diluted to 2x107 cell/ml in PBS 
(2x106 cells per 100µl vaccination dose). The treated cells were then injected into the 
right flank of mice.  
 
The same procedure was repeated after two to four weeks (boost).  
 
2.18 IFN-γ Assay 
This assay is based on the release of IFN-γ when CD8 cells are activated by their 
cognate epitope-MHC complex. The level of released IFN-γ correlates to the level of 
tumour/antigen specific immunity.  
 
Two weeks after vaccination (section 2.17), mice were euthanised via cervical 
dislocation and spleens were harvested under sterile conditions. A single-cell 
suspension of splenocytes was obtained by gentle mashing of the spleens using the 
flat end of a 2ml syringe plunger in a 70µm nylon cell strainer over a 50ml conical tube. 
Cells were flushed using T-cell media (TCM) (RPMI-1640 supplemented with 10% 
FCS, 1% Penicillin-Streptomycin, 1% essential amino acids and 1% sodium pyruvate) 
all from Sigma-Aldrich (MO-USA). Red blood cells were then lysed using red blood cell 
lysis buffer (Sigma-Aldrich, MO, USA). Splenocytes were then washed with PBS, spun 
down at 1,200rpm for 5 minutes then re-suspended at 5x106 cells/ml.  
 
Target cells and control cells (DT6606 and LLC respectively, or 32DP210 and SCC7) 
were trypsinised and treated with MMC for two hours at 37°C. They were then washed 
with PBS, spun down at 1,200rpm for 5 minutes and re-suspended in TCM at 5x105 
cells/ml.  
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In a round-bottomed 96-well plate, 100µl of the splenocytes re-suspension were co-
cultured in duplicate wells with 100µl of target cell solution giving an effector to target 
ratio of 10:1 (5x105 splenocytes and 5x104 target cells). Control wells contained 
splenocytes only in 200µl TCM. Plates were incubated for 72 hours at 37°C.  
 
Plates were spun down at 1,200rpm for 5 minutes and supernatant collected from each 
well. IFN-γ levels were measured using Murine IFN-γ ELISA kit (Biolegend, San Diego, 
CA, USA) following the manufacturer’s instructions.  
 
2.19 Immune cells phenotyping using flowcytometry 
Single cell suspension from spleen or inguinal lymph nodes was obtained as described 
above from vaccinated mice and washed twice in FACS buffer (PBS + 1% BSA). A 
master mix for each phenotyping group was prepared in advance (Table 2.6).  
 
1x106 cells of each organ were spun down and resuspended in the relevant master mix 
and incubated on ice away from light for 45 minutes. All antibodies were purchased 
from eBioscience (San Diego, CA, USA) and diluted 1:100 in FACS buffer. Stained 
cells were washed twice in FACS buffer and fixed in 2% formaldehyde diluted in FACS 
buffer. The latter was washed and cells were resuspended in FACS buffer and kept at  
4°C away from light over night when necessary. In a ddition, a representative sample of 
each organ was left unstained or stained in single colours and FMO (florescence minus 
one). These were used to set up voltages and gates. Data was acquired on BD 
LSRFortessa (BD Biosciences, San Jose, CA, USA).  
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Table 2.5 Labelled antibodies used for flowcytometry 
Marker Fluorochrome Laser and filter eBioscience ref  FMO 
Adaptive immunity 
CD3 PE Yellow-Green 582/15 12-0031-83  
CD4 PE Cy7 Yellow-Green 780/60 25-0041-82  
CD8 FITC Blue 530/30 11-0081-85  
CD44 eFluor 450 Violet 450/50 48-0441-82 Yes 
CD62L PerCP5.5 Blue 695/40 45-0621-82 Yes 
CXCR3 APC Red 670/14 17-1831-82 Yes 
 
Dendritic cells activation 
CD11c PerCP5.5 Blue 695/40 45-0114-80 Yes 
CD86 PE Yellow-Green 582/15 12-0862-81 Yes 
CD80 eFluor 450 Violet 450/50 48-0801-82 Yes 
MHCII APC Red 670/14 17-5321-81 Yes 
 
T cell homing 
CD3 PerCP5.5 Blue 695/40 35-0031-82  
CD4 PE Cy7 Yellow-Green 780/60 25-0041-82  
CD8 FITC Blue 530/30 11-0081-85  
α4β7 PE Yellow-Green 582/15 12-5887-82 Yes 
CCR9 APC Red 670/40 17-1991-82 Yes 
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Fig 2.2 Selecting for CD3+, CD4+ and CD8+ T cells.  
Flow cytometry was used to isolate T cells subtypes. The plots depict a representative 
sample of the gating strategy to isolate different T cell populations within the splenocytes 
obtained from a vaccinated mouse. A, B) Using FCS-A, SSC-A and FSC-H profiles, gates 
were drawn to exclude cell debris and cell duplets. C) CD3+ cells were selected within the 
single cell population. D) CD3+CD4+ and CD3+CD8+ T cells were selected using the 
relevant lasers and filters. 
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Intact cells were sorted using forward scatter area (FSC-A) and side scatter area (SSC-
A) profiles. Single cells were then selected using FSC-A and forward scatter height 
(FSC-H) profiles. A minimum of 20,000 events were recorded for each sample within 
the single cell gate. A detailed gating plan is explained in figures 2.2, 2.3, 2.4 and 2.5. 
Data was analysed using FlowJo V10 software (Tree Star Inc., San Carlos, CA, USA). 
 
Fig 2.3 Selecting effector memory and central memory T cell populations.  
Cells were stained using Anti-mouse CD44 and CD62L conjugated antibodies. The plots 
depict a representative sample of CD3+ CD4+ (as shown in Fig 2.2) splenocytes obtained 
from a vaccinated mouse. Cells were sorted using the blue 695/40 and violet 450/50 lasers. 
A) Using CD62L FMO sample, gate was set to separate CD62L+ and CD62L- cells.  B) 
Similarly, CD44+ and CD44- cells were identified.  C) A representative fully stained sample 
showing effector and central memory cells population.  
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2.20 Head and Neck tumours animal model 
SSC7, SSC-RLuc, B4B8, B4B8-RLuc, LY2 or Ly2-RLuc were trypsinised, washed with 
PBS and re-suspended to a concentration of 1x107-5x107 cell/ml in PBS. Mice were 
then injected with 100µl of the cell suspension either intra-orally in the right cheek or 
subcutaneously in the right lower flank giving a total of 1x106 to 5x106 cells /mouse 
depending on the cell line and individual experiment. Tumour growth, weight and 
clinical signs of lymph node metastasis were monitored twice a week. Mice were 
sacrificed according to Home Office guidelines if showing signs of tumour ulceration, 
bleeding, dyspnoea, distress or severe cachexia, if tumour size reached 1.44 cm2 or if 
Fig 2.4 Selecting α4β7+ and CCR9+ T cells.  
Cells were stained with anti-mouse α4β7 integrin PE and anti-mouse CCR9+ APC. A and 
C) histograms show FMO samples histograms that were used to set the gating. B and D) 
histograms shows representative sample of CD4+ cells (as isolated in Fig 2.2). The number 
depicts the percentage of positive cells out of the total population.   
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they lost 20% of total body weight. Tumours, lungs and draining lymph nodes were 
harvested and sent for histopathology analysis. 
 
2.20.1 Subcutaneous surgical excision model 
Tumour cells were injected as above. Tumours were carefully excised under 
continuous inhalation anaesthesia using isoflurane via nose cone once they reached 
200 mm3 in size or earlier if they started to ulcerate. A cuff of healthy skin and/or 
underlying muscle was excised as necessary to allow complete tumour clearance. 
Wounds were closed with interrupted sutures using 4.0 Vicryl Rapide™ (Polyglactin 
910, Ethicon, Edinburgh, UK) and Vetbond™ Tissue Adhesive (3M, St Paul, MN, 
USA). Buprenorphine (‘Vetergesic’, Alstoe Veterinary, York, UK), diluted 1:10 in 
Normal Saline (0.9% NaCl), was injected subcutaneously at an approximate dose of 
0.1 mg/kg to provide post-operative analgesia. Tumour recurrence, weight and clinical 
signs of lymph node metastasis were monitored twice a week. Mice were sacrificed 
and organs harvested as above. 
 
2.20.2 Orthotopic surgical excision model 
2x106 LY2 cells were injected orthotopically as above. Tumours were excised five days 
after injection via external skin incision under injection anaesthesia using ketamine 
(Narketane-10, 100 mg/ml, VÉTOQUINOL (UK) Ltd, Great Slade, UK) and xylazine 
(Rompun, 20 mg/ml, Bayer, Kiel, Germany) at an approximate dose of 100/10 mg/kg 
via intraperitoneal injection. Wound closure, post-operative care and monitoring were 
conducted as above.    
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2.21 Efficacy studies 
Mice were vaccinated as described previously (section 2.17). 
 
Two weeks after vaccination mice were injected subcutaneously in the left flank with 
5x106 viable DT6606 cells (unless otherwise specified) suspended in 100µl sterile PBS. 
Tumour growth and weight were monitored twice a week. Mice were sacrificed 
according to Home Office guidelines if showing signs of tumour ulceration, bleeding, 
dyspnoea, distress or severe cachexia, if tumour size reached 1.44 cm2 or if they lost 
20% of total body weight.  
 
3.22 Statistical analysis 
Statistical analysis was performed using Graphpad Prism 5 software. Specific statistical 
tests will be stated for each experiment in the results section. 
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Chapter three: Proof of concept 
 
3.1 Induction of tumour-specific immunity using virus-infected cancer cells 
3.1.1 Optimising the VICCV viral dose 
MTS assay was used to determine the required viral dose to kill 50 percent of DT6606 
and TB11381 murine pancreatic cancer cells. EC50 values were 12.8 pfu/cell and 0.35 
pfu/cell in DT6606 for Ad5 and VVL15 respectively and 23.1 pfu/cell and 0.05 pfu/cell 
for TB11381 (Fig. 3.1). To “guarantee” all tumour cells are killed by the virus and to 
prevent tumour developing in the vaccination site, an MOI=50 pfu/cell and 1 pfu/cell for 
Ad5 and VVL15 were selected. 
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Fig 3.1 Cytotoxicity of oncolytic viruses Ad5 and VVL15 in murine pancreatic cell 
lines.  
DT6606 and TB11381 cells were infected with 1:10 serial dilutions of Ad5 (top dilution 
MOI=1x104 pfu/cell) or VVL15 (Top dilution MOI=100 pfu/cell). Figures represent dose-
response curve for A) Ad5 in DT6606. B) VVL15 in DT6606. C) Ad5 in TB11381. D) VVL15 
in TB11381. E-F) EC50 values of both cell lines. 
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3.1.2 Induction of tumour specific immunity in a murine pancreatic cancer model 
An IFN-γ assay was performed to test the ability of the VICCV regimen to induce 
tumour-specific immune response in this murine pancreatic cancer model.  This assay 
is based on the release of IFN-γ when CD8 cells are activated by their cognate 
epitope-MHC complex. The level of released IFN-γ correlates to the level of antigen 
specific tumour immunity. 
 
Four groups of mice (n=3) were vaccinated with 2x106 DT6606 cells infected with 
various prime/boost viral combinations. Additionally, three control groups were 
vaccinated with PBS, cell lysate obtained by three freeze/thaw cycles or MMC-treated 
cells. When harvested, splenocytes were co-cultured with DT6606 cells, and the 
highest level of secreted IFN-γ, indicating the strongest anti-tumour response, was in 
the Ad/Ad group. This was significantly higher than all other treatment groups except 
Ad/VV (Fig. 3.2 A). This anti-tumour response appears to be tumour specific as the 
level of IFN-γ were significantly higher in the Ad/Ad group (p=0.0481, Paired t-test) and 
the Ad/VV group (p=0.032, Paired t-test) compared to the levels secreted from 
splenocytes co-cultured with LLC control cells (Fig 3.2 B). 
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3.2 Enhancing the safety of the vaccination regimen using secondary treatment 
The virus-infected cancer cells, as described above, are viable at the time of injection, 
albeit virus-infected. The success of the VICCV relies on the oncolytic virus, along with 
host defence mechanisms, to eradicate injected cells. Failure of these mechanisms 
represents a serious safety issue that would limit the translatability of the VICCV. To 
reduce such risk we added an extra safety measure by arresting the proliferation of the 
virus-infected cells using irradiation or chemotherapy agents.  
 
Fig 3.2 Ad/Ad and Ad/VV prime/boost VICCV combination induce the higest level of 
antitumour immunity.  
Seven groups of C57BL/6 mice (n=3) were vaccinated with PBS, DT6606 cell lysate or 
DT6606 tumour cells pre-treated with MMC, Ad5 or VVL15. Mice were boosted four weeks 
later.  Spleens were harvested and processed two weeks after boost. Isolated splenocytes 
were incubated for 72 hours with proliferation arrested A) DT6606 cells or B) control LLC 
cells. IFNγ production, as an indicator of CD8 activation, in the supernatant was measured 
by ELISA. IFNγ levels were normalized by subtracting background release from non-
stimulated splenocytes. One-way ANOVA with Tukey post-hoc test was used to compare 
groups. Columns represent the means ± SEM; asterisks denote the significance levels as 
comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
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To validate the irradiation dose required to arrest the proliferation of DT6606 cells a cell 
proliferation assay was performed. The results (Fig. 3.3 A) suggest that 30Gy dose 
was sufficient to inhibit growth in this cell line. 
 
 
 
MMC dose of 50µg/ml for 2 hours was previously validated by our group members 
[Ahmed et al. unpublished data] to be sufficient to arrest the proliferation of DT6606 
cells. The results were further confirmed (Fig 3.3 B). 
 
An MTX dose of 2µM applied for 24 hours was similarly validated by our group [El-
Khoury et al. unpublished data]. However the incubation period was not compatible 
with my VICCV regimen as life cycle of vaccinia virus is much shorter (8 hours). This 
Fig 3.3 Arrest of proliferation of murine pancreatic cancer cells using irradiation or 
chemotherapeutic agents.  
Figures represent DT6606 cell proliferation curve comparing number of viable cell over a 96 
hours period after treatment with A) Increasing dose of irradiation from 15Gy to 120 Gy B) 
50µg/ml MMC C) 2µM MTX applied for 2, 4 or 24 hours. D) Optimal doses were tested in 
TB11381 cell lines 
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means that by 24 hours many of the infected cells would have died and virus particles 
released into the supernatant potentially affecting the efficacy and safety of the VICCV. 
Shorter exposure periods of 2 and 4 hours were tested (Fig. 3.3 C) and both appear 
sufficient. 
 
These doses were confirmed in a second murine pancreatic cell line, TB11381 (Fig 3.3 
D). 
  
3.3 Induction of tumour specific immunity using virus-infected cancer cells plus 
secondary treatment 
3.3.1 Heterologous vaccination using Ad5 and VVL15 viruses 
To test the effect of the secondary treatment on the anti-tumour immunity of the 
VICCV, three groups of mice (n=3) were vaccinated with DT6606 infected with 
adenovirus prime and vaccinia virus boost. Two of these groups had a secondary 
treatment of Rx or MMC (MTX was introduced at a later stage in this study). Control 
groups of PBS and MMC-proliferation arrested cells were used. The results suggest 
that the secondary treatment had no effect on the level of the anti-tumour immunity 
induced by VICCV (Fig 3.4). Tumour specificity was similarly preserved. Comparing 
IFN-γ released when stimulated with DT6606 vs LLC showed significant difference 
across all treatment groups (Ad/VV group p=0.0097, Ad/VV+MMC group p=0.0182, 
Ad/VV group p=0.023, Paired t-test). 
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3.3.2 Homologous regimen using dl1520 virus 
The dl1520 mutant of adenovirus was chosen for this experiment as it is the only 
oncolytic virus licensed for clinical use (in China, H101 virus, Shanghai Sunway 
Biotech, China). The established safety record and the commercial availability of GM-
standard virus would make a potential clinical trial more feasible.  
 
Additionally we have tested MTX as a secondary treatment group due to the drug’s 
ability to induce immunogenic cell death [391] and enhance the anti-tumour immunity 
when combined with OVs [392]. 
Fig 3.4 Secondary treatment does not affect tumour-specific splenocyte activation 
post VICCV.  
Five groups of C57BL/6 mice (n=3) were vaccinated with PBS, MMC-treated DT6606 cells, 
Ad5-infected cells or Ad5 plus irradiation or MMC. Mice were similarly boosted four weeks 
later using VVL15.  Spleens were harvested and processed two weeks after boost. Isolated 
splenocytes were incubated for 72 hours with proliferation arrested A) DT6606 cells or B) 
control LLC cells. IFNγ production, as an indicator of CD8 activation, in the supernatant was 
measured by ELISA. IFNγ levels were normalized by subtracting background release from 
non-stimulated splenocytes. One-way ANOVA with Tukey post-hoc test was used to 
compare groups. Columns represent the means ± SEM; asterisks denote the significance 
levels as comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
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In this experiment, four groups of mice (n=3) were treated with homologous 
prime/boost VICCV using dl1520 alone or with one of three secondary treatments. In 
addition, to validate if the observed anti-tumour response was due to the virus infection 
or the secondary treatment, three control groups were introduced in which the cells 
were treated with Rx, MMC or MTX but no virus infection. PBS acted as a negative 
control. These results confirmed the previous finding that secondary treatment does 
not affect the induction of anti-tumour immunity and the specificity of the VICCV (Fig. 
3.5). 
 
 
 
 
Fig 3.5 Secondary treatment does not affect tumour-specific splenocyte activation 
post VICCV.  
Eight groups of C57BL/6 mice (n=3) were vaccinated with homologous prime/boost regimen 
using PBS or DT6606 cells treated with MMC, MTX, RX, dl1520 or dl1520 plus a secondary 
treatment. Spleens were harvested and processed two weeks after boost. Isolated 
splenocytes were incubated for 72 hours with proliferation arrested A) DT6606 cells or B) 
control LLC cells. IFNγ production, as an indicator of CD8 activation, in the supernatant was 
measured by ELISA. IFNγ levels were normalized by subtracting background release from 
non-stimulated splenocytes. One-way ANOVA with Tukey post-hoc test was used to 
compare groups. Columns represent the means ± SEM; asterisks denote the significance 
levels as comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
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Of note, DT6606 treated with MTX only resulted in high level anti-tumour immunity 
comparable to the virus treated groups. However, this was a single experiment with 
wide variation between the IFN-γ secreted from splenocytes derived from the three 
mice in the treatment group (as demonstrated with high error bars in fig 3.5 above). 
This high level expression was not seen in multiple comparable experiments performed 
by other team members [El-Khouri et al, unpublished data]. 
 
3.4 Efficacy of vaccination regimen 
3.4.1 Efficacy of various homologous and heterologous VICCV combinations 
To validate if the level of IFN-γ release from stimulated CD8 cells (section 3.1.2) 
correlates with clinical efficacy, five groups of mice (n=6 or 7) were vaccinated with 
either MMC-treated DT6606 cells or various homologous and heterologous Ad5 or 
VVL15-infected cells with a secondary treatment of MMC. Two weeks after boost mice 
were re-challenged with 5x106 DT6606 cells via subcutaneous injection in the contra 
lateral flank. Ad/Ad VICCV group showed significantly longer survival compared to 
other groups (Fig. 3.6 A). The shorter survival in the Ad/VV group was not related to 
tumour growth but to the death of four mice around day 35 due to fighting between 
male mice. In fact the Ad/Ad and Ad/VV groups were identical in terms of protection 
against tumour re-challenge (Fig. 3.6 B). 
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Fig 3.6 Efficacy study of VICCV using various homologous and heterologous virus 
combinations.  
5 groups of mice (n=6 or 7) were vaccinated with 2x106 MMC-treated DT6606 cells or 
heterologous VICCV regimen using the same number of cells infected with various 
combinations of AdV or VV plus MMC. Two weeks after boost, mice were re-challenged via 
subcutaneous injection with 5x106 viable DT6606 cells. A) Ad/Ad vaccination group resulted 
in significantly longer survival compared to other groups. B) The same data presented as 
recurrence rate after tumour re-challenge to account for mice dying from non-tumour related 
injuries. Fisher’s Exact test was used to compare various groups to control. p values were 
corrected to account for multiple group analysis. Asterisks denote the significance levels as 
comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
 
A 
 
 
 
 
 
B 
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3.4.2 Escalating tumour re-challenge dose 
High tumour burden remains a significant challenge facing any immunotherapy [393]. 
To test the limit of tumour burden our VICCV regimen can protect against, four groups 
of mice were vaccinated with DT6606 cells infected with adenovirus prime and vaccinia 
virus boost plus MMC secondary treatment. One control group vaccinated with MMC-
treated cells was also included. Two weeks later mice were challenged with an 
escalating dose of DT6606 subcutaneously. These results suggest that VICCV can 
protect against a tumour challenge three times the amount of the vaccination dose 
(Fig. 3.7).  
 
 
 
 
 
 
 
 
 
Fig 3.7 Escalating tumour re-challenge dose after VICCV.  
5 groups of mice (n=10 to 14) were vaccinated with 2x106 MMC-treated DT6606 cells or 
heterologous VICCV regimen using the same amount of cells infected with Ad5 plus MMC 
prime and VVL15 plus MMC boost. Two weeks after boost, mice were re-challenged via 
subcutaneous injection with increasing dose of viable DT6606 cells. VICCV appears to 
protect against tumour challenge three times the amount of vaccination dose. Fisher’s 
Exact test was used to compare various groups to control. p values were corrected to 
account for multiple group analysis. Aasterisks denote the significance levels as 
comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
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3.5 32Dp210 murine leukaemia model 
Having proved the efficacy of the VICCV in the pancreatic cancer model we wanted to 
test it in other models. We chose a leukaemia model as it is significantly different from 
other epithelial cancer models where the challenges are likely to be similar to 
pancreatic models. In addition, if this regimen proves successful, it will be easier to 
translate in leukaemia patients due to the ease of which we can harvest autologous 
cancer cells compared to pancreatic cancer. 
 
3.5.1 MTS and viral infectability 
To calculate the required viral dose for a safe VICCV regimen, MTS assay was 
performed on 32Dp210 cell line for both Ad5 and VVL15 giving EC50 values of 1945 
pfu/cell and 36 pfu/cell respectively (Fig 3.8 A). This is almost 500 times higher than 
that of pancreatic cell lines. Such high viral dose could lead to severe toxic effect on 
the mice. However, with the induction of secondary treatment, such high viral dose 
may not be necessary as the secondary treatment will arrest the proliferation of any 
cells not killed by the virus.   
 
We hypothesised that if a sufficient percentage of vaccine cells are infected there will 
be enough virus at the vaccination site to provide that “danger signal” required for an 
effective anti-tumour immunity.  
 
To test the infectibility of the 32Dp210 cells we infected them with AD5-GFP-PL11 and 
VVL15-RFP. Percentage of infected cells was determined using flow cytometry (Fig 3.8 
B-C). Based on these results we decide to use an MOI of 100 pfu/cell for Ad5 and 10 
pfu/cell for VVL15. 
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5.5.2 Secondary treatment 
Cell proliferation arrest using secondary treatment was validated (Fig. 3.8 D). These 
cells were sensitive to treatment with MMC, MTX or radiation at the doses used 
previously. 
 
 
 
 
 
 
 
 
3.5.3 Induction of tumour specific immunity 
C3H/HeN mice were vaccinated as described previously with 1x106 32Dp210 cells 
infected with various combinations of Ad5 and VVL15 plus MMC secondary treatment. 
Fig 3.8 Validation of cell kill, infectibility and cell proliferation arrest in 32Dp210 cell 
line.  
A) The graph represents EC50 values of both Ad5 and VVl15 in 32Dp210 cell line obtained 
from viral dose-response curve using MTS assay. B) Cell infectability represented as a 
percentage of fluorescent cells out of the total viable cells after infection with Ad5-GFP-PL11 
or VVL15-RFP with two different MOIs for each virus. C) Figure compares cell proliferation 
over a 96 hours period after treatment with Rx, MMC or MTX. 
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Unfortunately, our hypothesis was proven incorrect as there was no difference between 
viral groups and MMC control or between target and control cell line (Fig. 3.9).  
 
 
 
 
3.6 Effects of secondary treatment on oncolytic viruses 
Various aspects of the virus life cycle have been examined to establish how they are 
affected by the secondary treatment and to explain how that contributed to the 
difference in anti-tumour immune response observed between the DT6606 and the 
32Dp210 cell lines. All experiments were designed to match the in vivo work including 
viral dose, incubation period and secondary treatment.  
 
Fig 3.9 VICCV did not induce tumour specific immunity in the 32Dp210 model 
compared to control.  
Seven groups of C3H/HeN mice (n=3) were vaccinated with PBS, 1x 106 MMC-treated 
32dp210 cells or various homologous and heterologous prime/boost combinations using Ad5 
plus MMC and VVL15 plus MMC-treated cells. Spleens were harvested and processed two 
weeks after boost. Isolated splenocytes were incubated for 72 hours with proliferaion 
arrested A) 32Dp210 cells or B) control SCC7 cells. IFNγ production, as an indicator of CD8 
activation, in the supernatant was measured by ELISA. IFNγ levels were normalized by 
subtracting background release from non-stimulated splenocytes. One-way ANOVA with 
Tukey post-hoc test was used to compare groups. Columns represent the means ± SEM; 
asterisks denote the significance levels as comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 
0.01; *** p ≤ 0.001. 
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3.6.1 Viral replication 
The viral replication assay was performed. In the two pancreatic cell lines irradiation 
led to the reduction of the replication of both viruses while MMC and MTX treatments 
resulted in a near complete arrest of viral replication. The 32Dp210 cell line did not 
support adenovirus replication. On the other hand, vaccinia virus did replicate in these 
cells albeit to a much lower level compared to the other two (Fig 3.10 A-F). 
 
3.6.2 Viral proteins synthesis 
Despite the effect of secondary treatment on adenovirus replication, viral protein 
synthesis does not seem to be affected in both pancreatic cell lines. Similar levels of 
E1A protein were expressed regardless of the secondary treatment (Fig. 3.11 A and 
C). 
 
Vaccinia virus showed a similar picture for irradiation. However MMC and MTX 
treatment resulted in significant reductions in viral protein synthesis (Fig. 3.11 B and 
D). 
 
In comparison viral protein levels were significantly lower in the 32Dp210 cell lines (Fig. 
3.11 E and F) 
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Fig 3.10 The effect of secondary treatments on viral replication in DT6606, TB11381 
and 32Dp210 cell lines.  
DT6606 and TB11381 cells were infected with Ad5 at MOI=50 pfu/cell or VVL15 at MOI=1 
pfu/cell. 32Dp210 cells were infected at MOI 100 and 10 pfu/cell for Ad5 and VVL15 
respectively. Cells were then treated with Rx, MMC, MTX or left untreated as control. Cell 
lysate were then harvested at 24, 48, 72 and 96 hours. Viral titers were determined using 
TCID50 assay. Each virus/cell line/treatment/time point combination was performed in 
triplicates.  A, C and E) represent Ad5 replication in corresponding cell line. B, D and F) 
represent vaccinia virus replication. 
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Fig 3.11 The effect of secondary treatments on viral protein expression in 
DT6606, TB11381 and 32Dp210 cell lines.  
DT6606 and TB11381 cells were infected with Ad5 at MOI=50 pfu/cell or VVL15 at 
MOI=1 pfu/cell. 32Dp210 cells were infected at MOI 100 and 10 pfu/cell for Ad5 and 
VVL15 respectively. Cells were then treated with Rx, MMC, MTX or left untreated as 
control. Cell lysate were then harvested at 24 and 48 hours for western blotting using 
primary antibodies against adenovirus E1A protein and vaccinia virus. α-Tublulin was 
used as a loading control. A, C and E) represent Ad5 E1A protein expression in 
corresponding cell line. B, D and F) represent vaccinia virus protein expression. 
 
A     B 
 
 
      DT6606 
 
C     D 
 
 
      TB11381 
 
E     F  
 
 
      32Dp210 
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3.6.3 Viral DNA replication  
In the DT6606 cell line viral DNA replication was measured using qPCR. Copy 
numbers of viral DNA have more or less mirrored the pattern of protein expression (Fig 
3.12 A and B).  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Fig 3.12 The effect of secondary treatments on viral DNA reapplication in DT6606 cell 
line.  
DT6606 cells were infected with Ad5 at MOI=50 pfu/cell or VVL15 at MOI=1 pfu/cell. Cells 
were then treated with Rx, MMC, MTX or left untreated as control. Cell lysate were then 
harvested at 24, 48, 72 and 96 hours. DNA was extracted from and qPCR was performed as 
previously described. Each virus/cell line/treatment/time point combination was performed in 
triplicates. A) Graph represents adenovirus E1A gene copy numbers as compared to 
standard curve using purified viral DNA at 24 and 48 hours. B) Vaccinia virus VLTF-1 gene 
copy numbers calculated similarly. Columns represent the means ± SEM; asterisks denote 
the significance levels as comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
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3.7 Chapter three results summery 
 
• Virus infected cancer cell vaccine can induce tumour specific immune 
response. 
• The highest antitumour immune response was elicited in mice primed with cells 
pre-infected with adenovirus 
• There was no difference in immune response when mice were boosted with 
either adenovirus or vaccinia virus pre-infected cells 
• To enhance safety and arrest the proliferation of cancer cells prior to injection, a 
secondary treatment of radiation , mitomycin or mitoxantrone was added prior 
to injection 
•  Secondary treatment did not affect antitumour immunity 
• Irradiation resulted in a reduction of both adenovirus and vaccinia virus 
replication. Mitomycin and mitoxantrone led to complete arrest of viral 
replication. 
• Irradiation and mitomycin had limited effect on viral protein and viral DNA 
production while mitoxantrone reduced both.  
• Moving forward, mitomycin was chosen as a secondary treatment rather than 
mitoxantrone for the following reasons: 
o There was no difference in immune response, as measured by IFN-γ, 
between MTX and MMC treatment groups 
o MTX resulted in rapid cell killing. This varied depending on the cell line. 
MMC was more predictable, allowing better reproducibility of results 
o Cells treated with MMC survived longer in vitro. Although, not 
demonstrated in our experimental work, we anticipate the same to apply 
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in vivo allowing longer exposure of the infected tumour cells to the 
immune system 
o MTX interfered significantly in viral DNA and protein production 
especially in vaccinia virus making interpretation of results more difficult 
o MTX is known to induce an immunogenic cell death while MMC does 
not. It will be difficult to distinguish if elicited immune response is due to 
the viral infection or MTX.  
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Chapter four: Head and Neck cancer animal model 
 
For the purpose of this study three murine head and neck squamous cell carcinoma 
cell lines were obtained from our collaborators. These were SCC7, B4B8 and LY2 
cells. These cells were injected orthotopically or subcutaneously to establish tumours. 
The growth of these tumours can be easily monitored. However, lung and lymph node 
metastasis will require sacrificing a large number of animals to allow histopathological 
examination of these tissues. Alternatively, imaging techniques can be utilised to 
monitor metastasis. We decided to use luciferase bioluminescence due to its high 
sensitivity and fast turnaround time compared to CT or MRI scans.   
 
4.1 Establishment of Renilla luciferase stable head and neck cell lines 
B4B8, LY2 and SCC7 cell line were transfected with Renilla-puromycin lentivirus vector 
and selected in puromycin for 2 weeks. Luciferase expression was confirmed in all cell 
lines (Fig. 4.1)  
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4.2 HNSCC tumour model 
4.2.1 Subcutaneous tumour model 
To test the ability of Renilla luciferase-expressing cell lines to form tumours and 
metastasise to local lymph nodes and lungs, 1x106 cells were injected subcutaneously 
in the right flank of BALB/c mice. Tumour volumes were measured twice a week. Mice 
were culled according to Home Office guidelines. Tumours, lungs and ipsilateral 
inguinal lymph nodes were harvested at the point of sacrifice, fixed with 4% 
formaldehyde and sent to Barts Cancer Institute Pathology lab for histopathological 
haematoxylin and eosin (H&E) staining. We chose not to use the B4B8-RLuc cells for 
this model as it is known from literature that these cells do not metastasise [394] 
limiting its clinical relevance.  SCC7-RLuc tumours showed a rapid growth pattern 
leading to all mice being culled around three weeks after tumour inoculation. However 
Fig 4.1 Validation of luciferase expression from stable cell lines.  
1x105 SCC7, SCC7-RLuc, LY2, LY2-RLuc, B4B8 and B4B8-RLuc cells were plated in 
triplicate in a 24-wells plate and incubated overnight before being lysed. Coelenterazine was 
added to cell lysate and luminescence measured. Bar charts compares luminescence levels 
between parental and stable cell lines. Columns represent the means ± SEM. 
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there was no lung or node metastasis on histological examination (Fig 4.2). LY2-RLuc 
tumours did not grow and the experiment was terminated after 30 days.  
 
 
 
 
 
 
 
4.2.2 Orthotopic tumour model 
Similarly we tested the ability of the three luciferase tumour cell lines to form tumour 
and metastasise when implanted orthotopically in the right cheeks via intraoral injection 
under inhalation anaesthesia. Similar to the subcutaneous model, SCC7-RLuc cells 
showed a rapid growth pattern leading to the animals being culled at 17 days (Fig 4.3). 
Fig 4.2 Growth pattern and metastasis rates in subcutaneous HNSCC murine model.  
1x106 SCC7-RLuc and LY2-RLuc cells were injected subcutaneously in the flank of 5 
C3H/HeN and BALBC/c female mice respectively. Tumour sizes were measured twice a 
week. Lungs and lymph nodes were harvested at the point of animal sacrifice, fixed and 
stained to evaluate metastasis. The graph shows tumour growth curves over time. Points 
represent the means. Error bars represent SEM. ↓Xn indicates the number of animals culled 
at that time point. Table shows the number of animals developing primary tumours, lung 
metastasis and lymph node metastasis. 
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Only one animal showed a single lung metastatic tumour nodule (Fig 4.4) but no lymph 
nodes metastasis was seen.  
 
 
 
 
 
 
Fig 4.3 Growth pattern and metastasis rates in orthotopic HNSCC murine model.  
1x106 SCC7-RLuc, B4B8-RLuc and LY2-RLuc cells were injected in the cheek of 5 
C3H/HeN and BALBC/c female mice respectively. Tumour sizes were measured twice a 
week. Lungs and lymph nodes were harvested at the point of animal sacrifice, fixed and 
stained to evaluate metastasis. The graph shows tumour growth curves over time. Points 
represent the means. Error bars represent SEM. ↓Xn indicates the number of animals culled 
at that time point. Table shows the number of animals developing primary tumours, lung 
metastasis and lymph node metastasis. 
  
110
 
 
 
 
B4B8-RLuc showed a very slow growth with the animals surviving more than two 
months (Fig 4.3). Only two of the LY2-RLuc injected animals developed palpable 
tumours and even these two grow very slowly. However these mice started to lose 
weight around 30 days following tumour injection and started to develop large cervical 
lymph nodes (Fig 4.5). Histological examination showed 60% and 80% rate of lung and 
lymph nodes metastasis respectively (Fig 4.5). 
Fig 4.4 Lung metastasis from SCC7-RLuc orthotopic tumour 
H&E high power view (x100) showing single metastatic SCC7-RLuc tumour deposit (arrow) 
within lung tissue.  
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Fig 4.5 Lung and lymph node metastasis in orthotopic LY2-RLuc tumour model.  
H&E high power view (x100) showing A) disseminated metastatic LY2-RLuc tumour 
infiltration (arrows) within the lung tissue. B) metastatic nodule in the lung. C) lymph node 
metastasis destroying the normal architecture of the node.  D and E) post-mortem 
examination showing primary tumour (T) and metastatic cervical lymph nodes (white 
arrows).   
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To validate if the slow growth rate in LY2-RLuc and B4B8-RLuc tumours is related to 
luciferase transfixion or low number of injected tumour cells, we repeated the 
experiment using both parental and luciferase-expressing cell lines at a higher dose of 
5x106 cells. B4B8 tumours (Fig 4.6) showed an initial rapid growth phase followed by 
tumour regression. Tumours started to grow gradually after 30 days. On the other hand 
B4B8-RLuc tumours showed a very slow steady growth rate. Neither cell line showed 
lung or lymph node metastasis (Fig 4.7).  
 
 
Fig 4.6 Histological features of B4B8 tumours. 
H&E high power view (x200) of the orthotopic B4B8 tumours. T) shows tumour cells, s) 
shows fibrous stroma and arrow) shows infiltrating immune cells. 
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LY2 tumours grew rapidly with the animal losing weight rapidly leading to cull at 2 
weeks. 4 out of 5 mice developed lymph node metastasis but no lung metastasis. This 
was likely related to rapid tumour progression and early culls. The luciferase-
expressing cells did not grow into overt tumours except in one animal, however all 
animals had lung and lymph node metastasis (Fig 4.8). We suspect that the absence of 
primary tumours is likely to be a detection failure as the tumours are likely to be very 
small and embedded in the masseter muscle. This speculation is supported by our 
Fig 4.7 Growth pattern and metastasis rates in orthotopic B4B8 murine tumour model.  
5x106 B4B8 and B4B8-RLuc cells were injected in the cheek of 5 BALBC/c female mice. 
Tumour sizes were measured twice a week. Lungs and lymph nodes were harvested at the 
point of animal sacrifice, fixed and stained to evaluate metastasis. The graph shows tumour 
growth curves over time. Points represent the means. Error bars represent SEM. ↓Xn 
indicates the number of animals culled at that time point. Table shows the number of animals 
developing primary tumours, lung metastasis and lymph node metastasis. 
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observation in subcutaneous tumours where all mice developed tumours, albeit small 
(Fig 4.12).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.8 Growth pattern and metastasis rates in orthotopic LY2 murine tumour model.  
5x106 LY2 and LY2-RLuc cells were injected in the cheek of 5 BALBC/c female mice. 
Tumour sizes were measured twice a week. Lungs and lymph nodes were harvested at the 
point of animal sacrifice, fixed and stained to evaluate metastasis. The graph shows tumour 
growth curves over time. Points represent the means. Error bars represent SEM. ↓Xn 
indicates the number of animals culled at that time point. Table shows the number of animals 
developing primary tumours, lung metastasis and lymph node metastasis. 
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4.3 Surgical excision model 
4.3.1 Subcutaneous surgical excision model 
Head and neck cancer management often include surgical excision of the tumour 
followed by chemoradiotherapy. These tumours have a high rate of neck node 
metastasis [395, 396] and the most mortalities are due to locoregional recurrence 
[397]. To simulate these clinical characteristics we implanted LY2, LY2-RLuc, SCC7 or 
SCC7-RLuc tumour cells subcutaneously in the right flank of the animal. Tumour were 
excised when approaching 1 cm2 in size (maximum size permitted by Home Office is 
1.44 cm2) or if ulcerating. Animals were monitored for change of weight, local tumour 
recurrence and lymph node involvement. Animals were culled according to guidelines. 
Tumours, lungs and lymph nodes were harvested as previously described. 
 
SCC7 and SCC7-RLuc tumours (Fig 4.9) were injected subcutaneously at a dose of 
1x106 cells. They grew rapidly and recurred after surgical excision. However the 
animals remained healthy throughout with no weight loss or cachexia.  Animals were 
culled due tumours reaching the maximal permitted size. None of these animals 
developed lung or lymph node metastasis (Fig 4.10). 
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Fig 4.9 Histological features of SCC7 tumours. 
A) H&E low power view (x40) of subcutaneous SCC7 tumours. B) high power view (x200) 
showing tumour cells (T) invading subcutaneous muscles (arrow). C and D) Similar features 
were seen in SCC7-RLuc tumours. 
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Fig 4.10 Growth pattern, recurrence and metastasis rates in surgical excision HNSCC 
murine model using SCC7 cells.  
1x106 SCC7 and SCC7-RLuc cells were injected subcutaneously in the right flank of 5 
C3H/HeN female mice. Tumour sizes were measured twice a week and excised around 1 
cm2 in size or if ulcerating. Animals were monitored for tumour recurrence and weight loss.  
Lungs and lymph nodes were harvested at the point of animal sacrifice, fixed and stained to 
evaluate metastasis. The graph shows tumour growth curves over time. Points represent the 
means. Error bars represent SEM. Open circles represent time point of tumour excision. 
Arrows represent time point of animal cull. Xn indicates the number of animal treated or 
culled at that time point. Table shows the number of animals developing primary and 
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LY2 tumours (Fig 4.11) showed a slow initial growth pattern followed by a rapid 
increase in volume. All tumours showed tumour ulceration and invaded underlying 
muscle. Animals became severely cachexic around 10 days after excision and they all 
showed lung and node metastasis. The pattern was fairly similar, albeit slower, in the 
LY2-RLuc tumours (Fig 4.12). 
 
 
 
Fig 4.11 Histological features of LY2 tumours. 
A) H&E low power view (x40) of subcutaneous LY2 tumours showing less cohesive tumour front 
and more soft tissue infiltration compared to SCC7 tumours (Fig 4.9). B) high power view (x200) 
showing tumour cells (T) invading subcutaneous muscles (arrow) and subcutaneous fat tissue 
(f). C and D) Similar features were seen in LY2-RLuc tumours. 
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4.3.2 Orthotopic surgical excision model 
To improve the clinical relevance of the model we attempted to excise orthotopic LY2 
tumours five days after inoculation. We chose the parental cell line as it reliably forms 
overt primary tumours that can be easily palpated unlike the luciferase stable cells 
which grow into very small tumours. The model was technically challenging as the 
surgical procedure had to be performed under injection rather than inhalation 
Fig 4.12 Growth pattern, recurrence and metastasis rates in surgical excision HNSCC 
murine model using LY2 cells.  
5x106 LY2 and LY2-RLuc cells were injected subcutaneously in the right flank of 5 BALB/c 
female mice. Tumour sizes were measured twice a week and excised around 1 cm2 in size 
or if ulcerating. Animals were monitored for tumour recurrence and weight loss.  Lungs and 
lymph nodes were harvested at the point of animal sacrifice, fixed and stained to evaluate 
metastasis. The graph shows tumour growth curves over time. Points represent the means. 
Error bars represent SEM. Open circles represent time point of tumour excision. Arrows 
represent time point of animal cull. Xn indicates the number of animal treated or culled at 
that time point. Table shows the number of animals developing primary and recurrence 
tumours, lung metastasis and lymph node metastasis. 
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anaesthesia. By the time of excision, tumours were found to involve the masseter 
muscle and complete tumour resection couldn’t be achieved without damaging 
adjacent structures despite the use of surgical microscope. Two of the five mice 
perished in the perioperative period, likely due to the trauma of surgery and injection 
anaesthesia. The remaining three mice developed early recurrence and they had to be 
culled at day 16. By then they all had lung and lymph node metastasis (Fig 4.13).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.13 Timeline, recurrence and metastasis rates in Orthotopic surgical excision 
HNSCC murine model using LY2 cells.  
2x106 LY2 and LY2-RLuc cells were injected orthotopically in the right cheek of 5 BABL/c 
female mice. Tumour were excised at day 5. Animals were monitored for tumour recurrence 
and weight loss.  Lungs and lymph nodes were harvested at the point of animal sacrifice, 
fixed and stained to evaluate metastasis. The graph shows time line of tumour progress. 
Table shows the number of animals developing primary and recurrence tumours, lung 
metastasis and lymph node metastasis. 
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4.4 Chapter four results summery 
• SCC7 and SCC7-RLuc tumours grow rapidly, do not metastasis and the 
animals remain well with no weight loss or cachexia. It is a poorly 
representative model of head and neck clinical scenario 
• B4B8 orthotopic tumours grow slowly and do not metastasise. It can be used to 
represent a locally advancing HNSCC tumour 
• LY2 tumours grow rapidly and metastasise to lung and lymph nodes 
• LY2-RLuc cells do not always form overt primary tumours and they grow slower 
than the parental cells  tumours 
• LY2-RLuc tumours retained their capacity to metastasise to lung and lymph 
nodes. 
• Neither of the LY2 models is a true representative of HNSCC. However the can 
be used to simulate certain aspects of the human disease 
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Chapter five: Virus-infected cancer cell vaccine in head and 
neck cancer model 
 
5.1 In vitro validation of the suitability of the HNSCC cell lines for oncolytic virus 
treatment  
5.1.1 MTS cell killing assay in B4B8 and LY2 parental and luciferase-expressing cells 
Based on our findings in the proof of concept experiments we decided, for the 
remainder of this study, to use a homologous adenovirus vaccination regimen using 
our triple deleted adenovirus AdTD-C. As discussed in the introduction the unique triple 
gene deletions; E1ACR2, E1B19K and E3gp19K of this virus resulted in a safer and 
cancer selective virus with the ability to induce higher levels of antitumour immunity 
when compared to the dl1520 virus. 
 
MTS cell killing assay was used to confirm the susceptibility of the three HNSCC cell 
lines to oncolytic viral infection and to estimate the MOI required for the vaccination 
experiments. B4B8, LY2 were sensitive to adenovirus infection with EC50 values of 11 
and 6 pfu/cell respectively, while SCC7 was very resistant (Fig 5.1 A-D). All cell lines 
were sensitive to vaccinia virus infection with EC50 values between 0.2 and 1.6 pfu/cell 
(Fig 5.1 E-H). Based on these results we decided to use an MOI=20 pfu/cell to infect 
B4B8 and LY2 cells for vaccination and efficacy experiments. Due to its resistance to 
adenovirus infection and the shortcomings of its animal model, SCC7 cell line was 
deemed unsuitable for this study. 
 
In order to confirm that transduction and stable expression of Renilla luciferase does 
not interfere with the infectability of the B4B8 and LY2 cell lines, MTS assay was 
repeated and resulted in similar EC50 values compared to the parental cell lines (Fig 
5.2).  
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Fig 5.1 MTS cell killing assay in murine HNSCC cell lines.  
B4B8, LY2 and SCC7 cells were infected with 1:10 serial dilutions of AdTD-C (top dilution 
MOI=1x104 pfu/cell) or VVL15 (Top dilution MOI=100 pfu/cell). Figures represent dose-
response curve for A) AdTD in B4B8, B) AdTD in LY2, C) AdTD in SCC7, D) EC50 values of 
all cell lines, E) VVL15 in B4B8, F) VVL15 in LY2, G) VVL15 in SCC7 and  H) EC50 values 
of all cell lines. Data shown is a representative of two independent experiments.  
Fig 5.2 MTS cell killing assay in murine 
HNSCC cell lines stably expressing 
Renilla luciferase.  
B4B8-RLuc and LY2-RLuc cells were 
infected with 1:10 serial dilutions of 
AdTD-C (top dilution MOI=1x103 pfu/cell). 
Figures represent dose-response curve 
for A) AdTD in B4B8 -RLuc, B) AdTD in 
LY2-RLuc and  C) EC50 values of both 
cell lines.  
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5.1.2 Adenovirus replication   
Replication assay showed that AdTD-C virus did not replicate in any of the HNSCC cell 
lines tested (Fig 5.3). However, as demonstrated in the pancreatic cancer models, the 
lack of viral replication did not result in reduction of the antitumour immunity, as 
measured by IFN-γ release assay, or vaccine efficacy.  This will be further tested later 
in this chapter. 
 
5.1.3 Validation of VICCV safety  
Before embarking on in vivo experiments we validated if the combination of adenovirus 
infection and mitomycin can kill tumour cells to prevent a tumour developing at the 
vaccination site. This is particularly relevant in this model as adenovirus is replication-
deficient in the LY2 and B4B8 cell lines. Our results showed that the LY2 cells were 
more sensitive to Adenovirus infection compared to B4B8, which goes to confirm our 
MTS dose-response results. In the LY2 cells both adenovirus and combination 
treatment resulted in similar levels of cell killing over 4 days periods. In contrast, 
adenovirus infection alone was not sufficient to kill all the B4B8 cells (Fig 5.4). 
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Fig 5.3 Triple-deleted adenovirus does not replicate in murine HNSCC cells.  
B4B8, B4B8-RLuc, LY2 and LY2-RLuc cells were plated in 6-well plate at 2x105 cell/well and 
infected with AdTD-C at MOI=20 pfu/cell. Cell lysate were then harvested at 24, 48, 72 and 
96 hours. Viral titers were determined using TCID50 assay. Each virus/cell line/ time point 
combination was performed in triplicates. Figures represent A) AdTD-C replication in B4B8 
cell lines. B) AdTD-C replication in LY2 cell lines. Points represent mean TCID50 value of 
three corresponding wells. Error bars represent standard error of means (SEM). 
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5.2 Induction of tumour specific immunity following VICCV in HNSCC model 
5.2.1 VICCV using parental cell lines infected with AdTD virus 
An IFN-γ release assay was performed to test the ability of the VICCV to induce an 
antitumour immunity in HNSCC animal model. Five groups of animals (n=3) were 
vaccinated with either PBS, mitomycin (MMC)-treated LY2 (50 µg/ml), MMC-treated 
B4B8 cells, LY2 cells pre-infected with AdTD virus (MOI=20 pfu/cell) then treated with 
MMC or B4B8 cells pre-infected with AdTD virus then treated with MMC. Two weeks 
later the animals received homologues boost injections following the same protocol. 
Two weeks later mice were culled and IFN-γ release assay was performed. 
 
Splenocytes were stimulated using either the same cell line or cross-stimulated using 
the other HNSCC cell line to represent an autologous vs. allogeneic vaccination. In 
addition, to test the specificity of the antitumour immunity splenocytes were stimulated 
Fig 5.4 Combination of AdTD virus infection and mitomycin can kill HNSCC cells. 
5x104 B4B8 and LY2 cells were plated in triplicate in 24-wells plate. They were then infected 
with AdTD at MOI=20pfu/cell; treated with MMC or a combination. 100µl of MTS reagent 
was added to each well at 24, 48, 72 and 96 hours and incubated at 37° for one hour. All 
plates at different time points were normalised by subtracting background values. The mean 
optical density of untreated cells at 24 hours was designated the arbitrary unit 100%. 
Change of optical density correlates to the metabolic activity of viable cells in each well. 
Points represent the mean of three corresponding wells. Error bars represent standard error 
of means (SEM). 
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a control cell line, JC (murine breast cancer). Antitumour immunity was significantly 
higher in mice vaccinated with B4B8 + AdTD + MMC compared to those vaccinated 
with MMC-treated cells or naïve mice (Fig. 5.5 A). When cross-stimulated with LY2 
cells, this group (B4B8 + AdTD + MMC) expressed the highest level of IFN-γ. However 
that was not statistically different to the levels expressed when stimulated with the JC 
control cell line (Fig. 5.5 B-C).  
 
 
 
 
 
 
 
 
 
 
 
 
On the other hand, mice vaccinated with LY2 + AdTD + MMC resulted in a general 
trend of a higher IFN-γ expression compared to the other two vaccination groups, 
however that did not reach statistical significance (Fig 5.6). Splenocytes expressed 
higher levels of IFN-γ when stimulated with the “autologous” B4B8 cells, compared to 
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Fig 5.5 VICCV using B4B8 cells induced a tumour-specific immune response.  
Three groups of BALB/c mice (n=3) were vaccinated with PBS, MMC-treated B4B8 cells or 
AdTD pre-infected cells with MMC secondary treatment. Mice were similarly boosted two 
weeks later.  Spleens were harvested and processed two weeks after boost. Isolated 
splenocytes were incubated for 72 hours with proliferation-arrested A) B4B8 cells, B) LY2 
cells or C) JC control cells. IFNγ production, as an indicator of CD8 activation, in the 
supernatant was measured by ELISA. IFNγ levels were normalized by subtracting 
background release from non-stimulated splenocytes. One-way ANOVA with Tukey post-hoc 
test was used to compare groups. Columns represent the means ± SEM; asterisks denote 
the significance levels as comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
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LY2 and JC cells. However that did not reach statistical difference. This observation 
suggests that B4B8 cells are probably more immunogenic compared to LY2.  
 
 
 
 
 
 
 
 
 
 
 
5.2.2 VICCV using LY2-RLuc cells infected with AdTD virus 
As mentioned previously, the LY2-RLuc cell line appears to be suitable model to 
simulate recurrence of HNSCC following surgical excision. To evaluate the suitability of 
this cell line for VICCV regimen we repeated the IFN-γ assay using LY2-RLuc cell line. 
We hoped that this experiment would help us understand if increased immunogenicity 
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Fig 5.6 VICCV using LY2 cells did not result in a statistically significant tumour-
specific immune response.  
Three groups of BALB/c mice (n=3) were vaccinated with PBS, MMC-treated LY2 cells or 
AdTD pre-infected cells with MMC secondary treatment. Mice were similarly boosted two 
weeks later.  Spleens were harvested and processed two weeks after boost. Isolated 
splenocytes were incubated for 72 hours with proliferation-arrested A) LY2 cells, B) B4B8 
cells or C) JC control cells. IFNγ production, as an indicator of CD8 activation, in the 
supernatant was measured by ELISA. IFNγ levels were normalized by subtracting 
background release from non-stimulated splenocytes. One-way ANOVA with Tukey post-hoc 
test was used to compare groups. Columns represent the means ± SEM; asterisks denote 
the significance levels as comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
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(likely against Luciferase) is behind the slower growth rate of the LY2-RLuc tumours 
compared to the parental cells. 
 
Mice were vaccinated with LY2-Rluc cells treated with mitomycin or the same cells pre-
infected with AdTD virus then treated with mitomycin. Splenocytes harvested from 
vaccinated animals were then stimulated in vitro with either LY2-RLuc or parental cells. 
Immune responses as measured by means of secreted IFN-γ showed no significant 
difference between the two cell lines (Fig 5.7 A and B).  
 
In addition we stimulated these splenocytes with either B4B8 or B4B8-RLuc cells. The 
immune response appears to be much stronger (**, One way ANOVA with Tuekey post 
hoc test) compared to that generated against LY2 cells (Fig 5.7 C and D). These 
results appear to be very similar to that obtained when mice were vaccinated with LY2 
parental cells as shown in the previous section. 
 
Since immune response does not appear to be the cause for reduced growth rate of 
LY2-RLuc tumours we investigated if the transfixion of luciferase has led to growth 
attenuation of these cells. Cell proliferation rate appears to be slower in luciferase- 
expressing cells and more so in LY2 compared to B4B8 (Fig 5.8). 
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Fig 5.7 VICCV using LY2-RLuc cells did not result in a statistically significant tumour-
specific immune response.  
Three groups of BALB/c mice (n=3) were vaccinated with PBS, MMC-treated LY2-RLuc cells 
or AdTD pre-infected cells with MMC secondary treatment. Mice were similarly boosted two 
weeks later.  Spleens were harvested and processed two weeks after boost. Isolated 
splenocytes were incubated for 72 hours with proliferation-arrested A) LY2-RLuc cells, B) 
LY2 cells, C) B4B8-RLuc cells or D) B4B8 cells. IFNγ production, as an indicator of CD8 
activation, in the supernatant was measured by ELISA. IFNγ levels were normalized by 
subtracting background release from non-stimulated splenocytes. One-way ANOVA with 
Tukey post-hoc test was used to compare groups. Columns represent the means ± SEM; 
asterisks denote the significance levels as comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 
0.01; *** p ≤ 0.001. 
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5.3 Efficacy of VICCV in HNSCC model 
In order to test the therapeutic potential of the VICCV we used an orthotopic tumour 
model using B4B8 parental cell line. This model simulates a clinical scenario of an 
advanced unrespectable head and neck cancer. We injected 3x106 cells into the right 
cheek of 30 female BALB/c mice. Mice were grouped in cages of five animals. Cages 
were randomised to treatment group using random numbers generator on Microsoft 
Excel software. Tumour size and weight were recorded twice a week. Mice were 
sacrificed according to Home Office guidelines if showing signs of tumour ulceration, 
bleeding, dyspnoea, distress or severe cachexia, if tumour size reached 1.44 cm2 or if 
they lost 20% of total body weight. Vaccination with AdTD pre-infected B4B8 cells with 
a secondary treatment of mitomycin C resulted in an initial regression and slower 
tumour growth (Fig. 5.9 A). On the long term the vaccinated group had a longer median 
survival of 79 days compared to 64 and 69.5 of the PBS and MMC groups respectively. 
Although this difference did not reach statistical significance there was a trend of longer 
Fig 5.8 Stable transduction of Renilla luciferase gene attenuates the proliferation of 
LY2 cells.   
2x105 cells of B4B8, B4B8-RLuc, LY2 and LY2-RLuc were plated in triplicate in 6-wells plate. 
Number of viable cells was counted at 24, 48 and 72 hours. Two-way ANOVA with 
Bonferroni post-hoc test was used to compare groups. Points represent the means ± SEM; 
asterisks denote the significance levels as comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 
0.01; *** p ≤ 0.001. 
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survival in the AdTD vaccination group with three animals surviving past 110 days (Fig. 
5.9 B).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.9 Efficacy of VICCV in B4B8 orthotopic tumour model.  
Three groups of BALB/c mice (n=10) were inoculated in the right check with 3x106 B4B8 
tumour cells. Seven days later animals were randomized to three groups and vaccinated 
with PBS, MMC-treated B4B8 cells or AdTD pre-infected cells plus MMC secondary 
treatment. Mice were similarly boosted two weeks later. A) The graph shows tumour 
growth rates of the three treatment groups until the first animal in each group was culled. 
Two-way ANOVA with Bonferroni post-hoc test was used to compare groups. Points 
represent the means ± SEM; asterisks denote the significance levels as comparing: ns 
non-significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. B) Kaplan-Meier survival curve 
showing a trend of longer survival in the AdTD vaccination group although that did not 
reach statistical significance.  
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5.4 Functional mechanisms 
To help understand the mechanisms behind the antitumour efficacy we looked into 
different aspects of the immunological response including T cell response, PAMPs 
expression and antigen presenting cells activation. 
 
5.4.1 Immunophenotyping of T cells following VICCV using parental cell lines 
Using fluorescence cytometry, we investigated the changes in the immune profile of T 
cells is response to vaccination with virus-infected HNSCC cells in comparison to naïve 
mice and those vaccinated with MMC-treated matching cells. From the same 
experiment described above, splenocytes were stained for CD3, CD4 and CD8 
expression and profiled into cytotoxic T cells (CD3+ CD8+) and helper T cells (CD3+ 
CD4+) following the gating strategy discussed previously. 
 
In addition, cells were stained for the secondary lymphoid organs homing cell adhesion 
molecule, CD62L and the cell surface glycoprotein, CD44. The latter is upregulated in 
activated memory T cells while CD62L expression is lost in both effector and effector 
memory T cells allowing them to circulate in peripheral tissues. Based on these two 
markers TEM was defined as CD44HiCD62LLo and TCM as CD44HiCD62LHi.  
 
Vaccination with B4B8 cells pre-infected with AdTD virus plus MMC showed a 
significantly higher level of CD8+ TEM population, and a proportional drop in TCM 
population, compared to naïve mice or those vaccinated with MMC-treated cells. 
Similar trend was observed in mice vaccinated with LY2 cells however it did not reach 
statistical significance (Fig 5.10 A).  
 
Similar pattern was observed in the CD4+ population albeit less dramatic (Fig. 5.10 B). 
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5.4.1.2 Immunophenotyping of T cells following VICCV LY2-RLuc cells 
Similarly we investigated the immune response and the change in T cell populations 
following VICCV using LY2-RLuc cells pre-infected with AdTD virus then treated with 
MMC. Treatment group mice showed a small increase in effector memory population 
more prominent in the cytotoxic CD8+ population (Fig 5.11). These changes were 
almost identical to those seen with parental cells. 
Fig 5.10 VICCV with HNSCC cells pre-infected with AdTD virus enhances the 
generation of an effector memory T cell population.  
Five groups of BALB/c mice (n=3) were vaccinated with PBS, MMC-treated LY2 cells, 
MMC-treated B4B8 cells or AdTD pre-infected cells with MMC secondary treatment. Mice 
were similarly boosted two weeks later.  Spleens were harvested and processed two 
weeks after boost. Splenocytes were stained for CD3, CD4, CD8, CD44, CD62L and 
profiled into various populations using fluorescence cytometry. A) shows the change of the 
CD8+ TEM and TCM populations. The top row shows a dot plot three representative mice 
one of each LY2 treatment group. The second row shows the B4B8 vaccination groups. 
The third row shows the gating strategy using samples stained for all colours except CD44 
(FMO CD44) or CD62L (FMO CD62L). The bar charts depict the effector and central 
memory populations out of the total CD8+ population in the LY2 and B4B8 vaccination 
groups. B) shows similar changes in the CD4+ populations. One-way ANOVA with Tukey 
post-hoc test was used to compare groups. Columns represent the means ± SEM; 
asterisks denote the significance levels as comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 
0.01; *** p ≤ 0.001. 
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5.4.2 PAMPs expression following AdTD infection of HNSCC cells 
Despite lack of replication in B4B8 and LY2 cells, early and late viral proteins were still 
being expressed following triple-deleted adenovirus infection. In keeping with our 
previous findings in pancreatic cancer model, mitomycin C doesn’t appear to affect 
viral proteins production (Fig 5.12) 
 
Fig 5.11 VICCV with LY2-RLuc cells pre-infected with AdTD virus induces a modest 
increase in CD8+ effector memory T cell population.  
Three groups of BALB/c mice (n=3) were vaccinated with PBS, MMC-treated LY2 cells or 
AdTD pre-infected cells with MMC secondary treatment. Mice were similarly boosted two 
weeks later.  Spleens were harvested and processed two weeks after boost. Splenocytes 
were stained for CD3, CD4, CD8, CD44, CD62L and profiled into various populations 
using fluorescence cytometry. The top row shows dot plots of CD4+ cells of three 
representative mice one of each LY2 treatment group. The second row shows CD8+ 
population. The third row shows the gating strategy using samples stained for all colours 
except CD44 (FMO CD44) or CD62L (FMO CD62L). The bar charts depict the effector and 
central memory populations out of the total CD4+ and DC8+ population. One-way ANOVA 
with Tukey post-hoc test was used to compare groups. Columns represent the means ± 
SEM; asterisks denote the significance levels as comparing: ns non-significant; * p ≤ 0.05; 
** p ≤ 0.01; *** p ≤ 0.001. 
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5.4.3 Dendritic cells activation following VICCV 
As part of the experiment described in section 5.2.1, local draining lymph nodes (right 
inguinal) were harvested and mashed to obtain a lymphocyte single cell suspension as 
described previously. Cells were stained for CD11c, MHCII and CD80. Dendritic cells 
population (CD11c+ MHCII+) was isolated using fluorescence cytometry. In addition 
dendritic cells were isolated similarly from the harvested spleens of these mice. The 
percentage of activated dendritic cells (CD80+) was determined. There was no 
demonstrable difference between the various vaccination groups (Fig 5.13). While 
disappointing, the result was not surprising as the total number of DCs out of the total 
lymphocytes population was very small. This meant that the slightest change to the 
FACS gating led to large percentage variation. In addition, the samples were obtained 
Fig 5.12 Mitomycin C secondary treatment does not affect viral protein production 
following AdTD infection.  
B4B8 and LY2 cells were treated with MMC at a concentration 50µg/ml, infected with AdTD 
at MOI=20 pfu/cell or a combination treatment. Cell lysate were then harvested at 24 and 48 
hours for western blotting using primary antibodies against adenovirus E1A and hexon 
proteins. Venculin was used as a loading control. 
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two weeks after boost injection, while DC activation and migration to local lymph nodes 
to activate T cells takes place within the first few days after antigen exposure.  
 
 
 
 
 
 
 
 
 
Fig 5.13 Dendritic cell activation following VICCV.  
Five groups of BALB/c mice (n=3) were vaccinated with PBS, MMC-treated LY2 cells, 
MMC-treated B4B8 cells or AdTD pre-infected cells with MMC secondary treatment. Mice 
were similarly boosted two weeks later.  Spleens and inguinal lymph nodes were 
harvested and processed two weeks after boost. Cells were stained for CD11c, MHCII 
and CD80. Dendritic cells (CD11c+ MHCII+) were selected using florescence cytometry. 
The graphs show the percentage of activated DCs (CD80+) of the total DC populations in 
A, B) spleens and D, C) lymph nodes. One-way ANOVA with Tukey post-hoc test was 
used to compare groups. Columns represent the means ± SEM; asterisks denote the 
significance levels as comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
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5.5 Chapter five results summery 
• LY2 and B4B8 cells, and their luciferase-expressing sub-clones, were susceptible 
to adenovirus infection 
• Neither cell supported adenovirus replication 
• Adding a secondary treatment of mitomycin did not affect the virus ability to kill 
these cells. In fact, combination treatment resulted in better cell killing in B4B8 
cells.  
• Mitomycin treatment did not affect viral protein production as seen previously in 
pancreatic cell lines. 
• Vaccinating mice with B4B8 cells pre-infected with AdTD virus and treated with 
mitomycin resulted in significantly higher immune response compared to 
vaccination with cells treated with mitomycin alone. This immune response was cell 
line-specific. 
• Vaccination with LY2 pre-infected cells showed a trend towards a better immune 
response however that did not reach statistical significance. Similar results were 
seen in mice vaccinated with LY2-RLuc cells  
• In mice vaccinated with LY2 or LY2-RLuc, there was a much higher IFN-γ response 
against B4B8 cells. This suggests that B4B8 cells are more immunogenic 
compared to LY2 
• Vaccination with B4B8 cells pre-infected with AdTD virus led to an increase in 
effector memory T cells of both CD4+ and CD8+ phonotypes  
•  This effect was much smaller in LY2 vaccinated mice 
• In an orthotopic tumour model of B4B8 our vaccination regimen led to a decrease 
in tumour growth rate and a trend towards increased survival of these mice   
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Chapter six: Construction and validation of CCL25-armed triple-
deleted adenovirus 
 
6.1 Construction of AdTD-CCL25  
Following cloning of CCL25 gene in the AdTD vector (Section 2.6 and appendix I), 16 
colonies were picked from AdTD-CCL25 transformation and grown in Kanamycin-LB 
overnight. DNA of each was extracted and PCR performed to confirm insertion and 
direction of CCL25 gene (Fig 6.1).  
 
Based on the PCR results, DNA extracted from colonies 2 and 4 were sent for 
sequencing using E3gp19K primers. Correct sequence and direction of colony 2 was 
confirmed, while colony 4 showed a missing segment of the CCL25 gene. AdTD-
CCL25 vector from colony 2 and AdTD were linearised using PacI digestion (Appendix 
I). They were subsequently transfected into HEK293 cells to produce AdTD-CCL25 
and AdTD-C viruses. CPE was observed for both viruses. 100 µl of each transfection 
lysate was used for virus primary expansion. DNA of each virus was extracted from 
residual lysate and used to validate the triple-gene deletion and the insertion of CCL25 
gene using Ad5 standard primers set [388] and CCL25 primers respectively (Fig 6.2, 
6.3 and table 6.1). In addition supernatant was collected to confirm CCL25 expression 
using ELISA. 
 
Once confirmed both viruses were expanded, purified, titrated and stored at -80°C.  
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Fig 6.1 PCR confirmation and clone selection of AdTD-CCL25 virus.  
Following cloning of murine CCL25 gene into the AdTD vector, DNA was transformed into 
competent E.Coli and grown on kanamycin-agar dish overnight. DNA extracted using 
Miniprep kit, PCR performed and run on agarose gel. A) a schematic diagram of the CCL25 
gene inserted into the gp19k region of the Adenovirus  E3 gene. Broken lines demonstrate 
the three primers sets and the expected size of the PCR fragments. ADP is Adenovirus 
death gene.  B) shows PCR product of all colonies using E3gp19k external primers. Correct 
colonies showed a smaller amplified fragment compared to AdTD control. C) shows further 
PCR confirmation using CCL25 internal primers. All tested colonies showed a DNA 
fragment identical in size to CCL25 control. D) shows PCR product obtained using 
E3gp19k forward primer and CCL25 reverse primer. Amplified fragment shows correct 
orientation of inserted CCL25 gene in colonies 2, 4,15 and 16. 
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Table 6.1 Expected size of amplified segment using standard Ad5 primer sets  
Set 5’ binding site 3’ binding site Target gene Expected size (bp) 
1 476 853 E1A start 377 
2 767 1029 E1A-CR2 262 
3 1069 1453 E1A end 384 
4 1554 2086 E1B-19k 532 
5 2073 2440 E1B-55k 367 
6 2383 3434 E1B-55k 1051 
7 29915 31038 E3B 1123 
8 28715 29135 E3-gp19K 420 
 
  
Fig 6.2 Vectors map showing gene deletions and PCR expected fragment size using 
Ad5 standard 1-8 primer sets and CCL25 primers.  
AdTD-C and AdTD-CCL25 vectors used in this study in comparison to wild type adenovirus 
5 (WT Ad5). Triple gene deletions at E1A-CR2, E1B-19k and E3GP19K regions are 
demonstrated. AdTD-C backbone virus contains Chloramphenicol resistant gene (Chlr) for 
clone selection flanked by two SwaI restriction enzyme sites.  AdTD-CCL25 virus was cloned 
by insertion of CCL25 gene at that region to replace the Chlr gene (Section 2.6). Ad5 
standard 1-8 primer sets and CCL25 primers with expected PCR fragment size are 
demonstrated on the relevant regions. 
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Fig 6.3 Validation of AdTD-CCL25 virus using Ad5 standard 1-8 primer pairs and 
CCL25 primers.  
DNA was extracted from purified AdTD-C and AdTD-CCL25 virus using DNA extraction kit 
and used for PCR reactions. Reduction of fragment size can be seen in primer set 2 and 4 
corresponding to deletions in the E1A-CR2 and E1B-19k regions respectively. Primer set 8 
showed complete lack of DNA amplification as the reverse primer of the set is within the 
deleted region. Finally PCR reaction using CCL25 primers confirmed the presence of CCL25 
gene in the expanded and purified virus. 
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6.2 Validation of replication, CCL25 expression and cell killing of AdTD-CCL25 in 
a panel of pancreatic cancer cell lines 
6.2.1 Replication and CCL25 expression at MOI=50 pfu/cell 
CCL25 expression was confirmed in murine pancreatic cancer cell lines; DT6606, 
TB11381 and pkpa130200 (Fig 6.4 A). Interestingly, CCL25 was expressed from all 
cell lines however its levels dropped dramatically after 24 hours. Although this 
observation could be explained by the short half-life of CCL25 in culture at 37°C, one 
would expect a continuous CCL25 expression from viral-infected cells to replenish the 
denatured protein until all cells are dead. In addition, viral replication assay of the same 
experiment showed no replication of AdTD-CCL25 virus in all three cell lines contrary 
to the control virus (Fig 6.5 B). 
 
Various different hypotheses could explain these results; they will be discussed in 
details in the discussion chapter (Chapter 8). In this experiment we used our 
adenovirus standard dose of MOI=50pfu/cell. To get a more accurate replication data 
and to help explain the previous findings we proceeded to perform an MTS cell killing 
assay. This will quantify the potency of each virus and allow us to repeat replication 
assay based on the EC50 value. 
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Fig 6.4 AdTD viral replication and CCL25 expression in murine pancreatic cancer 
cells.  
DT6606, TB11381 and pkpa130200 cells were plated in 6-well plate at 2x105 cell/well and 
infected with AdTD-C and AdTD-CCL25 virus at MOI=50 pfu/cell. A-C) represents change of 
viral titer over a 4 days time course. Cell lysate were then harvested at 24, 48, 72 and 96 
hours. Viral titers were determined using TCID50 assay. Each virus/cell line/ time point 
combination was performed in triplicates. D-E) shows change of CCL25 expression as 
measured by ELISA in the supernatant over the time course. Points represent mean CCL25 
concentration or TCID50 value of three corresponding wells. Error bars represent standard 
error of means (SEM). 
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6.2.2 MTS cell killing assay in murine and human pancreatic cell lines 
MTS cell killing assay in DT6606, TB11381 and in human pancreatic cancer cell lines 
SUIT2 showed AdTD-CCL25 to be ten to twenty folds more potent at cell killing (Fig 
6.5).  
 
 
 
 
 
 
 
 
 
 
 
Fig 6.5 AdTD-CCL25 virus is more potent than AdTD-C virus in murine and human 
pancreatic cancer cell lines.  
DT6606, TB11381 and SUIT2 cells were infected with 1:10 serial dilutions of AdTD-C or 
AdTD-CCL25 (top dilution MOI=1x103 pfu/cell) Figures represent dose-response curve for 
both viruses in A) DT6606, B) TB11381 and C) SUIT2. D) Represents EC50 values of all cell 
lines. Un-paired t-test was used to compare the two viruses. Columns represent EC50 value 
means ± SEM; asterisks denote the significance levels as comparing: ns non-significant; * p 
≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
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6.2.3 Viral replication and CCL25 expression at MOI=10 pfu/cell 
 
 
 
 
 
 
 
 
 
Fig 6.6 AdTD viral replication and CCL25 expression in murine and human pancreatic 
cancer cells.  
DT6606 and SUIT2 cells were plated in 6-well plate at 2x105 cell/well and infected with 
AdTD-C and AdTD-CCL25 virus at MOI=10 pfu/cell. In addition one group of DT6606 cells 
were treated with mitomycin C for 2 hours after viral infection before all samples were 
washed twice in PBS. A-C) represents change of viral titer over a 4 days time course. Cell 
lysate were then harvested at 24, 48, 72 and 96 hours. Viral titers were determined using 
TCID50 assay. Each virus/cell line/ time point combination was performed in triplicates. D-E) 
shows change of CCL25 expression as measured by ELISA in the supernatant over the time 
course Points represent mean CCL25 concentration or TCID50 value of three corresponding 
wells. Error bars represent standard error of means (SEM). 
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Repeat viral replication and CCL25 expression using a lower MOI of 10 pfu/cell 
showed a more persistent CCL25 expression and confirmed both viruses to be 
replication competent in DT6606 and SUIT2 cell lines. Additionally, treating DT6606 
cells with mitomycin after viral infection did not affect CCL25 expression but reduced 
viral replication in keeping with previous results (Fig 6.6). This will be particularly 
relevant to in vivo experiments as our vaccination protocol requires a secondary 
treatment with mitomycin prior to injection. 
 
6.3 Comparing AdTD-C vs AdTD-CCL25 cell killing potency 
Daily microscopic examination of the various experiments described in the previous 
section highlighted an interesting observation that AdTD-CCL25 virus kills cultured 
cells at a much faster rate compared to the AdTD-C control virus. Since CCL25 gene 
expression is driven by an early adenovirus promoter we hypothesised that CCL25 will 
start to be expressed in the first few hours after viral infection. This was confirmed in 
the DT6606 cell line (Fig 6.7). A synergistic effect of CCL25 and adenovirus infection 
could explain the early cell killing witnessed and be behind the increase potency of the 
AdTD-CCL25 virus. 
 
  
 
 
Fig 6.7 CCL25 expression levels peak at 
12 hours after AdTD-CCL25 infection. 
DT6606 cells were plated in 6-well plate at 
2x105 cells/well and infected with AdTD-
CCL25 virus at MOI=10 pfu/cell. The 
graph shows change of CCL25 as 
measured by ELISA in the supernatant 
over a 24 period. Points represent mean 
CCL25 concentration of three separate 
wells. Error bars represent standard error 
of means (SEM). 
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To further examine this hypothesis, the difference of cell killing ability over a time 
course and its correlation with CCL25 levels was tested in a panel of murine cell lines. 
Combining these results showed cells behaved in three distinctive manners.  
 
The first group including CMT93, DT6606, TB11381 and 4T1, cell lines were all 
sensitive to adenovirus infection with the AdTD-CCL25 virus consistently more potent 
at cell killing compared to control virus. CCL25 levels peaked early on then dropped 
sharply towards the late time points (Fig 6.8 and 6.9). SCC7 and CT26 cells were more 
resistant to adenovirus infection with no demonstrable difference between the two 
viruses. It appears that these two cell lines support early virus protein synthesis evident 
by the gradual increase of CCL25, under the control of early virus promoter, over the 
time course (Fig 6.10). LLC cells were not sensitive to either virus and did not express 
CCL25 (Fig 6.11) suggesting that the resistant to adenovirus infection is probably at 
the cell entry level. In addition, CCL25 was not directly toxic in two of the most 
sensitive cell lines; TB11381 and CMT93 (Fig 6.12) 
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Fig 6.8 AdTD-CCL25 is more potent than AdTD-C in a panel of murine cell lines. 
DT6606, TB11381, CMT93 and 4T1 cells were plated in 6-well plates at 2x105 cell/well and 
infected with AdTD-C and AdTD-CCL25 virus at MOI=10 pfu/cell. The percentage of cell 
killing was then determined using an MTS assay. Points represent the mean percentage of 
dead cells in three independent wells. Error bars represent standard error of means (SEM). 
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Fig 6.9 CCL25 expression in a panel of murine cell lines.  
DT6606, TB11381, CMT93 and 4T1 cells were plated in 6-well plates at 2x105 cell/well and 
infected with AdTD-C and AdTD-CCL25 virus at MOI=10 pfu/cell. The graphs show change 
of CCL25 as measured by ELISA in the supernatant over a four days time course. Points 
represent mean CCL25 concentration of three independent wells. Error bars represent 
standard error of means (SEM). 
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Fig 6.10 AdTD-CCL25 shows similar potency compared to AdTD-C in a CT26 and 
SCC7 murine cell lines.  
Cells were plated in 6-well plates at 2x105 cell/well and infected with AdTD-C and AdTD-
CCL25 virus at MOI=10 pfu/cell. The percentage of cell killing was then determined using an 
MTS assay. A) shows the percentage of dead cells over a 4 days time course. Points 
represent the mean percentage of dead cells in three independent wells. B) show change of 
CCL25 as measured by ELISA in the supernatant over the same time period. Points 
represent mean CCL25 concentration of three independent wells. Error bars represent 
standard error of means (SEM). 
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Fig 6.11 LLC cells are resistant to adenovirus infection and do not express CCL25 
after AdTD-CCL25 virus infection.  
LLC cells were plated in 6-well plates at 2x105 cell/well and infected with AdTD-C and AdTD-
CCL25 virus at MOI=10 pfu/cell. The percentage of cell killing was then determined using an 
MTS assay. A) shows the percentage of dead cells over a 4 days time course. Points 
represent the mean percentage of dead cells in three independent wells. B) shows change 
of CCL25 as measured by ELISA in the supernatant over the same time period. Points 
represent mean CCL25 concentration of three independent wells. Error bars represent 
standard error of means (SEM). 
Fig 6.12 CCL25 has no direct toxicity on TB11381 and CMT93 cells.  
Cells were plated in 6-well plates at 1x105 cell/ml. CCL25 was added to the media to a final 
concentration of 1, 5 and 10 ng/ml. Untreated cells were used as a control. 24 hours later 
cells were trypsinised and the number of viable cells was determined using trypan blue 
exclusion test. The same was repeated at 48 and 72 hours. Points represent the mean 
number of viable cells in three independent wells. Error bars represent standard error of 
means (SEM). 
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Miss A Ibrahim, an MsC student working in our lab under my supervision, further 
examined the differences between AdTD-C and AdTD-CCL25 at every stage of the 
viral life cycle. Her results showed an earlier viral DNA replication and protein 
expression in cells infected with AdTD-CCL25. Her results are included in appendix III. 
 
Due to the fact that the main direction of my work is cancer vaccination, I did not 
continue this line of investigation. It would have been interesting to look at the 
difference between these cell lines and their response to adenovirus infection at a 
molecular level especially that both adenovirus and CCL25/CCR9 interacts with the 
PI3K/AKT and the Notch signalling pathways [398-402]. This work will be continued by 
other colleagues in our lab as further insight into these relations might provide a 
platform to enhance the oncolytic efficacy of adenovirus. 
 
6.4 Chapter six results summery 
• CCL25 gene was successfully cloned into the E3 region of a triple-deleted 
adenovirus  
• The cloned virus AdTD-CCL25 was replication competent 
• CCL25 expression was confirmed in a panel of murine cell lines infected with the 
recombinant virus 
• AdTD-CCL25 appears to be more potent at killing cancer cells compared to the 
parental virus due to an unknown mechanism 
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Chapter seven: VICCV using CCL25-armed adenovirus in 
pancreatic cancer model 
 
Antitumour immune response induction following distant vaccination, as is the case in 
our regimen, may not be sufficient to induce a therapeutic effect. T cells trafficking to 
the tumour site is an integral part of the immune response.  As discussed previously, 
we hypothesised that vaccination with pancreatic tumour cells pre-infected with AdTD-
CCL25 might induce expression of α4β7 integrin on T cells leading to pancreas 
homing. This is mediated via the interaction between α4β7 and cell adhesion molecule 
MAdCAM-1. 
 
7.1 Induction of α4β7 T cell phenotype following vaccination with DT6606 cells 
pre-infected with AdTD-CCL25 
7.1.1 Subcutaneous vaccination 
Our first aim was to test the hypothesis that T cell priming in the presence of the gut 
homing chemokine, CCL25, will result in the induction of gut homing phenotype 
characterised by the expression of α4β7 integrin. Mice were vaccinated 
subcutaneously with DT6606 cells pre-infected with AdTD-CCL25. Control groups of 
PBS, MMC-treated cells and AdTD-C pre-infected cells were also tested. One week 
after boost mice were culled and lymphocytes were isolated from spleen, local draining 
lymph node (inguinal) and distant lymph node (axillary). Percentage of CD8+ cells (Fig 
7.1) and CD4+ cells (Fig 7.2) expressing α4β7 integrin and CCR9 were determined 
using florescence cytometry. This preliminary experiment showed an increase level of 
T cells expressing α4β7 integrin (more prominent in CD4+) in the AdTD-CCL25 group 
but no increase in CCR9. This would suggest that this increase is the result of CCL25 
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expression from pre-infected tumour cells rather than an upregulation of its receptor 
CCR9.  
 
7.1.2 Intraperitoneal vaccination 
In parallel to the above-mentioned experiment we vaccinated mice via intraperitoneal 
injections. This is based on the hypothesis that vaccination within a certain anatomical 
location would induce a homing phenotype to that organ. However, this was not the 
case for either CD8 (Fig 7.3) or CD4 (Fig 7.4) cells. Expression of α4β7 integrin was 
fairly similar between all vaccination groups with no added advantage of CCL25. 
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Fig 7.1 Induction α4β7 integrin on CD8+ T cells following subcutaneous vaccination 
with tumour cell pre-infected with AdTD-CCL25.  
Four groups of C57BL/6 mice (n=3) were subcutaneously vaccinated with homologous 
prime/boost regimen using PBS or DT6606 cells treated with MMC, AdTD-C or AdTD-
CCL25 virus. Spleens were harvested and processed one week after boost. Isolated 
splenocytes were stained for CD3, CD4, CD8, α4β7 and CCR9. Percentage of CD3+CD8+ 
cells expressing α4β7 in A) spleen, B) inguinal and C) axillary lymph nodes. D, E and F) 
represent CCR9 expression in the same organs respectively. One-way ANOVA with Tukey 
post-hoc test was used to compare groups. Columns represent the means ± SEM; 
asterisks denote the significance levels as comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 
0.01; *** p ≤ 0.001. 
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Fig 7.2 Induction α4β7 integrin on CD4+ T cells following subcutaneous vaccination 
with tumour cell pre-infected with AdTD-CCL25.  
Four groups of C57BL/6 mice (n=3) were subcutaneously vaccinated with homologous 
prime/boost regimen using PBS or DT6606 cells treated with MMC, AdTD-C or AdTD-
CCL25 virus. Spleens were harvested and processed one week after boost. Isolated 
splenocytes were stained for CD3, CD4, CD8, α4β7 and CCR9. Percentage of CD3+CD4+ 
cells expressing α4β7 in A) spleen, B) inguinal and C) axillary lymph nodes. D, E and F) 
represent CCR9 expression in the same organs respectively. One-way ANOVA with Tukey 
post-hoc test was used to compare groups. Columns represent the means ± SEM; 
asterisks denote the significance levels as comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 
0.01; *** p ≤ 0.001. 
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Fig 7.3 Induction α4β7 integrin on CD8+ T cells following intraperitoneal vaccination 
with tumour cell pre-infected with AdTD-CCL25.  
Four groups of C57BL/6 mice (n=3) were subcutaneously vaccinated with homologous 
prime/boost regimen using PBS or DT6606 cells treated with MMC, AdTD-C or AdTD-
CCL25 virus. Spleens were harvested and processed one week after boost. Isolated 
splenocytes were stained for CD3, CD4, CD8, α4β7 and CCR9. Percentage of CD3+CD8+ 
cells expressing α4β7 in A) spleen, B) mesenteric and C) axillary lymph nodes. D, E and F) 
represent CCR9 expression in the same organs respectively. One-way ANOVA with Tukey 
post-hoc test was used to compare groups. Columns represent the means ± SEM; 
asterisks denote the significance levels as comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 
0.01; *** p ≤ 0.001. 
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Fig 7.4 Induction α4β7 integrin on CD4+ T cells following intraperitoneal vaccination 
with tumour cell pre-infected with AdTD-CCL25.  
Four groups of C57BL/6 mice (n=3) were subcutaneously vaccinated with homologous 
prime/boost regimen using PBS or DT6606 cells treated with MMC, AdTD-C or AdTD-
CCL25 virus. Spleens were harvested and processed one week after boost. Isolated 
splenocytes were stained for CD3, CD4, CD8, α4β7 and CCR9. Percentage of CD3+CD4+ 
cells expressing α4β7 in A) spleen, B) mesenteric and C) axillary lymph nodes. D, E and F) 
represent CCR9 expression in the same organs respectively. One-way ANOVA with Tukey 
post-hoc test was used to compare groups. Columns represent the means ± SEM; 
asterisks denote the significance levels as comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 
0.01; *** p ≤ 0.001. 
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7.2 Efficacy of AdTD-CCL25 VICCV in transgenic pancreatic cancer model 
Based on our observation above and on the increased potency of the AdTD-CCL25 
virus (MTS assay results in chapter 6), we decided to use an MOI=5 pfu/cell and a 
subcutaneous vaccination route. Since treatment with mitomycin C does not seem to 
affect CCL25 production (Fig 6.7) and to enhance the safety of vaccination regimen we 
decided to add MMC as a secondary treatment in keeping with our previous work. KPC 
transgenic mice ( K-rasLSL.G12D/+; p53R172H/+; PdxCre) were vaccinated subcutaneously at 
10 weeks old with DT6606 cell pre-infected with either AdTD-CCL25 or AdTD-C control 
virus and then treated with MMC. These mice recapitulate the natural sequence of 
genetic and histological changes seen in human pancreatic cancer. By 10 weeks of 
age they would have developed early pancreatic ductal adenocarcinoma (PDAC) 
tumours. Due to the aggressive disease progression in this mouse model we decided 
to boost after two weeks rather than four.  
 
Our efficacy experiment showed a trend towards increased survival in both viral 
vaccination groups compared to PBS (Fig. 7.5). Although this survival increase did not 
reach statistical difference, it represents a positive result in our opinion. In this 
experiment we vaccinated the mice with 2x106 pre-infected cells in keeping with our 
previous work. There is convincing evidence from clinical trials that antitumour immune 
response is dose-dependent in whole cell vaccines [403]. We speculate that 
vaccination with higher dose will enhance our vaccine efficacy. This will be necessary 
to overcome the aggressive tumour process in KPC mice. 
 
On the other hand, there was no difference between the two viral vaccine groups. This 
will be examined in detail in the following sections. 
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7.3 Gut homing and antitumour immunity induction by VICCV regimen using 
DT6606 and AdTD-CCL25 virus 
In the efficacy experiment, cells were treated with MMC prior to injection. In addition we 
used a lower MOI and a shorter prime-boost interval. These were different from the 
conditions used in the preliminary experiment described above (section 7.1).  
 
Concurrently with the efficacy study we tried to validate that these changes did not 
affect the induction of α4β7 integrin on T cells. 
 
Fig 7.5 VICCV using AdTD-CCL25 virus did not increase survival in KPC mice.  
KPC mice were randomised at weaning into one of three treatment groups: PBS (n=10), 
VICCV using AdTD-C (n=12) virus or AdTD-CCL25 (n=13). Each mouse in the VICCV 
groups received a subcutaneous injection of 2x106 DT6606 cells pre-infected with 
corresponding virus at MOI=5 pfu/cell then treated with MMC for 2 hours at ten weeks old 
then boosted two weeks later. Mice were monitored twice a week and culled according to 
home office guidelines. Kaplan-Meier survival curve showing no overall difference between 
the groups (p>0.05). The author designed the experiment, wrote the protocol and analysed 
the data. This experiment was performed by staff at the Sino-British Research Centre for 
Molecular Oncology, Zhengzhou University, Zhengzhou, China. 
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Mice were vaccinated with DT6606 cells pre-infected with AdTD-CCL25 or AdTD-C 
control virus and treated with MMC. The experiment had two arms with the only 
difference is the prime/boost interval. 
 
7.3.1 Induction of antitumour immunity 
In keeping with our previous experience, vaccinated mice showed stronger anti-tumour 
immune response, evident by higher levels of IFN-γ secreted from ex vivo splenocytes 
stimulated by tumour cells, compared to PBS-vaccinated mice. There was no 
difference in IFN-γ levels between the two viruses or the different prime/boost intervals 
(Fig 7.6). 
 
 
 
 
 
 
 
 
 
 
Fig 7.6 Induction of antitumour immunity following VICCV using AdTD-CCL25 virus. 
Six groups of C57BL/6 mice (n=3) were subcutaneously vaccinated with homologous 
prime/boost regimen using PBS or DT6606 cells treated with AdTD-C or AdTD-CCL25 virus 
followed by a secondary treatment with mitomycin C. Mice were boosted either two or four 
weeks later.  Spleens were harvested and processed one week after boost. Isolated 
splenocytes were incubated for 72 hours with proliferation-arrested DT6606 cells or LLC 
cells. IFNγ production, as an indicator of CD8 activation, in the supernatant was measured 
by ELISA. IFNγ levels were normalized by subtracting background release from non-
stimulated splenocytes. Two-way ANOVA with Bonferroni post-hoc test was used to 
compare groups. Columns represent the means ± SEM; asterisks denote the significance 
levels as comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
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7.3.2 Induction of T cells gut-homing phenotype  
In the same experiment described above, splenocytes were stained for CD3, CD4 and 
CD8. Percentage of T cells expressing α4β7 integrin was determined using 
fluorescence cytometry. Contrary to our preliminary experiment we didn’t detect any 
difference between the AdTd-CCL25 group and the control virus or even the PBS 
treated mice (Fig 7.7).  
 
 
 
 
 
 
 
Of note, the percentage of CD8+ cells expressing α4β7 integrin in this experiment was 
significantly higher compared to all other experiments including the PBS group. This is 
Fig 7.7 Induction α4β7 integrin on CD8+ and CD4+ T cells following subcutaneous 
vaccination with tumour cell pre-infected with AdTD-CCL25.  
In the same experiment described above (fig 7.6) isolated splenocytes were stained for 
CD3, CD4, CD8, α4β7 and CCR9. Fig A) shows the percentage of CD3+CD8+ cells 
expressing α4β7. Fig B) shows expression on CD3+CD4+. The two groups in each graph 
represent different prime/boost intervals. Two-way ANOVA with Bonferroni post-hoc test 
was used to compare groups. Columns represent the means ± SEM; asterisks denote the 
significance levels as comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
  
167
likely to be caused by technical issues at flowcytometry stage as the Laser voltages 
were set too narrowly which meant differentiating various populations was difficult 
despite the kind assistance of our FACS Lab manager. The experiment was included 
for the sake of completion. However the results interpretation needs to be treated with 
caution. 
 
7.4 VICCV using AdTD-CCL25 virus in TB11381 cell line. 
Following the border line results of the efficacy studies and the failure to induce α4β7 in 
the matching functional study we decided to test our hypothesis using TB11381 murine 
pancreatic cell line.  
 
In two separate experiments, C57BL/6  mice were vaccinated using TB11381 cells pre-
infected with AdTD-CCL25 and treated with mitomycin C. In the first experiment an 
MOI=5 was used (Fig 7.8) and an MOI=25 in the second (Fig 7.9). Neither dose 
induced a higher expression of α4β7 integrin compared to control treatments.  
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Fig 7.8 Induction α4β7 integrin on CD8+ and CD4+ T cells following subcutaneous 
vaccination with TB11381 tumour cell pre-infected with AdTD-CCL25.  
Four groups of C57BL/6 mice (n=3) were subcutaneously vaccinated with homologous 
prime/boost regimen using PBS or DT6606 cells treated with mitomycin C, AdTD-C or 
AdTD-CCL25 virus at an MOI=25 pfu/cell followed by a secondary treatment with mitomycin 
C. Mice were boosted four weeks later.  Spleens were harvested and processed one week 
after boost. Isolated splenocytes were stained for CD3, CD4, CD8 and α4β7. The graph 
shows the percentage of CD3+CD8+ or CD3+CD4+ cells expressing α4β7. One-way 
ANOVA with Tukey post-hoc test was used to compare groups. Columns represent the 
means ± SEM; asterisks denote the significance levels as comparing: ns non-significant; * p 
≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
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Due to the lack of efficacy and the negative results in three separate experiments we 
decided not to pursue this line of investigation any further. The disparity between these 
experiments and our preliminary one will be discussed in further detail in the discussion 
chapter. 
 
7.5 Dissection of the immune response following VICCV using TB11381 cells 
7.5.1 Induction of antitumour immunity 
Repeating the α4β7 induction experiment using TB11381 cells provided us with an 
opportunity to validate the VICCV regimen in a third model in addition to the DT6606 
and the HNSCC cell lines tested in previous chapters.  
Fig 7.9 Induction α4β7 integrin on CD8+ and CD4+ T cells following subcutaneous 
vaccination with TB11381 tumour cell pre-infected with AdTD-CCL25.  
Four groups of C57BL/6 mice (n=3) were subcutaneously vaccinated with homologous 
prime/boost regimen using PBS or DT6606 cells treated with mitomycin C, AdTD-C or 
AdTD-CCL25 virus at an MOI=5 pfu/cell followed by a secondary treatment with mitomycin 
C. Mice were boosted four weeks later.  Spleens were harvested and processed one week 
after boost. Isolated splenocytes were stained for CD3, CD4, CD8 and α4β7. The graph 
shows the percentage of CD3+CD8+ or CD3+CD4+ cells expressing α4β7. One-way 
ANOVA with Tukey post-hoc test was used to compare groups. Columns represent the 
means ± SEM; asterisks denote the significance levels as comparing: ns non-significant; * p 
≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
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Vaccination of mice with TB11381 cells pre-infected with either virus resulted in an 
increased IFN-γ production from splenocytes when incubated with their cognate 
tumour cells. This was a tumour-specific response as stimulation with LLC cells 
resulted in significantly lower levels (AdTD p=0.0099, AdTD-CCL25 p= 0.0413 ) (Fig 
7.10) 
 
 
 
 
 
 
 
 
 
7.5.2 Immunophenotyping of T cell response following VICCV using TB11381 cells 
Similar to our findings in HNSCC model, vaccination with pre-infected TB11381 cells 
resulted in an increase in effector memory T cells (CD44HiCD62LLo) in both CD4+ (Fig 
7.11) and CD8+ Cells (Fig 7.12). 
Fig 7.10 VICCV using TB11381 cells induced a tumour-specific immune response. 
Four groups of C57BL/6 mice (n=3) were vaccinated with PBS, MMC-treated TB11381 cells 
or cells pre-infected with AdTD-C or AdTD-CCL25 virus plus MMC secondary treatment. 
Mice were similarly boosted four weeks later.  Spleens were harvested and processed one 
week after boost. Isolated splenocytes were incubated for 72 hours with proliferation-
arrested TB11381 cells or LLC control cells. IFNγ production, as an indicator of CD8 
activation, in the supernatant was measured by ELISA. IFNγ levels were normalized by 
subtracting background release from non-stimulated splenocytes. One-way ANOVA with 
Tukey post-hoc test was used to compare groups. Columns represent the means ± SEM; 
asterisks denote the significance levels as comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 
0.01; *** p ≤ 0.001. 
  
171
 
 
 
 
 
 
 
 
 
 
Fig 7.11 VICCV with TB11381 cells pre-infected with AdTD virus enhances the 
generation of an effector memory CD4+ population.  
Four groups of mice (n=3) were vaccinated with PBS, MMC-treated TB11381 cells or cells 
pre-infected with AdTD or AdTD-CCL25 plus MMC secondary treatment. Mice were similarly 
boosted four weeks later.  Spleens were harvested and processed one week after boost. 
Splenocytes were stained for CD3, CD4, CD8, CD44, CD62L and profiled into various 
populations using fluorescence cytometry. The dot plots show a representative mouse one 
of each treatment group. The bar charts depict the effector and central memory populations 
out of the total DC4+ population. One-way ANOVA with Tukey post-hoc test was used to 
compare groups. Columns represent the means ± SEM; asterisks denote the significance 
levels as comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
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Fig 7.12 VICCV with TB11381 cells pre-infected with AdTD virus enhances the 
generation of an effector memory CD8+ population.  
Four groups of mice (n=3) were vaccinated with PBS, MMC-treated TB11381 cells or cells 
pre-infected with AdTD or AdTD-CCL25 plus MMC secondary treatment. Mice were similarly 
boosted four weeks later.  Spleens were harvested and processed one week after boost. 
Splenocytes were stained for CD3, CD4, CD8, CD44, CD62L and profiled into various 
populations using fluorescence cytometry. The dot plots show a representative mouse one 
of each treatment group. The bar charts depict the effector and central memory populations 
out of the total DC8+ population. One-way ANOVA with Tukey post-hoc test was used to 
compare groups. Columns represent the means ± SEM; asterisks denote the significance 
levels as comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
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7.6 Chapter seven results summery 
• Subcutaneous vaccination with pancreatic cancer cells pre-infected with AdTD-
CCL25 virus resulted in an increase in T cells expressing α4β7 integrin. 
• No such increase was seen when mice were vaccinated intraperitoneally. 
• Repeat experiments after adding secondary treatment of mitomycin was not 
successful. There was no difference between vaccination groups in three 
independent experiments. 
• Vaccinating KPC mice with DT6606 cells pre-treated with AdTD or AdTD-
CCL25 led to an increase in survival. However there was no significant 
statistical difference between the two viral groups. 
• In keeping with our previous experience, vaccination with DT6606 or TB11381 
pancreatic cancer cells pre-treated with either adenovirus resulted in a tumour 
specific immune response. 
• Similarly, there was an increase in effector memory T cells in both viral groups 
compared to control. 
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Chapter eight: Discussion 
 
8.1 Proof of concept 
8.1.1 Efficacy of virus-infected cancer cell vaccine 
There is abundant evidence in the literature that the immune system plays a major role 
in the anti-tumour effect of OVs [6-9]. Our group has shown recently that intratumoural 
(IT) injection of AdV followed by VV in a Syrian hamster subcutaneous pancreatic 
tumour model led to complete regression of the tumours. More importantly, we have 
demonstrated that this treatment induced a T cell-mediated tumour specific immunity 
capable of protecting treated animals against tumour re-challenge [80].  
 
The current study utilises these findings to develop a prime/boost virus-infected cancer 
cell vaccine (VICCV). Cancer cells treated with either AdV or VV for 4 hours and 2 
hours respectively were injected subcutaneously in the animal. This short period of 
exposure to the virus allows enough time for attachment and internalisation. After cell 
injection, the virus continues its life cycle and replication in vivo leading to cell lysis and 
immunogenic cell death. The released DAMPs and PAMPs activate DCs which co-
present TAA to T cells resulting in an anti-tumour immunity. 
 
In our proof of concept experiment, VICCV resulted in an anti-tumour immunity capable 
of protecting the animals from tumour re-challenge up to three times the vaccination 
dose (2x106 and 6x106 cells for vaccination and re-challenge respectively). Higher 
tumour re-challenge doses seem to overwhelm the immune system and the VICCV lost 
its protective ability. This result was in keeping with evidence from clinical trials. It is 
well documented that tumour vaccination and immunotherapy does not work well in 
patients with high tumour burden [404, 405].  
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Other groups have shown effective anti-tumour immunity using a similar approach with 
other OVs. Vaccination with NDV-infected cells resulted in protective anti-tumour 
immunity in pre-clinical experiments [259, 406, 407] and clinical trials [262, 327, 408, 
409]. Similarly, vaccination with tumour cells infected with vesicular stomatitis virus led 
to protective anti-tumour immunity [410]. 
 
8.1.2 Homologous vs. heterologous prime/boost VICCV 
Prime-boost vaccination is a long established strategy to generate long-lasting 
immunity [411, 412]. In the context of viral vectors vaccination, heterologous prime-
boost where two different viral vectors are used may be required to circumvent the anti-
viral immunity against the prime virus [413]. 
 
Our group has tested the VICCV regimen in Syrian hamster subcutaneous tumour 
model. The vaccination led to protective immunity preventing tumour progression on 
tumour re-challenge. In the Syrian hamster model all viral groups were significantly 
better than vaccination with MMC-treated cells. Prime vaccination with Ad5-infected 
cells followed by boost with VVL15-infected cells resulted in the highest level of 
protection against tumour re-challenge compared to other prime/boost combinations 
[Wang et al, unpublished data] (Fig 8.1). The results of the efficacy study in the Syrian 
hamster model seems to reflect our group’s previous experience [80] that heterologous 
treatment with AdV-infected cells prime and VV-infected cells boost offers the best 
protection against tumour progression. 
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The picture seems slightly different in the mouse model. 
 
As a measure of tumour-specific immunity we used IFN-γ release assay. This assay is 
based on the release of IFN-γ when CD8 cells are activated by their cognate epitope-
MHC complex. In each experiment, mice were vaccinated with tumour cells pre-treated 
with an oncolytic virus or with MMC as a control. In some experiments, more control 
groups were introduced using Rx or MTX-treated cells to compare the anti-tumour 
immunity induced by the secondary treatment alone vs. virus plus treatment. All 
experiments included a PBS-treated group to exclude non-specific immunity caused by 
animal related factors such as general or injection site infection, general anaesthesia 
and so forth. Two weeks after boost mice were euthanized and spleens were 
harvested. We incubated isolated splenocytes with proliferation-arrested target tumour 
Fig 8.1 Vaccination with virus-infected tumour cells can induce a protective 
antitumour immunity.  
Five groups of Syrian Hamsters (n= 9 or 10) were vaccinated (Prime) with HPD-1NR cells 
pre-treated with Mitomycin (MMC), Adeno Virus (Ad) or Vaccinia Virus (VV). Four weeks 
later vaccination was repeated (boost). The animals were challenged two weeks after boost 
with HPD-1NR cells (1x107 cells) via subcutaneous injection and tumours’ sizes were 
monitored over 30 days period. Two-way ANOVA test with Bonferroni post-test analysis was 
used to compare various groups.  
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cells, control tumour cells or media only. The latter group was used as a measure of 
non-specific IFN-γ released from other cells, mainly natural killer cells. The background 
IFN-γ was then deducted from the total released in each target and control tumour 
samples and the difference was represented on column chart. This measure should 
correlate to the level of specific tumour/antigen immunity.  
 
IFN-γ assay results in the mouse model showed that priming the animals with AdV-
infected cells offered a significant increase in anti-tumour immunity when compared to 
VV-infected cells or control groups. There was a general trend of a higher immune 
response in homologues (AdV/AdV) compared to heterologous vaccination (AdV/VV) 
although that did not reach statistical significance. These results were accurately 
reflected in the prime/boost efficacy study in subcutaneous model.  
 
8.1.3 Safety and translatability of the VICCV 
Injecting viable tumour cells, albeit virus-infected, as a vaccine raises few safety and 
ethical concerns that will impact the potential translatability of our VICCV. First, can we 
guarantee all injected tumour cells will be virus-infected? Even if they were all infected, 
does that guarantee all cells will be killed by the OV? Second, can we reliably monitor 
the injected tumour cells for early detection of cell survival? What form of monitoring is 
required? Finally, in case some injected cells survived the viral infection and developed 
a tumour in injection site, what would be the rescue plan? 
 
To overcome these challenges the safety of the VICCV needs to be enhanced. One 
approach would be to use higher MOI for viral infection. However, that will increase the 
toxicity of the treatment due to a higher viral dose. Alternatively, we can  monitor cells, 
via a labelling system incorporated in the OV, to guarantee all injected cells are 
infected. The third approach, that we adapted, would be to add a secondary treatment 
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to arrest the proliferation of vaccine cells prior to injection in the form of irradiation or a 
chemotherapeutic agent. 
 
After validating the required doses of Rx, MMC and MTX to arrest the proliferation of 
vaccination tumour cell lines, the effect of these treatments on viral replication was 
tested. Irradiation led to moderate reduction of viral replication while MMC and MTX 
treatment led to the complete arrest of AdV replication and a significant reduction of 
VV’s.  
 
Contrary to our expectations, this reduction of viral replication did not lead to reduction 
in anti-tumour immunity. These findings were later confirmed in murine HNSCC cells 
where adenovirus is replication-defective. This seems to reflect other groups 
experience were vaccination with non-replicating OVs did not impact anti-tumour 
immunity [410]. We speculated that despite the lack of viral replication, the virus in 
combination with secondary treatment was still killing vaccination cells resulting in the 
release of the required DAMPs and PAMPs to generate an effective anti-tumour 
immunity. This was confirmed in the HNSCC model. Adenovirus in these cell lines was 
replication defective however it was still capable of killing the cells. Adding mitomycin 
did not reduce cell killing. To the contrary, it resulted in better cell killing in the B4B8 
cell line (Fig 5.4). 
 
While, in-depth investigation of immunogenic cell death mechanisms is beyond the 
scope of this study and is the subject of a PhD project of another team member [El-
Khouri et al, unpublished data], I investigated the effect of secondary treatments on 
PAMPs release in the form of viral proteins and viral DNA. Radiation and MMC seem to 
have little impact on viral proteins production and viral DNA replication while MTX 
resulted in some reduction in both.  
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From these results it appears that a strong anti-tumour immunity requires a viral 
infection with sufficient dose to kill tumour cells and release associated DAMPs and 
PAMPs. Virus replication does not seem to be a deciding factor in the overall success 
of the cancer vaccine.  
 
8.2 HNSCC animal model 
8.2.1 Pros and cons of the HNSCC tumour models 
SCC7 and SCC7-RLuc cell lines were very consistent at developing primary tumours 
either subcutaneously or orthotopically. The luciferase stable transduction doesn’t 
seem to affect the viability of these cells or how they behave in vivo. SCC7 tumours 
grew rapidly to reach the maximum size limit within two to three weeks. However, 
despite the large tumour size these animals remained well throughout with steady 
weight increase and no sign of cachexia or muscle wasting. Metastatic disease was 
limited in this model. We only observed a single lung metastasis in one out of 20 
animals tested. This seems to contradict the finding of the original paper describing the 
orthotopic model were they found lung and lymph node metastasis in 15 out 20 
animals tested [414]. However other authors using this model could not replicate these 
results when using the tumour model [415]. Various authors have used the SCC7 cells 
as a metastatic model by injecting these cells in the mouse tail vain [415-417]. 
However in our opinion this is a poor representation of the tumour spread seen in head 
and neck cancer patients. It simply represents tumour embolus in distant organs 
bypassing the continuous natural process of tumour cells invasion and migration. 
Another potential shortcoming of this tumour model is the tissue origin of these cells. 
Despite its wide use as a HNSCC cell line, the SCC7 cells originated from a 
spontaneously occurring SCC of the abdominal wall of the C3H mice rather than their 
upper aerodigestive tract [418].  
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B4B8 is a murine SCC cell line derived from BALB/c oral keratinocytes treated with the 
chemical carcinogen 4NQO before being transplanted and re-isolated in SCID mice 
[381]. Tumours derived from this cell line show histological features of well-
differentiated squamous cell carcinoma [381, 394]. In our experiments we found 
tumours originating from this cell line to be slow growing with no lung or lymph node 
metastasis, similar to previously published studies [394, 419]. This growth and 
metastasis pattern does not accurately resemble human disease progression however; 
we believe this to be a useful model to represent an unrespectable locally advancing 
disease. In particular, this could be a useful model to test vaccination and other 
immunotherapy treatments where the longer survival of the animal allows a sufficient 
timeframe for repeated vaccination boosts and development of a strong immune 
response. The stable transduction of the B4B8 cells doesn’t seem to affect the ability of 
these cells to form tumours in vivo.  
 
LY2 cells were isolated from lymph node metastasis after inoculation with PAM212 
squamous cell carcinoma cells [382]. The latter is a spontaneously transformed cell 
line derived from neonatal keratinocytes of male BALB/c mice [383]. The LY2 cells 
exhibits a more aggressive growth and metastatic phenotype compared to the parental 
line [382]. In our experience subcutaneous and orthotopic tumours derived from this 
cell line grow rapidly to reach maximum size limit between two and three weeks. The 
tumour had a high affinity to lungs and lymph nodes with almost all animals showing 
metastasis to both organs. The only exception was the orthotopic tumour model where 
we did not observe any lung metastasis. In this experiment we injected 5x106 cells into 
the right cheeks of the animals. All the animals in this experiment were culled at day 
16, while the time required for overt lung metastasis to form is around three weeks 
[394]. We believe that the tumour dose used was probably too high resulting in the 
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rapid demise of these animals. Over all, the orthotopic LY2 model (possibly using a 
lower number of injected cells) is the most accurate representative of the human head 
and neck cancer out of the three cell lines.  
 
Contrary to the other two cell lines, transfecting LY2 cells with Renilla luciferase did 
change the phenotype of these cells. The LY2-RLuc has a reduced ability to form 
primary tumours and resulted in a slower growth rate. In the orthotopic tumour model 
we reported tumour formation rate between 10 to 20%. In contrast, all animals in the 
subcutaneous model (5x106 injection dose) formed tumours, albeit slow growing. This 
low tumour formation rate in the orthotopic model is likely to be due to our inability to 
differentiate small slow-growing tumours from the underlying masseter muscle by 
manual palpation. IVIS luminescence imaging system would have helped to show 
small tumours embedded into the muscle. Unfortunately the imaging system, along 
with most of the Biological Services Unit (animal house) and the animal imaging suit, 
were unavailable for large parts of this study due to refurbishment. The rate of lung and 
lymph node metastasis is slightly reduced compared to parental cells which make the 
luciferase tumour model even closer to the human disease. Another added benefit of 
this model is the prolonged survival of these animals in comparison to parental cells 
making it more suitable model for vaccination and immunotherapy approaches. 
 
8.2.2 Surgical excision model    
Treatment of most head and cancers would involve surgical resection of the tumour 
and the main cause for mortality is locoregional recurrence. To simulate this clinical 
scenario we used our cells in a surgical excision model. Despite the lack of metastasis 
of the SCC7 model we decided to test it as there is evidence that surgical excision can 
promote metastasis and stimulate the growth of any minimal residual disease [420]. In 
our experiment most animals developed local recurrence between 7 to 10 days after 
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excision that grew in a similar pattern to the primary tumour leading to the animals 
needing to be culled almost three weeks later. This surgical model had the same 
shortcomings described previously. There was no lung or lymph node metastasis and 
the animals remained well until the point of sacrifice.  
 
Similarly the LY2 and LY2-RLuc cells behaved in a predictable manner in the 
subcutaneous surgical excision model. The growth rates and metastasis were in 
keeping with our previous results. Of note all mice in these groups developed skin 
ulceration at injection site leading to early excision in four out of ten mice. This early 
excision didn’t lead to reduction in metastasis however it might prove problematic for 
experiments requiring intratumoural injections. I attempted an orthotopic surgical 
excision model using LY2 parental cells however this was a significantly challenging 
model as described previously limiting its applicability.  
 
Subcutaneous tumour models in general do not reflect site-specific tumour growth and 
metastasis behaviour related to different blood supply, immune cell composition, local 
stromal components and site-specific organ invasion. The latter is particularly relevant 
to HNSCC where dysphagia and dyspnoea caused by tumours involving the upper 
aerodigestive tract are some of the key features of the human head and neck cancers. 
However flank tumours are not without their advantages. They are easy to access and 
measure, surgical excision is fairly simple, they drain to inguinal nodes which are easy 
to assess clinically and simple to harvest and finally, the lack of impingement on the 
upper aerodigestive tract allows longer survival and humane care of the animals. 
Regardless of which model is used one needs to keep in mind that a model is just that, 
a model. Models’ shortcomings, differences in biology and host response between 
human and mouse need to be taken into account when extrapolating experimental data 
into human disease [421, 422]. 
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8.3 VICCV in head and neck cancers 
8.3.1 Model validation 
Since this was our lab first experience with the B4B8 and the LY2 cells we aimed to 
validate these cells suitability for oncolytic viral therapy. MTS cell killing assay showed 
both cell lines to be amenable to adenovirus infection with an EC50 value of around 10 
pfu/cell for both cell lines. Based on this we decided to use a dose of 20 pfu/cell for all 
our in vivo and in vitro experiment in keeping with our previous work (working dose 
approximately double the EC50 value). To the contrary SCC7 cells were very resistant 
to adenovirus infection with an EC50 value over 2,500 pfu/cell which meant these cells 
will not be suitable for my VICCV treatment. All three cell lines were amenable to 
vaccinia virus infection. Luciferase stable cell lines were similarly sensitive to 
adenovirus infection with slightly higher EC50 values. The two experiments (parental 
vs. stable) were performed independently. A variety of factors could affect the outcome 
of this assay including media, cells, incubation period between cell plating and 
infection, and viral exposure to room temperature making the comparison of two 
independent experiments difficult. The moderate increase of EC50 value is probably 
within the margin of variability of the MTS assay.  
 
As is the case with the majority of murine cells, the LY2 and B4B8 cells and their 
luciferase stable cell lines did not support human adenovirus replication. Based on our 
proof of concept data we speculated that this lack of replication would not affect 
antitumour immunity. Our INFγ assay results discussed in the next section seems to 
support this hypothesis. 
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8.3.2 VICCV-induced antitumour immunity  
In two independent experiments we measured IFN-γ released from splenocytes of 
vaccinated mice as an indicator of antitumour immunity. In the first of these 
experiments mice were vaccinated with B4B8 or LY2 parental cells. As expected, 
splenocytes of mice vaccinated with B4B8 cells pre-infected with AdTD and treated 
with mitomycin released the highest level of IFN-γ when stimulated in vitro with B4B8 
cells indicating the highest level of antitumour immunity compared to naïve mice or 
mice vaccinated with MMC treated cells. In addition, the highest IFN-γ was against 
B4B8 cells compared to LY2 or the JC control cell line indicating a cell-specific immune 
response.  
 
The results were not as predictable in the LY2 vaccinated mice. Firstly there was no 
significant difference in immune response between mice vaccinated with virus-infected 
cells and the other treatment group or even naïve mice. Secondly there was no 
difference if splenocytes were stimulated with LY2 cells or JC cells. Interestingly, 
immune response was significantly higher when splenocytes were stimulated with 
B4B4. This difference between the two cell lines suggests that B4B8 cells are more 
immunogenic than LY2 cells. We speculate that some tumour antigens sre expressed 
in a much higher level in B4B8. High throughput sequencing might provide some 
answers if it can identify the presence of neoantigens in both cell lines. 
 
In the second experiment we vaccinated mice with LY2-RLuc cells. The results appear 
to be very similar to these of the parental cell lines. B4B8 cells were significantly more 
immunogenic compared to LY2. Luciferase transduction does not seem to increase the 
immunogenicity of these cells however it attenuates their growth and duplication rates. 
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8.3.3 T cell activation and effector memory induction as a response to VICCV 
The introduction of an antitumour immune memory is key to the success of any tumour 
vaccine. Effector memory cells and CD8+ in particular play a crucial rule in the immune 
response to cancer. These cells have lost their lymphoid tissue homing capacity and 
primarily populate peripheral tissues. They play a sentinel role and are capable of 
immediate activation and expansion when faced with their cognate antigen to generate 
a strong antitumour response.  In experimental tumour models the induction of CD8+ 
TEM phenotype lasted up to five months after tumour resection and was capable to 
protect animals against tumour re-challenge either intradermally or intravenously [423]. 
In a clinical setting the induction of TEM phenotype correlated with better survival and 
antitumour response [424, 425].  
 
In our head and neck cancer model we tested if vaccination with adenovirus pre-
infected cells can lead to activation of T cells and development of a memory 
phenotype. Our results demonstrated that vaccination with pre-infected B4B8 cells 
results in an increase in the TEM population of both CD4+ and CD8+ cells, and a 
proportional drop of the TCM population. This increase was less prominent and did not 
reach statistical significance for either LY2 or LY2-RLuc vaccinated mice.  
 
It is to be acknowledged that the increase in effector memory is not purely related to 
antitumour immunity as part of the increase of this population is derived from T cell 
targeting adenovirus than tumour cells. The distinction between the two groups could 
be technically difficult to assess. One way would be to use viral antigen pentamer to 
detect antiviral T cells. Other members of our lab [El-Khouri et al, unpublished data] 
attempted this experiment using vaccinia virus antigen B8R without success as the 
total percentage of these cells out of the total population was less than 1% making data 
interpretation unreliable. Nevertheless, we believe this TEM increase to be mainly in the 
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antitumour population as, firstly, the total starting viral dose is very small and large 
proportion of it will be invariably lost in the infection and multiple wash steps. Only a 
small proportion of the total virus volume will be carried into the animal. In addition 
these cell lines do not support adenovirus replication keeping the total viral particles 
count relatively small. Secondly, the disparity between the two cell lines suggests that 
this increase in TEM population is probably derived from the tumour specific subset 
rather than an antiviral population as both cell lines where infected at same MOI and 
the same number of cells were used for vaccination. 
 
8.3.4 Efficacy of the VICCV in head and neck cancer model 
To test if this anti-B4B8 immune response can translate into efficacy we tested our 
VICCV as a therapeutic vaccine in a locally advancing disease model. Mice were 
inoculated orthotopically in the right cheek and the tumours were allowed to grow for a 
week before the prime vaccination using adenovirus pre-infected B4B8 cells at a 
distant site (right flank). Animals were boosted twice at two weeks intervals. Up to day 
55 when the first animal was culled in each treatment group there was a significant 
slowing of the tumour growth. This led to a trend increase in the overall survival of 
these animals however that did not reach statistical difference. Although on the surface 
these results were not as impressive as our previous efficacy results in DT6606 
subcutaneous inoculation model (Chapter 3) were complete tumour rejection was 
achieved; this orthotopic model is a lot more realistic and closer to a real clinical 
scenario. The orthotopic site of the tumour and its impingement on the upper 
aerodigestive tract (not dissimilar to HNSCC patients) meant other factors such as 
feeding and breathing affected the overall survival of these animals. In a true clinical 
scenario such factors could be overcome, even in unresectable tumours, via assisted 
breathing and feeding i.e. insertion of tracheostomy tube or tumour debulking and 
enteral feeding methods.  
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The lack of significant tumour regression in our vaccination model should not be 
interpreted as a failure of the vaccine. Evidence from clinical trials using the poxvirus-
based PROSTVAC vaccine (also known as PSA-TRICOM) showed that the reduction 
of tumour growth rate is more important for the overall survival than rapid tumour 
regression seen with chemotherapy [426]. The findings of these trials supports the 
notion that cancer vaccines are most effective when used in patient with low tumour 
burden. Combining vaccination with other traditional treatments that can significantly 
reduce tumour volume such as surgery or chemotherapy (as the case in the 
PROSTVAC trials) will theoretically lead to a much improved overall survival. The 
paradigm of increase survival in vaccination patients despite the lack of tumour 
regression is further explored below (Fig 8.2). Although this theoretical model is based 
on prostate cancer trials we believe it to be particularly applicable to head and neck 
cancer patients were the biggest killer is locoregional recurrence secondary to minimal 
residual disease post surgical excision. Cancer vaccination in this group could 
significantly slow down the growth rate of the recurrent disease leading to increased 
patients’ survival.  
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8.4 VICCV using AdTD-CCL25 virus 
8.4.1 Why is AdTD-CCL25 more potent at killing cancer cells? Or is it? 
The increased efficacy of AdTD-CCL25 virus was first noted during daily observation of 
infected cells in viral validation experiments (replication and CCL25 expression). It 
became apparent that the CCL25-armed virus killed the cells at much earlier time point 
compared to control virus. These results were confirmed in our first virus validation 
experiment (Fig 6.5) using an MOI=50 pfu/cell. This is our standard dose for 
adenovirus infection in DT6606 and TB11381 cell lines. In this experiment we found 
that CCL25 levels dropped rapidly after 24 hours, and the AdTD-armed virus didn’t 
replicate in these cells.  
Fig 8.2 Vaccination vs traditional cancer 
therapies.  
A) Traditional cancer treatment including 
surgery and chemoradiotherapy lead to rapid 
tumour regression followed by rapid increase 
while vaccination therapy leads to slowing of 
tumour growth rate leading to increased 
survival. Arrow represent treatment point, * 
denotes terminal point and broken line shows 
growth curve if left untreated. Graph B) shows 
the effect of tumour burden at the initiation of 
vaccination on the overall survival of the 
patient. Overall survival can be enhanced by 
initiating vaccination at an earlier time point. 
Graph C) shows the effect of combining 
vaccination with traditional cancer treatment 
resulting in a significant increase of overall 
survival. This model is based on PROSTVAC 
clinical trials data. Figure adapted from [421]. 
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Various different reasons could explain these results. Firstly, viral titration is incorrect 
which means the AdTD-CCL25 was being delivered in a much higher dose. Secondly, 
AdTD-CCL25 is replication-defective. Thirdly, AdTD-CCL25 is more potent at killing 
cancer cells compared to control virus possibly due to a synergistic effect between 
adenovirus and CCL25.  
 
Initially each of the two viruses was titrated independently at the point of mass 
production. The TCID50 assay, by its very nature, could be affected by viability of 
JH293 cells used in titration or variation of assay conditions such as media, incubation 
temperature, etc.  Titration of both viruses was repeated by the author and 
independently by my colleagues Mr M Yuan and Miss A Ibrahim (results not shown) 
showing consistent values.  
 
Once satisfied with the titration, I proceeded to calculate the EC50 value for each virus 
in the cell lines of interest. The MTS assay showed the AdTD-CCL25 virus to be 
around 20 times more potent compared to control virus. This meant that our starting 
dose of MOI=50 pfu/cell was too high. Repeat replication experiment using an MOI=10 
pfu/cell (Fig 6.7) exclude the second hypothesis and showed that the AdTD-CCL25 
virus was replication competent in the cell lines of interest. As expected, the virus 
replicated better in human cell line SUIT2 compared to murine ones.  
 
Our final hypothesis was that the AdTD-CCL25 virus was more potent at killing cancer 
cells. That could be either due to a better, earlier replication of AdTD-CCL25 virus 
leading to rapid killing of all cells within the first 24 hours; or it could be related to 
CCL25 toxicity killing these cells within the first 24 hours preventing viral replication. 
The latter was fairly simple to exclude as recombinant CCL25 protein was not directly 
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toxic to cells (Fig 6.11). This left us with the possibility that the AdTD-CCL25 virus is in 
fact more potent at cell killing. This was confirmed in a number of murine cell lines (Fig 
6.8). Simultaneously we looked into CCL25 expression in these cell lines. We could not 
demonstrate a correlation between the level of CCL25 and viral potency suggesting no 
synergistic effect between the two. This was later confirmed by my MSc student Ms A 
Ibrahim as she found that adding recombinant CCL25 to backbone AdTD virus did not 
increase its cell killing ability. She went on to demonstrate that AdTD-CCL25 virus has 
a faster life cycle including earlier DNA replication and viral protein synthesis due to an 
as-yet unexplained mechanism. 
 
However, and of a potentially critical importance, when we titrated the viruses using a 
picogreen assay we had paradoxical results. This assay measures the number of viral 
particles (vp) based on the amount of viral DNA in the purified viral stock. It does not 
distinguish between viable and dead virus particles. To the contrary, the TCID50 assay 
is a functional assay measuring viable infectious viral units. The vp/pfu ratio for our in-
house produced adenoviruses is around 10:1 – 20:1. This was correct for the AdTD-C 
virus however the ratio was around 700:1 for the CCL25-armed virus. This could simply 
represent a poor quality batch of the AdTD-CCL25 virus and suggest the possibility of 
direct toxicity of the cells. It is however difficult to explain how this direct toxicity affects 
a variety of cell lines but does not affect the JH293 cells (when both viruses added in 
equal volumes to the JH293 cells during the TCID50 assay, the control virus was 
almost ten fold better at killing cells). Furthermore, when Ms Ibrahim tested the 
difference between the two viruses in terms of life cycle she used both methods of 
titration and came to similar conclusion.  
 
In conclusion, we are still to explain the difference in cell killing potency between the 
two viruses and the paradox of picogreen vs TCID50 titration. More work need to be 
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done in this area possibly looking at a molecular level and the interaction between the 
virus and CCL25 pathway. 
 
8.4.2 Induction of T cells gut-homing phenotype secondary to AdTD-CCL25 VICCV 
In our pilot experiment when we vaccinated mice with pancreatic cancer cell lines pre-
infected with AdTD-CCL25 virus via subcutaneous route we achieved significant 
increase in T cells expression α4β7 integrin in spleens, local and distant lymph nodes. 
The increase was more prominent in CD4+ cells. Contrary to our expectations, and our 
collaborators experience, we did not detect this increase when vaccinating the mice 
intraperitoneally. We speculated that this difference was related to the anatomical 
nature of the vaccination site. Subcutaneous vaccination will keep all the injected cells 
in close proximity allowing viral spread between the cells resulting in CCL25 to be 
expressed to a high level in a sustained fashion. To the contrary, intraperitoneal 
injection will lead to tumour cells being dispersed around the abdominal cavity possibly 
limiting viral spread between the cells.  
 
Based on the success of the pilot experiment we moved to add a secondary treatment 
of mitomycin to bring it in line with our pre-infected cell vaccination. Unfortunately we 
could not replicate the pilot experiment success despite repeating the experiment in 
different pancreatic cancer cell lines using different viral dose. I scrutinised my 
methods closely and re-analysed my flowcytometry results using different gating 
strategies with the help of experienced members of the team but the results were 
consistent (with the exception of CD8+ cells in the DT6606 vaccination experiment as 
explained previously, Section 7.3.2). The main difference between the experiments 
was the addition of mitomycin. Although I have validated that CCL25 expression is 
maintained with MMC treatment, we know from our proof of concept data that it 
significantly reduces viral replication. Similar to intraperitoneal vaccination, the lack of 
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viral replication and cell to cell spread might limit the level and sustainability of the 
CCL25. This remains largely speculative explanation. It would have been interesting to 
measure CCL25 levels at the site of vaccination although it might be technically 
challenging and will require a large number of animals. A more realistic approach 
would have been to fuse CCL25 with a reporter gene such as green florescent protein 
where expression levels could be monitored with IVIS imaging in real time with having 
to sacrifice animals at each time point. In light of time limit of this study and most 
importantly the limited efficacy results in KPC mice we decided not to pursue this line 
of investigation any further.  
 
8.4.3 Antitumour immunity in the AdTD-CCL25 vaccination model 
Although the model failed to deliver a statistically significant therapeutic effect in the 
KPC mice or an increase expression of α4β7 integrin it did provide us with vital 
information on antitumour immune response in a second tumour model.  
 
IFN-γ assay in both DT6606 and TB11381 were in line with my previous results in the 
HNSCC model and the proof of concept experiments. Infecting the cells with 
adenovirus prior to injecting them resulted in a strong cell-specific immune response. 
Arming the virus with CCL25 gene does not change this response. Similarly the pattern 
of T cell activation and the increase in effector memory population following vaccination 
with TB11381 cells was very similar to that generated after vaccination with B4B8 cells. 
 
8.4.4 Prime/boost interval 
Deciding the prime/boost schedule for our VICCV regimen was a subject of much 
debate at the early stages of this project. Most published literature suggests an interval 
between two to three months [427, 428]. However it was difficult to extrapolate this 
data to our vaccine as most of these studies are based on infectious diseases data 
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from human trials rather than cancer vaccine. In addition most of vaccination trials use 
antibody response rather than cellular response as a determining factor. Finally the 
difference in biology, immune response and tumour growth rates between human and 
mouse complicates matter further. At the end we decided to take a pragmatic approach 
and chose a four weeks interval. However, rapid tumour growth in KPC transgenic 
mice dictated a shorter interval. We compared anti tumour immune response after 
vaccination with pre-infected DT6606 cells with different vaccination interval (Fig7.6). 
There was no significance different between two and four weeks. We decided to use 
two weeks in our efficacy results for both KPC mice and the B4B8 orthotopic model.  
 
Irrespective of what the “optimal” interval is, it remains only relevant to this experiment. 
We do not believe such interval will translate well to human trials due to the differences 
mentioned above. Vaccination schedule should be decided based on actual patients’ 
data and it might need to be incorporated in phase I/II trial.  
 
8.5 Potential for improvement and clinical applicability 
8.5.1 Enhancing antitumour immunity using combination therapies 
Combining oncolytic virotherapy, including our pre-infected cell vaccine, with other 
cancer treatments is an area of great promise. Traditionally, chemotherapy was not 
believed to be compatible with cancer vaccination due to myeloid suppression and the 
resultant immunodeficiency. However, evidence from basic research and clinical trials 
seems to support the use of combination therapy [429]. One such example in 
pancreatic cancer is Gemcitabine. It can suppress Myloid-derived suppressor cells 
(MDSC) in the tumour microenvironment resulting in a stronger anti-tumour immune 
response [430]. On the other hand, gemcitabine is a nucleoside analogue that inhibits 
DNA synthesis including that of double stranded DNA viruses [431]. Using these 
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agents in a sequential rather than combination manner might be the key to effective 
therapy [432].   
 
Similarly, combining our VICCV with immune checkpoints inhibitors is an area that 
requires more investigation and optimisation. PD-1 and CTLA-4 inhibitors might 
enhance the OV-induced antitumour immunity by creating a favorable immune profile 
in the tumour microenvironment [433, 434]. We tested our DT6606 and the HNSCC 
cell lines for expression PDL-1 (Fig 8.3) with the LY2 cells showing the highest 
expression levels making them a potential model for combination therapy.  
 
 
 
 
 
 
 
 
8.5.2 Enhancing immune response using cytokines-armed viruses 
One of the main advantages of viruses as vaccine vectors is their ability to 
accommodate transgenes, including cytokines, and express them to a high level. Using 
Fig 8.3 PDL-1 expression in a panel of murine cell lines.  
1x106 DT6606, LY2 and B4B8 cells were stained for PDL-1 using anti-mouse PDL-1 
antibodies PE 1:200  or Isotype Control Mouse IgG1 PE (eBioscience, San Diego, CA, USA) 
. CT26 cells were used as a positive control as we have confirmed their expression of PDL-1 
previously using Western Blot. Expression levels were measured using florescence 
cytometry.  
CT26          DT6606 
LY2          B4B8 
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cytokines-armed adenovirus in my VICCV regimen can enhance the resultant 
antitumour immune response. Rational selection of different cytokines for prime and 
boost based on function can enhance the various stages of the developing immune 
response. We speculate that using a cytokine that can enhance antigen presentation, 
such as GM-CSF and Fms-like tyrosine kinase 3 ligand (Flt3L), for prime and a 
cytokine that can stimulate a T-cell response, such as IL-12 or IL-21, for boost will elicit 
the strongest antitumour immune response.  
 
Our group has a well-established track record working with cytokines armed oncolytic 
viruses. IL-12 armed triple-deleted adenovirus [P Wang et al, unpublished data] or 
Lister strain vaccinia virus [J Ahmed et al, unpublished data] has shown better efficacy 
and stronger antitumour immunity compared to backbone virus in pancreatic and lung 
tumour models. Similarly our group has found that intratumoural injection of vaccinia 
virus armed with IL-10 dampened antiviral immune response resulting in prolonged 
viral persistence in pancreatic tumours. This led to stronger anti-tumour immunity and 
improved survival in both subcutaneous and transgenic pancreatic cancer mouse 
models [28]. Although these experiments were all direct antitumour injection it seems 
that the resultant immune response is an, if not the most, important factor behind the 
efficacy. In all these experiments the addition of the cytokine did not significantly 
change the potency of the virus in vitro but enhanced it in vivo highlighting the role of 
the immune system. 
 
8.5.3 CXCR3-mediated T cell homing 
Although our CCL25-induced gut homing experiment was largely unsuccessful we still 
believe there is enough merit in the approach to warrant further investigation. Evidence 
from preclinical experimental work shows that CXCR3-mediated T cell homing plays an 
important role in antitumour immunity [435]. In addition it plays a role trafficking CD8+ 
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cells to virus infected cells [436]. We have shown in one pilot experiment that our 
VICCV using adenovirus-infected DT6606 cells can lead to an increase CD4+ and 
CD8+ T cells expressing CXCR3 (Fig 8.4).  
 
We are currently constructing a triple deleted adenovirus expressing the CXCR3-ligand 
CXCL10. We would like to combine this virus with our vaccination. We are 
hypothesising that intratumoural injection of the CXCL10-armed virus will enhance T 
cell trafficking to the tumour site. Alternatively, other approaches that enhance the 
production of CXCL10 via the activation of the Toll-like receptors could be used in 
combination with our vaccination regimen. One such approach is to combine 
vaccination with polyinosinic-polycytidylic acid stabilised by lysine and 
carboxymethylcellulose (poly-ICLC) [437]. If successful, these combinations could 
represent a promising new strategy to target tumour cells.  
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8.6 Conclusion and future work 
Virus infected cancer cell vaccine is a promising strategy in the fight against cancer. It 
utilises oncolytic viruses’ ability to kill tumour cells in a combination of immunogenic 
and non-immunogenic cell death modes providing the immune system with the “danger 
Fig 8.4 VICCV increased the proportion of T cells expressing CXCR3.  
Two groups of mice (n=3) were vaccinated with either PBS or DT6606 cells pre-infected with 
AdTD plus MMC secondary treatment. Mice were similarly boosted four weeks later.  
Spleens were harvested and processed one week after boost. Splenocytes were stained for 
CD3, CD4, CD8, CXCR3 and profiled into various populations using fluorescence cytometry. 
The line graphs show a representative mouse of each treatment group. The bar charts 
depict the CXCR3+ cells out of the total CD4+ and CD8+ populations in naïve and 
vaccinated mice. One-way ANOVA with Tukey post-hoc test was used to compare groups. 
Columns represent the means ± SEM; asterisks denote the significance levels as 
comparing: ns non-significant; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
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signal” required to induce an antitumour immune response. This danger signal is likely 
to be a combination of danger- and pathogen-associated molecular patterns.  
 
We have shown that our vaccination regimen can induce a tumour-specific immune 
response capable of protecting the animals against tumour re-challenge. In addition, 
our VICCV can enhance the pool of the effector memory T cells in a variety of tumour 
models. We have demonstrated our vaccination efficacy in subcutaneous tumour 
models where vaccinated mice were able to reject tumour cells on re-challenge. The 
efficacy was less impressive in orthotopic HNSCC model and in the transgenic 
pancreatic tumour model. In general, immunotherapeutic treatments are less effective 
when used as monotherapy in advanced tumours. Most current clinical trials use a 
combination of immunotherapy and traditional cancer treatments. Although such 
combination was not tested in the thesis, we believe this will be true for our 
vaccination. 
 
This project has brought this vaccination regimen one step closer to a clinical trial by 
enhancing the safety of the proposed treatment via the addition of a secondary 
treatment in the form of radiation or chemotherapeutic agents to arrest the replication 
of the injected tumour cells. Further work is required to establish the safest and most 
effective secondary treatment. We can see a great potential in combining the virus pre-
infection with a chemotherapeutic agent that can further enhance the immune 
response.  
 
In the immediate future, we will be testing our VICCV in other head and neck cancer 
models such as LY2-RLuc and HCPC-1 in Syrian Hamsters. The latter provides the 
opportunity to excise orthotopic tumours in combination with vaccination. The next step 
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would be to test other treatment combination such as chemoradiotherapy and immune 
checkpoints inhibitors.  
 
On the long term, we believe this vaccination has the potential to go into clinical trials. I 
envisage this to be an effective treatment after surgical excision in head and neck 
cancer with advanced nodal disease and extracapsular tumour spread. These patients 
would be at a great risk of locoregional recurrence due to minimal residual disease. An 
effective vaccination targeting these micro metastasis would hopefully slowdown this 
process.  
 
Another potential clinical application would be to combine our VICCV with neoadjuvant 
intratumoural oncolytic viral injection. In this treatment the injected oncolytic virus will 
result in direct tumour lysis and induce an antitumour immune response, effectively an 
in situ vaccination. Following surgical excision and chemoradiotherapy the patient will 
receive repeated boost injections of VICCV using a different virus to pre-infect the 
cells. 
 
I do believe there is merit, and a clinical need, for this vaccination regimen. I hope I will 
be in a position to bring it to the clinic in the not too distant future.  
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Appendix I: AdTD-CCL25 cloning enzymatic reactions  
 
AdTD vector digestion with SwaI 
Plasmid DNA 6 µl (852.6 ng/µl) 
SwaI 5 µl 
BSA 1 µl 
NEB Buffer 3 10 µl 
H2O 78 µl → 25° for 4 hours 
 
AdTD vector dephosphorylation  
Digestion reaction 100 µl 
rSAP 5 µl → 37° for 1 hours 
 
 
 
 
 
 
 
 
Fig i.1 Confirmation of SwaI digestion of AdTD vector.  
AdTD vector was digested with SwaI restriction enzyme as 
described above then dephsphorylated with recombinant 
Shrimp Alkaline Phosphatase (rSAP). 5µl of the enzymatic 
reaction were diluted in 15µl of water and run on agarose 
gel. Image shows digested fragment size as expected 
(1093bp) 
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pCMV6-Entry-mCCL25-MycDDK digestion with EcoRI 
Plasmid DNA 8 µl (621 ng/µl) 
EcoRI 3 µl 
EcoRI Buffer  5 µl 
H2O 34 µl → 37° for 2 hours 
 
EcoRI digestion site blunting 
EcoRI reaction 50 µl  
dNTP 5 µl 
DTT  3 µl 
Blunting enzyme mix 2 µl → RT for 15 minutes, DNA 
extracted using GFX extraction kit 
and eluted in 40µl H2O 
 
 
pCMV6-Entry-mCCL25-MycDDK second digestion with SmaI 
Extraced DNA 40 µl  
SmaI 3 µl 
NEB CS Buffer 5 µl 
BSA 0.5 µl 
H2O 1.5 µl → 25° for 2 hours, Run on gel, 
Insert DNA band cut out and 
extracted using GFX extraction kit 
 
 
 
 
 
 
Fig i.2 Confirmation of double digestion of pCMV6-
Entry-mCCL25-MycDDK vector.  
pCMV6-Entry-mCCL25-MycDDK vector was 
sequentially digested with EcoRI and SmaI restriction 
enzymes as described above. 5µl of the enzymatic 
reaction were diluted in 15µl of water and run on 
agarose gel. Image shows digested fragment size as 
expected (497bp). 
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AdTD-CCL25 Ligation 
 
AdTD-CCL25 Vector Control 
AdTD vector DNA 1 µl (202 ng/µl) 1 µl (202 ng/µl) 
CCL25 insert DNA 6 µl (19 ng/µl) - 
T4 DNA Ligase  1 µl 1 µl 
Ligase Buffer 1 µL 1 µL 
H2O 1 µl 7 µl → 16° overnight 
 
AdTD-CCL25 Colony 2 and AdTD plasmid digestion with PacI 
 
AdTD-CCL25 AdTD 
Plasmid DNA 40 µl (214.2 ng/µl) 23 µl (434.8 ng/µl) 
PacI 6 µl 6 µl 
NEB CS Buffer  10 µl 10 µl 
H2O 34 µl 61 µl → 37° for 2 hours 
 
  
Fig i.3 Confirmation of PacI digestion of AdTD-CCL25 
colony 2 vector.  
DNA from AdTD-CCL25 ligation reaction was transformed 
into E.Coli and grown on kanamycin-agar dish. Correct 
ligation was confirmed with PCR and sequencing from 
colony 2 (section 6.1). DNA extracted from colony 2 of 
AdTD-CCL25 was digested with PacI restriction enzyme 
as described above. 5µl of the enzymatic reaction were 
diluted in 15µl of water and run on agarose gel. Image 
shows digested fragment size as expected (2864bp). 
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Appendix II: Buffers and Western blot gels 
 
Buffer Composition Storage 
FACS Buffer Sterile PBS + 1% BSA 4 °C 
ACK lysis buffer 0.15 M NH4Cl + 10 mM KHCO3 + 0.1 mM Na2EDTA in H2O (pH to 7.2-7.4) RT 
NP40 Protein lysis 
buffer  
50 mM Tris (pH7.4) + 150 mM NaCl + 10 mM 
CaCl2 + 1% NP40 + 1 protease inhibitor tablet 
(Roche Applied Science, #11873580001) in 
H2O (for 50 ml) 
 
-20 °C 
5X loading buffer  50 mM Tris, 4% SDS, 10% glycerol, 5% Mercaptoethanol, 0.01% Bromophenol Blue -20 °C 
WB running buffer  10 % of 10 X Tris-Glycine-SDS Buffer (National Diagnostics) + 90% H2O RT 
WB transfer buffer  10% of 10 X Tris-Glycine Buffer (National Diagnostics) + 10% methanol + 80% H2O RT 
WB Blocking buffer  
10% of 10 X Tris-buffered saline (TBS, National 
diagnostics) + 0.1% Tween-20 (Sigma Aldrich) 
+ 5% skimmed powder milk (Sigma Aldrich) in 
H2O 
 
RT 
WB washing buffer 
(TBST) 
10% of 10 X Tris-buffered saline (TBS, National 
diagnostics) + 0.1% Tween-20 (Sigma Aldrich) 
in H2O  
RT 
 
 
 
 
 8% gel 10% gel 12% gel Stacking gel 
ProtoGel (30%) 5.4 ml 6.6 ml 8 ml 1.3 ml 
4x ProtoGel Resolving 
buffer 5 ml 5 ml 5 ml - 
4x ProtoGel Stacking 
buffer - - - 2.5 ml 
H2O 9.4 ml 8.2 ml 6.8 ml 6.1 ml 
TEMED 20 µl 20 µl 20 µl 10 µl 
10% ammonium 
persulfate (APS) 200 µl 200 µl 200 µl 50 µl 
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Appendix III: Further investigation into the effect of CCL25 onto 
adenovirus life cycle 
 
Disclaimer: this section was written by Miss A. Ibrahim and formed part of her MSc 
thesis. The concept of this study and all experiments were designed by C. Al Yaghchi. 
Experimental work was carried out by A. Ibrahim under my supervision.   
 
III.I Viral titration  
The stock viruses were quantified by titration in both a TCID50 assay and a 
picogreen assay, yielding concentrations in plaque-forming units (PFU)/ml and viral 
particles (vp)/ml, respectively (Table 5). The PFU/ml values were used for infection in 
cell cytotoxicity assays while both values were used in infection for viral DNA and 
protein quantification.  
Table 5. Virus concentrations determined by viral titration assays 
* as determined by TCID
50
 assay 
** as determined by picogreen assay 
 
For comparative reasons and to ensure that we are not over-infecting the cell 
by using the PFU/ml concentrations, both MOIs of 100 vp/cell and 10 PFU/cell 
infections were used to quantify viral protein and DNA.  
 
III.II Cell cytotoxicity 
 A cell kill dose-response assay was done to determine an appropriate 
multiplicity of infection (MOI) for the proceeding experiments. A PFU/cell of 100 and 101 
allowed 50% cell kill with Ad-TD-CCL25 and Ad-TD, respectively in both TB11381 and 
4T1 cells (Figure 8). As a result, we decided to continue with an MOI of 10 PFU/cell for 
the infections going forward. The EC50 values were determined from the variable slope. 
The mean EC50 values for Ad-TD in TB11381 and 4T1 cells are 32.55 and 15.78 
PFU/cell, respectively and 5.04 and 0.63 PFU/cell for Ad-TD-CCL25. Ad-TD-CCL25 is 
more potent than Ad-TD in both TB11381 (p=0.0001) and 4T1 (p=0.0005) cell lines 
(Figure 9). 
Virus vector PFU/ml* Viral particles/ml** 
Ad-TD 9.74x109 1.81x1011 
Ad-TD-CCL25 1.32x109 9.24x1011 
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Figure 8. Ad-TD and Ad-TD-CCL25 viral dose-response curves in TB11381 and 
4T1 cell lines. (A) and (B) dose-response curves for Ad-TD- and Ad-TD-CCL25-
infected TB11381 cells, respectively. (C) and (D) dose-response curves for Ad-TD- and 
Ad-TD-CCL25-infected 4T1 cells, respectively. The cells were infected with serial 
dilutions (1:10) of either virus in six replicates per three separate plates. The curves 
were constrained to fit between 0 and 100% cell kill using GraphPad Prism 5.0 
software. 
 
Figure 9. Ad-TD-CCL25 is significantly more potent than Ad-TD. Graphical 
representation of the 50% effective concentrations (EC50) in (A) TB11381 and (B) 4T1 
cells determined by the non-linear regression of the dose-response curves. The 
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statistical analysis was conducted using an unpaired student t-test. (A) ***, p=0.0001; 
(B) ***, p=0.0005. 
Cell cytotoxicity was then assessed at a MOI of 10 PFU/cell at four time points 
(24, 48, 72, 96 hr) in order to determine differences between the two viral vectors over 
time. The cell cytotoxicity of Ad-TD + recombinant CCL25 (20 ng/ml) was also 
assessed to determine any direct effect CCL25 exerts on the cells. Ad-TD + 
recombinant CCL25 behaved similarly to Ad-TD, and did not demonstrate increased 
toxicity or increased potency (Figure 10). Ad-TD-CCL25 was significantly more 
cytotoxic than Ad-TD (p<0.05) and Ad-TD + rCCL25 (p<0.01).  
  
 
 
Figure 10. Ad-TD-CCL25 is more cytotoxic than Ad-TD over time. (A) TB11381 and 
(B) 4T1 cells were infected with either Ad-TD, Ad-TD-CCL25 or Ad-TD + recombinant 
CCL25 (20 ng/ml). MOI = 10 PFU/cell. Each biological time point was assayed in 
triplicates. The percentage cell kill was significantly higher with Ad-TD-CCL25-infected 
cells compared to Ad-TD and Ad-TD + CCL25. The statistical analysis was conducted 
using a one-way ANOVA. *, p<0.05. 
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In this same experiment, cell cytotoxicity was assessed before and after a four 
hour wash post-infection, a time point when CCL25 is not being produced by Ad-TD-
CCL25. This investigated whether CCL25 produced by Ad-TD-CCL25 after the four 
hours increases the internalization of the viral particles that remained in the medium in 
the unwashed samples. Ad-TD-CCL25 was not shown to undergo increased 
internalization in both cell lines; no significant differences were seen in cell kill when 
comparinig if the viruses were washed or not washed away (Figure 11). 
 
 
 
Figure 11. Ad-TD-CCL25 does not exhibit increased internalization. (A) TB11381 
and (B) 4T1 cells were infected with either Ad-TD or Ad-TD-CCL25 with or without a 
wash four hours post-infection. MOI = 10 PFU/cell. Each biological time point was 
assayed in triplicates. There were no statistically significant differences observed in cell 
cytotoxicity after washing away the virus in both viral vectors. The statistical analysis 
was conducted using a students t-test.  
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III.III Viral protein expression 
The TB11381 cell line was chosen for further investigation of viral protein and 
DNA quantification. In order to determine if replication occurs quicker in Ad-TD-CCL25-
infected cells, we performed Western Blotting for one early and one late-transcribed 
protein, E1A and hexon, respectively. Ad-TD-CCL25-infected samples expressed E1A 
(55 kDa) as early as 12 hours p.i. and at a higher level than Ad-TD (Figure 12A). 
Densitometric analysis revealed a 23 fold difference and a 15 fold difference in E1A 
expression at 12 and 24 hours, respectively. A similar observation was seen with 
hexon; Ad-TD-CCL25-infected TB11381 cells expressed hexon (108 kDa) as early as 
24 hours (80 fold difference), while Ad-TD still did not express hexon at 48 hours 
(29.62 fold difference). As expected, the earlier time points and mock-infected samples 
do not express E1A or hexon. Figure 12B is a Western Blot also probed for E1A and 
hexon, however the TB11381 cells were infected with 100 vp/cell in order to study any 
differences in the two infection methods. In these samples, E1A was also expressed as 
early as 12 hours, and densitometric analysis shows very similar expression at 24 
hours between Ad-TD and Ad-TD-CCL25 (1.107). At 48 hours, Ad-TD-CCL25 
expresses E1A almost two folds higher than Ad-TD. The trend is not as consisent with 
hexon expression levels, which will be discussed below.   
 
 
 
A 
  
209
 
Figure 12. Ad-TD-CCL25-infected cells express viral proteins earlier. TB11381 
cells were infected with Ad-TD or Ad-TD-CCL25 (A) MOI = 10 PFU/cell and (B) 100 
vp/cell, and cell lysates were collected for protein harvest at 0, 12, 24 and 48 hours 
post-infection. Western blotting was used to assess protein levels of early protein, E1A 
and late coating protein, hexon. Relative densities were calculated using Image 
Studio™ Lite Software 5.0.21. The blots are representatives of two repeated 
experiments. PCNA was used as a loading control. 
 
II.IV Viral DNA replication 
 Lastly, we investigated viral DNA replication using qPCR. The intracellular DNA 
copy numbers were determined as measured by E2A levels. Ad-TD-CCL25-infected 
TB11381 cells had higher E2A copy numbers compared to Ad-TD at 24 hours in both 
PFU/cell (Figure 13A p=0.0005) and vp/cell infected cells (Figure 13B p=0.0103). In 
the PFU/cell-infected cells (Figure 13A), Ad-TD-CCL25-infected cells also had higher 
E2A copy numbers at 48 hours (p=0.0223). The data is represented as a fold change 
in order to distinguish any differences between the two methods of infection. Overall, 
the two methods resulted in similar results. 
B 
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Figure 13. Ad-TD-CCL25 replicates more rapidly than Ad-TD. TB11381 cells were 
infected with Ad-TD or Ad-TD-CCL25 (A) MOI = 10 PFU/cell (B) MOI = 100 vp/cell, and 
DNA was purified from the samples. Quantitative PCR (qPCR) was used to determine 
the intracellular viral DNA copy number as measured by E2A levels (by comparison to 
an Ad5 standard curve) at 4, 8, 12, 24 and 48 hours post-infection (t=0). Each sample 
was assayed in triplicate and each time point assay was performed in biological 
triplicates. The results are presented as the fold change compared to t=0, which was 
arbitrarily set to 1. E2A was not amplified in the mock-infected sample (not shown). 
The statistical analysis was conducted using an unpaired two-tailed student t-test at 
each time point. (A) *, p=0.0223; ***, p=0.0005 (B) *, p=0.0108. 
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IV. DISCUSSION 
IV.I Characterization of Ad-TD-CCL25 virus vector 
Virion replication and CCL25 production  
The first step in validating the new viral vector Ad-TD-CCL25 as an oncolytic 
virus was to characterize its ability to infect, replicate in as well as lyse cancer cell 
lines. Preliminary work performed by Chad Al-Yaghchi demonstrated that Ad-TD-
CCL25, like its backbone virus, Ad-TD, is replication-competent and unlike Ad-TD, 
produces CCL25 upon replication (Figure 6). This demonstrates that the cloning of 
CCL25 into the viral genome does not affect the replication competency of Ad-TD-
CCL25, and moreover, that the CCL25 transgene is transcribed and its soluble product 
is released during virion assembly. Theoretically, CCL25 produced by the OV should 
attract immune cells such as T-cells to the site of infection i.e. the tumour site, and as a 
result, enhance antitumour effects in vivo41. Studies investigating the chemotaxis of 
chemokine-expressing oncolytic viruses demonstrate migration of immune cells 
towards the OV-infected cells in vitro and in vivo41,42. Oncolytic vaccinia virus 
expressing CCL5 induced lymphocyte chemotaxis, increased persistence of the virus 
within the tumour and enhanced therapeutic benefits when combined with a DC 
vaccine41. An adenovirus expressing CCL5 also correlated with an increase in 
proinflammatory cytokines, DC infiltration and antigen-specific CD8+ T-cell responses42. 
Therefore, Ad-TD-CCL25 should possess similar chemotaxis properties. The ability of 
the OV to not only directly lyse cells more efficiently (which is only accounted for a 
small part of OV-mediated antitumour effects) but also attract the immune system will 
allow Ad-TD-CCL25 to be an effective therapy.  
 
Viral titration 
Titration of the two viruses was determined by two separate assays, which 
yielded different units of measure. The TCID50 assay determines the ability of the virus 
to form a plaque per unit of volume (PFU/ml), therefore is a functional measurement of 
the virions. The picogreen assay, however, determines the viral particle count per unit 
of volume, a quantitative measurement. The viral particle count for Ad-TD-CCL25 was 
700x more concentrated than in PFU/ml, which may be owed to the quality of the viral 
particles i.e. the presence of high levels of immature virions. A possible explanation for 
the discrepancy is that the increased potency of Ad-TD-CCL25 allows for more cell 
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death of the JH293 cells during titration, thus the viral particles that are harvested and 
purified may not be fully packaged virions. 
Viral cytotoxicity 
 A cell cytotoxicity assay at various dilutions of the viruses was done to 
determine the half maximal effective concentrations (EC50) and thus an appropriate 
MOI for all further infections performed in this study. Ad-TD killed 50% of the cells at a 
MOI of 101 while Ad-TD-CCL25 killed 50% of the cells at a MOI of 100 PFU/cell. This 
means that Ad-TD-CCL25 is more potent, and if we use MOI of 10 PFU/cell, technically 
the Ad-TD virus added at infection is 10 fold higher than it should be to be equally 
infectious as Ad-TD-CCL25. Therefore, any differences noted in the further 
investigations such as protein expression and gene copy numbers are dramatic. My 
results confirm preliminary data (Figure 7), demonstrating increased potency exhibited 
by Ad-TD-CCL25 compared to Ad-TD. Cell kill was then determined at a MOI of 10 
PFU/cell, where Ad-TD-CCL25 was significantly more cytotoxic over four days. Ad-TD 
+ recombinant CCL25 behaved similarly to Ad-TD alone, concluding that the 
transcription of CCL25 by Ad-TD-CCL25 in someway is involved in its increased 
potency. Moreover, this also demonstrates that CCL25 is not cytotoxic (this was also 
confirmed in a specific assay by our laboratory- data not shown). 
 
IV.II Investigating viral internalization 
In order to determine if the reason for increased potency occurred at viral 
internalization, the virus was washed away after four hours post-infection. This allowed 
for only the viral particles that have attached and internalized within that time to 
replicate within the cells. Since CCL25 is not expressed by Ad-TD-CCL25 within the 
first four hours, if there was increased cell kill without a virus wash, it would suggest 
that CCL25 somehow increased the amount of virus that is being internalized. 
Therefore, since no significant differences in the results were seen, we can conclude 
that the internalization of the virus was independent of the CCL25 in the growth 
medium. Our laboratory has previously shown that vascular endothelial growth factor 
(VEGF)-A produced by tumour cells promoted vaccinia virus (VV) entry into host cells 
through activation of the Akt pathway and was associated with increased potency of 
the virus43. Similarly, Cheshenko et al demonstrated that silencing of Akt prevented 
calcium release, which blocked viral entry and inhibited plaque formation by 90% 
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compared to the control44. It was thus hypothesized that CCL25 through binding to 
CCR9 on host cells and signaling through PI3K/Akt may promote viral entry. Ad is 
internalized very efficiently; approximately 85% of the added viral particles are 
internalized within 10 minutes of attachment23. It would thus be necessary to wash 
away the virus earlier (e.g. 10 minutes to 2 hours) in order to ensure that the maximal 
amount of virus has not entered within that time. This experiment can be improved 
investigating viral attachment, internalization and trafficking within the cell, using 
qPCR45. To assess binding, the cells should be left in the cold for one hour post-
infection and then washed with cold buffer to remove unbound virus particles. This is 
because at 37°C, viral attachment and entry is prom oted. The cells can then be 
collected for total DNA preparation and qPCR analysis. For assessing internalization, 
the washed cells are placed at 37°C for various int ervals and the attached, but 
uninternalized viral particles can be removed with 2 mg/ml of substilin reagent and the 
cells can be collected for DNA preparation. Next, the nuclear fractions can be 
separated using a kit (NE-PER nuclear and cytoplasmic kit, Pierce, Thermo Scientific) 
in order to assess trafficking into the nuclear pore. If there are differences in the viral 
genome copy numbers, it would suggest differences at either one of these points in the 
viral lifecycle, which should then be investigated further (discussed below). It is 
possible that through binding of CCL25 on CCR9 on the tumour cells, attachment, 
internalization or trafficking of Ad-TD-CCL25 may enhanced, leading to increased 
replication and/or potency. Wang et al showed that carcinoembryonic antigen-related 
adhesion molecule 6 (CEACAM6) blocked adenovirus trafficking to the nucleus through 
the Src pathway, which interfered with the cytoskeleton of cancer cells, resulting in 
attenuated infectability by adenovirus45. 
IV.III Viral protein expression 
 The greater potency of Ad-TD-CCL25 was thought to possibly be due to quicker 
transcription and translation of viral proteins that are necessary for replication or virion 
assembly. The Ad chromosome carries five early (E) transcription units, two delayed 
and one major late unit. Protein was harvested from Ad-TD and Ad-TD-CCL25-infected 
cells and probed for an early protein E1A, as well as for hexon, a late viral coating 
protein in a Western blot (Figure 12). E1A expression was detected earlier (at 12 
hours) in Ad-TD-CCL25-infected TB11381 cells compared to Ad-TD-infected cells. E1A 
is the first transcription unit to be expressed in the host nucleus. E1A activates 
transcription by binding to cellular transcription factors and promotes host cell entry into 
the S phase of the cell cycle23. Therefore, earlier E1A transcription may suggest faster 
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replication of Ad-TD-CCL25, which may account for its increased potency. Hexon was 
also detected earlier with Ad-TD-CCL25 (at 24 hours) (Figure 12A), which further 
proves this hypothesis, as the coating protein is needed to complete virion packaging 
in the cytosol and release from the host cell23. In Figure 12B, we observed that E1A is 
slightly higher expressed in Ad-TD-CCL25-infected cells, however hexon seems to be 
expressed at higher levels in Ad-TD-infected cells. This can be explained by the higher 
amount of Ad-TD mature infectious particles that are entering the cells. When using 
vp/cell concentrations, there are 10 infectious Ad-TD viral particles per cell added to 
the medium compared to one infectious Ad-TD-CCL25 viral particle. This should thus 
result in more virus entering the cells and thus higher (or equal) viral protein expression 
in the Ad-TD infected cells compared to the Ad-TD-CCL25-infected cells. 
IV.IV Viral DNA replication 
E2A, also known as DBP (DNA-binding protein) is primarily responsible for 
initiating DNA replication23. Therefore, the E2A gene was chosen to investigate 
differences in DNA replication between the two viral vectors. The qPCR results (Figure 
13) show significant differences in E2A amplification in Ad-TD-CCL25-infected 
TB11381 cells at 24 hours, and although not statistically significant, a similar trend at 
48 hours (Figure 13B). These results suggest that DNA replication is occurring more 
rapidly in Ad-TD-CCL25, and is consistent with the Western Blots described above. In 
Figure 13B, a slight increase (not statistically significant) is seen at 12 hours between 
the two virus copy numbers, which may also suggest quicker replication in Ad-TD-
CCL25. E1A expression was detected as early as 12 hours, thereby complimenting 
these findings. 
On the contrary, in Figure 13A, Ad-TD-infected cells had a higher fold change 
in copy number compared to Ad-TD-CCL25, which is most likely due to more cell death 
with Ad-TD-CCL25, which was observed under the microscope before harvest. The 
quality of Ad-TD-CCL25 viral particles merits more investigation. That said, as 
described above, at a MOI of 10 PFU/cell, Ad-TD is technically 10 fold more 
concentrated than Ad-TD-CCL25, therefore this may just signify increased cell kill with 
Ad-TD-CCL25, thereby making it a more effective oncolytic virus. 
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Appendix IV: Review article 
1249Immunotherapy (2015) 7(12), 1249–1258 ISSN 1750-743X10.2217/imt.15.90 © 2015 Future Medicine Ltd
The poor prognosis of pancreatic cancer patients signifies a need for radically 
new therapeutic strategies. Tumor-targeted oncolytic viruses have emerged as 
attractive therapeutic candidates for cancer treatment due to their inherent ability 
to specifically target and lyse tumor cells as well as induce antitumor effects by 
multiple action mechanisms. Vaccinia virus has several inherent features that make 
it particularly suitable for use as an oncolytic agent. In this review, we will discuss 
the potential of vaccinia virus in the management of pancreatic cancer in light of 
our increased understanding of cellular and immunological mechanisms involved in 
the disease process as well as our extending knowledge in the biology of vaccinia 
virus.
Keywords:฀immunotherapy฀•฀oncolytic฀virus฀•฀pancreatic฀cancer฀•฀vaccinia฀virus
Pancreatic cancer remains one of the most 
 difficult cancers to diagnose and treat. It is 
the fifth most common cause of cancer death 
in the UK with 1 and 5 years survival of 20.8 
and 3.3%, respectively. These figures have 
hardly improved since the early 1970s [1]. 
Complete surgical resection remains the 
only curative treatment. Unfortu nately, 
less than 20% of pancreatic tumors are 
amenable to surgical excision at the time 
of diagnosis. However, even with complete 
surgical resection prognoses remains poor 
with 5 years survival around 20% [2,3]. 
Gemcitabine is the main chemotherapeu-
tic agent approved for advanced pancreatic 
cancer. Despite being shown to improve life 
expectancy compared with 5-flurouracil, 
effect remains modest with median sur-
vival around 6 months [4].  Combining gem-
citabin therapy with erlotinib led to mini-
mal increase in life expectancy from 5.9 to 
6.2 months [5].  Therefore, new  treatment 
strategies are clearly  imperative.
Vaccinia virus (VV) has played a 
 prominent role in one of the greatest achieve-
ments in medical history: the eradication of 
smallpox (caused by Variola virus). Since 
then, VV has been developed as a vector 
for  vaccines against infectious diseases such 
HIV,  influenza, malaria and tuberculosis as 
well as in  immunotherapies [6] and oncolytic 
therapies for cancer [7,8]. With regards to the 
latter, the earliest studies, which mainly used 
replication attenuated VV recombinants for 
fear of toxicity, were relatively disappoint-
ing in the clinic. Replication competent 
VVs retain their ability to lyse tumor cells 
and spread through tumor tissue. Recent 
advances in DNA recombinant technol-
ogy enabling the rational manipulation of 
the viral backbone, coupled with the ever 
increasing knowledge gains in the fields of 
molecular virology and cancer cell biol-
ogy have aided the development of safe and 
 efficacious tumor-targeted oncolytic VVs. 
These are currently at the forefront of the 
most  promising novel anticancer agents.
In this review, we will explore the  potential 
of tumor-targeted oncolytic VV in the 
 management of pancreatic cancer in light 
of our increased understanding of cellular 
and immunological mechanisms involved in 
the disease process as well as our extending 
knowledge in the biology of VV.
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Tumor-targeted oncolytic viruses as a new 
class of cancer therapeutics
Targeted therapy of cancer using oncolytic viruses 
(OV) has generated much interest over the past 
decades in the light of the limited efficacy and the sig-
nificant side effects of standard cancer therapeutics for 
advanced disease [9]. OVs have become an increasingly 
popular anticancer therapy platform due to their abil-
ity to selectively infect and lyse tumor cells (Figure 1). 
Cancer selectivity of OVs could be a result of natural 
tropism [10,11] or via genetic modification [9]. OVs can 
target multiple cellular pathways [12–14] minimizing the 
risk of tumor resistance and induce different modes of 
cell death [15–18]. In addition, OVs can break down 
the immunosuppressive tumor microenvironment and 
induce a long-lasting tumor-specific immunity [19,20] 
(Figure 2). OVs can specifically deliver therapeutic pro-
teins into tumors at increasing levels following viral 
replication within the malignant cells. Furthermore, 
OVs can function in synergy with conventional can-
cer treatments of chemoradiotherapy [21–24]. Finally, 
OVs as a treatment platform are amenable to adjust-
ment and development following our ever-increasing 
 understanding of cancer cells, the virus and host 
immune responses to both tumor and virus.
H101, an adenovirus with E1B 55K gene deletion 
(Oncorine; Shanghai Sunway Biotech, Shanghai, 
China) was licensed in China in 2005 as the world’s 
first OV for treatment of head and neck cancer when 
combined with chemotherapy [25]. The similar virus, 
dl1520 (also known as, ONYX-015) has been adminis-
tered by intratumoral injection under CT guidance into 
locally advanced primary tumors of pancreatic cancer 
patients in Phase I/II trials. The treatments were well 
tolerated, but no objective responses were seen in any 
of the patients with virus alone, and only 10% (2/21) 
patients showed objective response when gemcitabine 
was used in combination [26–28]. Another virus that 
entered clinical trials is HF10, a Herpes Simplex virus 
armed with granulocyte-macrophage colony-stimu-
lating factor (GM-CSF). Phase I trial of intratumoral 
injection into nonresectable pancreatic tumors proved 
to be safe with some encouraging clinical results [29]. 
These early results warrant further investigation to 
seek more powerful agents for this cancer.
Favorable features of vaccinia virus for 
cancer treatment
VV is a member the poxvirus family. It is a double-
stranded DNA virus ∼192 kbp in size. It can be sta-
bly accommodate up to 25 kbp of cloned exogenous 
DNA [30]. Structurally, it consists of a core region 
composed of viral DNA and a various viral enzymes 
including RNA polymerase and polyA polymerase 
encased in a lipoprotein core membrane. The outer 
layer of the virus consists of double lipid membrane 
envelope [31,32]. VV has two major forms of infectious 
virions; the intracellular mature virions, as described 
above, which is released upon cell lysis and the extra-
cellular enveloped virion released from the cells via cell 
membrane fusion. The latter has an additional lipid 
bilayer membrane wrapped around the intracellular 
mature virion particle.
VV has many inherent characteristics that make 
it an ideal choice for oncolytic virotherapy. VV has a 
short life cycle of 8 h that takes place in its entirety in 
the cytoplasm eliminating the risk of genome integra-
tion. Replication usually starts 2 h after infection, at 
which time the host cell nucleic acid synthesis shuts 
down as all cellular resources are directed toward viral 
replication [33,34]. Cell lyses takes place between 12 
and 48 h releasing packaged viral particles. Further-
more, the virus does not depend on host mechanisms 
for mRNA transcription making it less susceptible to 
biological changes of the host cell [33,35].
Unlike other OVs, VV does not have a specific 
 surface receptor for cell entry allowing it to infect a wide 
range of cells unhindered by the lack of  expression of 
said receptor. They depend on a number of  membrane 
fusion pathways for cell entry [36,37].
The existence of various antigenically distinct forms 
of the mature virus allows it to evade host immune sys-
tem. extracellular enveloped virion form of the virus is 
encapsulated in a host-derived envelope, with incorpo-
rated viral proteins, that contains several host comple-
ment control proteins [38–40]. In addition, VV infected 
cells secret Vaccinia complement control protein which 
binds an inactivate C4b and C3B inhibiting the classic 
and alternative complement activation pathways [41–43]. 
VV therefore can be  disseminated relatively unharmed 
in the blood stream to reach  distant tumors  allowing 
Figure 1. Tumor selectivity of oncolytic viruses. Tumor-targeted oncolytic 
viruses can exploit defective cellular pathways in cancer cells (top). 
oncolytic viruses can infect and replicate in cancer cells leading to cell lysis 
and release of viral particles. These in turn infect neighbor tumor cells and 
so forth. In normal cells (bottom) cellular defense mechanisms prevents 
viral replications.
Oncolytic 
virus
Cancer cell
Normal cell
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systemic delivery of the virus [44], which is more 
 suitable for the treatment of the advanced pancreatic 
 cancer.
The hypoxic nature of pancreatic cancer contributes 
to its aggressive and treatment-resistant phenotype. In 
contrast to adenovirus [45], we have found that hypoxic 
conditions did not affect replication, viral proteins pro-
duction, cytotoxicity and transgene expression of the 
Lister strain of VV [46]. These results suggest that VV 
could be suitable for management of pancreatic cancers 
and potentially other hypoxic tumors.
Finally, VV has a good safety track record following 
its use as a vaccine for over a century. Minor and less 
severe side effects include fever, rash and inadvertent 
inoculation. Moderate-to-severe side effects include 
eeczema vaccinatum, generalized vaccinia, progres-
sive vaccinia and postvaccinial encephalitis [47]. Sides 
effects are rare with an incident of less than 1:10,000 
and severe side effects in particular are extremely 
rare [48]. Genetically modified recombinant VV could 
be potentially safer due to their tumor selectivity. 
Recent clinical trial of JX-594 virus in hepatocellular 
carcinoma showed the treatment to be well tolerated 
with mainly flu-like symptoms in all patients and a 
single severe side effect [8].
How Vaccinia virus selectively kills cancer 
cells by multiple action mechanisms
VV has a natural tropism to cancer cells [49,50]. The 
virus can utilize activated molecular pathways in 
tumor cells to aid its replication [51–53]. In fact, many 
of the hallmarks of cancer [54] make tumor cells sus-
ceptible to viral replication including immune escape, 
sustained cell proliferation and resisting cell death. In 
the case of VV, the EGFR family [55], potentially plays 
an important role in tumor selectivity. The viral SPGF, 
an EGF-like growth factor carried by VV, can activate 
host cellular pathways leading to increased viral rep-
lication [56]. In addition, Ras–GTP-activating protein 
S3H domain-binding protein, overexpressed in most 
human cancers [57], plays a role in VV replication by 
complementing the activity of the VITF-2 [58].
Various approaches can be utilized to enhance tumor 
selectivity of OVs. The virus depends for its replication 
in normal cells on a set of genes that prepare the cell 
resources for viral replication and block apoptotic path-
ways. Deleting these genes will limit the virus ability 
to replicate in normal cells. However, these pathways 
are often disrupted in cancer cells allowing the mutant 
virus to replicate despite the defective genes. One such 
example is the disruption of the vaccinia thymidine 
kinase gene (TK gene) affecting the virus ability to 
synthesize deoxyribonucleotides [59,60]. Normal cells 
have a much smaller reserve of  deoxyribonucleotides, 
 compared with tumor cells, limiting the ability of VV 
to replicate. Another example is the deletion of the 
B18R gene encoding the secreted IFN-binding  protein 
that blocks IFNα signaling [61]. In normal cells, this 
gene deletion attenuates viral replication due to IFN 
antiviral effect while cancer cells remain permis-
sive to VV replication as IFN signaling is often dis-
rupted [62,63]. In addition, altering the expression of 
crucial vaccinia viral gene by microRNA also enables 
tumor-specific viral replication, which is a potentially 
novel and versatile platform for engineering VVs for 
cancer virotherapy [64].
GLV-1h68 is a replication-competent VV targeted 
at tumor cells by mutation of J2R (encoding  thymidine 
kinase) and A56R (encoding hemagglutinin) loci. 
This virus was shown to be effective against human 
pancreatic cancer cell line in vitro and in nude mice 
xenografts. Importantly this efficacy was enhanced 
Figure 2. Multiple modes of actions of tumor-targeted oncolytic viruses. 
Oncolytic viruses (OV) can kill cancer cells via a variety of mechanisms. 
First, they directly infect, replicate and lyse tumor cells sparing normal 
cells. Released virions can infect neighbor tumor cells and so forth. Second, 
OVs can induce immunogenic cell death associated with the release of 
pathogen-associated molecular patterns and damage-associated molecular 
patterns. In addition viral infection results in the release of cytokine and 
chemokines deviating the immune response toward a cytotoxic profile. 
Dendritic cells can pick tumor-associated antigens released from lysed 
tumor cells and prime CD8+ T cells to induce a tumor-specific immune 
response. Third, OV infection can result in vascular shutdown caused 
by direct viral invasion of endothelial cells and thrombosis caused by 
cytokine-mediated neutrophils accumulation. 
CD8: Cytotoxic T cell; DC: Dendritic cell; EC: Endothelial cell; N: Neutrophil;  
TAA: Tumor-associated antigen; TC: Tumor cell; VV: Vaccinia virus.
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when virus therapy was combined with gemcitabine 
and  cisplatin [65]. GLV-1h151, a virus with similar gene 
deletions but different marker proteins transgenes [66], 
was found to be effective in vivo and in vitro against 
human pancreatic cancer cell lines.  Combining the 
virus with radiotherapy resulted in a synergistic 
 antitumor effect [67].
In addition to direct cell lysis, VV can utilize  vascular 
shut down to kill noninfected tumor cells [44,68–69]. 
This is believed to be caused by accumulation of 
neutro phils in blood vessels, mediated by cytokines and 
chemokines, leading to intravascular thrombosis [69]. 
In addition, VV can infect and destroy tumor-associ-
ated endothelial cells further contributing to vascular 
collapse [62]. Although this process has not been spe-
cifically shown in pancreatic tumors, we believe it to 
play an important role in the multimechanistic antitu-
mor effect of VV, as pancreatic cancers are often well-
vascularised and high microvascular density correlates 
with poor outcome after surgical excision [70]. To fur-
ther capitalize on this process we have rationally armed 
Lister strain VV with endostatin–angiostaten fusion 
gene, a well-documented angiogenesis inhibitor [71]. 
The resultant VVhAE virus proved to be tumor selec-
tive in vitro and in vivo. It resulted in suppression of 
angiogenesis and prolonged survival of mice bearing 
human pancreatic cancer xenografts [50].
Vaccinia virus as immunomodulatory agent
The ability of OVs to alter the immune composition of 
the, ordinarily, immune-suppressive tumor microenvi-
ronment led to a new line of thinking of their mecha-
nism of action. Large body of evidence suggests that 
antitumor immunity, where the virus is acting as an 
oncotropic immunomodulator, is the key determinant 
of a successful onclytic virotherapy [72–74].
VV kills cancer cells via a combination of necrosis 
and immunogenic apoptosis resulting in the release 
of damage associated molecular patterns [75–78] and 
pathogen associated molecular patterns [79–81] as well 
as the release of viral antigens into the tumor. This 
process leads to a strong inflammatory response that 
can overcome the immune suppression within the 
tumor microenvironment. In addition, tumor cell lysis 
releases tumor-associated antigens (TAA) into this 
inflammatory environment. Dendritic cells recruited 
by the virus can in turn pick up these exposed TAAs 
and cross-prime CD8+ T cells resulting in a potent 
antitumor adaptive immune response. It has been dem-
onstrated that an oncolytic VV (JX549) could induce 
tumor-specific immunity in human cancer patients [82] 
and preclinical study [20]. Therefore, oncolytic viro-
therapy may be considered as a method of vaccination 
in situ, enabling the adaptive immune response to clear 
residual disease as well remote metastatic cancer cells 
and provide long-term surveillance against relapse.
In the context of vaccination, heterologous prime-
boost immunization regimen using recombinant 
adenovirus prime and VV boost has been shown to 
enhance CD8+ T-cell immunogenicity with protective 
efficacy against malaria in a mouse model [83,84]. So, 
it seems logical that combining two different OVs for 
cancer treatment may induce a stronger tumor- specific 
immunity. We have, for the first time, combined 
the use of oncolytic adenovirus and VV, in a prime-
boost strategy, for treatment of established tumors in 
the hope to harness the host immune response to the 
infected tumor cells. We found that sequential treat-
ment via intratumoral injection with oncolytic adeno-
virus followed by oncolytic VV resulted in complete 
eradication of subcutaneous pancreatic cancer grafts 
in Syrian hamsters. More importantly, the surviv-
ing animals developed a long-lasting tumor-specific 
immune response that protected them against tumor 
 rechallenge. This process was shown to be T-cell 
dependent [20].
Arming VV with various cytokines and chemokines 
can further enhance its antitumor activity. IL-10, a 
cytokine produced by Th2 T cells, is a potent inhibitor 
of antiviral immune response [85]. We have found that 
arming VV with IL-10 dampened antiviral immune 
response resulting in prolonged viral persistence in 
pancreatic tumors. This led to stronger antitumor 
immunity and improved survival in both subcutaneous 
and transgenic pancreatic cancer mouse models [86].
Vaccinia virus as vaccine vector
The first use of a recombinant virus armed with an 
 antigen from a different organism as a vaccine vec-
tor was reported over 30 years ago. VV armed with 
hepatitis B surface antigen gene was able to induce a 
protective immunity against hepatitis in chimpan-
zees [87,88]. Since then there has been a great progress in 
recombinant VV vaccines in the veterinary field [89,90]. 
Unfortunately this success did not extend to human 
infectious diseases vaccines, mainly due to the lengthy 
and more stringent process for human licensing, with 
only a handful of recombinant VV vectors in current 
clinical trials [91–94].
One of the significant challenges for cancer vaccina-
tion lies in developing strategies to improve the delivery 
of antigens to antigen-presenting cells in vivo, allowing 
effective antigen processing and presentation and acti-
vation of a potent immune response against a unique 
background of immune tolerance toward ‘self ’ TAAs. 
Viral vectors have become attractive antigen delivery 
systems as they mimic a natural viral infection, resulting 
in induction of cytokines and co-stimulatory molecules 
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that provide a powerful adjuvant effect and elicit potent 
cellular immunity [74,95].
Survivin is a member of the inhibitor of apoptosis 
family expressed in a variety of cancers. It plays a cru-
cial role in tumor survival and drug resistance [96]. It 
is expressed during embryonic development but absent 
from differentiated cells [97]. Survivin is overexpressed 
in 70–80% of pancreatic cancers and is associated with 
resistance to chemoradiotherapy [98,99]. Vaccination 
with Vaccinia Ankara virus, a nonreplicating attenu-
ated VV strain, armed with survivin induced survivin-
specific CD8+ immune response resulting in a modest 
antitumor effect. When combined gemcitabine anti-
tumor immunity and efficacy improved significantly. 
This is likely to be related to gemcitabine suppression 
of myeloid-derived suppressor cells [100].
The only VV-based cancer vaccine to enter clini-
cal trials is PANVAC-V, a VV expressing carcino-
embryonic antigen and mucin-1, both highly expressed 
in pancreatic cancers. The two antigens were packaged 
with three costimulatory molecules: B7.1 (cluster of 
differentiation 80), ICAM-1 (intracellular adhesion 
molecule one) and LFA-3 (leukocyte function-asso-
ciated antigen-3) known collectively as TRICOM. 
To further enhance the immune response, the vac-
cination was delivered as a heterologous prime/boost 
regimen using a nonreplicating fowlpox vector express-
ing the same antigens and costimulatory molecules 
(PANVAC-F) [101]. GM-CSF was administered at the 
injection site as an adjuvant to enhance local antigen 
processing and presentation. In a Phase I clinical trial, 
the vaccine was found to be safe and well tolerable. It 
generated an antigen-specific immune response toward 
carcinoembryonic antigen and mucin-1 which corre-
lated with increased survival [102]. However, Phase III 
trial (NCT00088660) targeting patients with meta-
static pancreatic cancer who failed gemcitabine 
treatment failed to meet its therapeutic targets and 
was terminated [103]. The vaccine is currently under 
investigation for direct intratumoral injection under 
 endoscopic ultrasound guidance with encouraging 
results of Phase I trial [104].
Future perspective
There has been a great interest in VV in recent years. 
Its safety, cancer tropism, amenability to genetic 
 modification and ability to target solid tumors via a 
variety of mechanism of actions have made it a near-
perfect onclytic virus to target pancreatic cancers. 
Nevertheless, as with any new therapeutic agents VV 
therapy need to overcome many hurdles and challenges 
before it enters routine clinical practice.
The first challenge is the selection of the right VV 
strain. The nonvaccine strain Western Reserve (WR) 
VV is widely used in the lab. JX-963, a GM-CSF 
armed mutant of WR VV with deletion of both the 
Thymidine Kinase and the Viral Growth Factor gene, 
has been reported as the most potent tumor-targeted 
oncolytic VV [52]. Other strains, such as the European 
vaccine Lister strain, are largely untested. We recently 
evaluated the antitumor potency and biodistribu-
tion of different VV strains using in vitro and in vivo 
models of cancer, including pancreatic cancer models. 
The Lister strain virus with Thymidine Kinase gene 
deletion (VVΔTK) demonstrated superior antitumor 
potency and cancer-selective replication in vitro and 
in vivo, compared with WRDD, especially in human 
cancer cell lines and immune-competent hosts. Fur-
ther investigation of functional mechanisms revealed 
that Lister VVΔTK presented favorable viral biodistri-
bution within the tumors, with lower levels of proin-
flammatory cytokines compared with WRDD, sug-
gesting that Lister strain may induce a diminished host 
inflammatory response [105]. Our comprehensive study 
indicates that the Lister strain VV with TK deletion 
is a particularly promising VV strain for the develop-
ment of the next generation of tumor-targeted onco-
lytic therapeutics. We anticipate that more and more 
people will use the Lister stain of VV as a backbone to 
develop new OVs for cancer treatment in the future.
Further genetic modifications of VV might enhance 
its oncolytic ability. Disruption of the N1L gene 
reduces virulence and inhibits VV replication in the 
brain reducing the risk postvaccinial encephalitis, 
a rare but significant complication of VV vaccina-
tion [106,107]. Our unpublished work on N1L-deleted 
VV suggests that N1L-deleted VV resulted in a supe-
rior antitumor efficacy compared with N1L-intact 
VV  [Ahmed J et al., Unpublished Data]. In addition, arming 
the new generation of VV with immune-modulatory 
genes or other therapeutic genes that enhance the 
 antitumor immunity is a future for cancer treatment 
using  tumor-targeted OVs.
Achieving the right immune response is of a 
 paramount importance. Increasingly safer viruses 
permits the use of higher doses to maximize thera-
peutic effect [8], however higher viral load might devi-
ate the immune response toward antiviral immunity 
resulting in rapid viral clearance and reduced anti-
tumor immunity. Manipulating the immune system 
with  cytokine-armed viruses is not without its risks 
 including serious autoimmune side effects [108].
Systemic delivery of VV is particularly relevant in 
pancreatic cancer as most pancreatic tumors present 
with distant metastasis at the time of diagnosis. One 
such virus (JX594) has recently been shown to effec-
tively target tumors after intravenous infusion, making 
it an ideal OV for treatment of inaccessible tumors such 
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as pancreatic cancer [7]. To date, the systemic delivery 
of OVs has been shown to be safe but not efficacious 
mainly due to the rapid clearance of these agents by 
the immune system [109]. When designing new strat-
egy to enhance the systemic delivery of VV lessons can 
be learnt from other OVs. Serotype exchange [110,111], 
engineering new serotypes [112] and the use of chemical 
shielding [113] have been successfully used with other 
OVs. In fact the latter strategy have been used to modify 
the nonreplicating Vaccinia Ankara vaccine vector to 
circumvent pre-existing anti-VV immunity [114]. Other 
approaches include pharmacologically  modifying the 
immune response to reduce the  neutralization of the 
systemically delivered OVs [115–117].
Combining oncolytic virotherapy with traditional 
cancer treatments is an area of great promise. Gem-
citabine can suppress myloid-derived suppressor cells 
in the tumor microenvironment resulting in a stron-
ger antitumor immune response [118]. On the other 
hand, gemcitabine is a nucleoside analogue that inhib-
its DNA synthesis including that of double-stranded 
DNA viruses [119]. Using these agents in a sequential 
rather than combination manner might be the key to 
effective therapy [120]. Similarly, combining OVs with 
immune checkpoints inhibitors is an area that requires 
more investigation and optimization. PD-1 and 
CTLA-4 inhibitors might enhance the OV-induced 
antitumor immunity by creating a favorable immune 
profile in the tumor microenvironment [121,122].
Despite the challenges, the field of oncolytic viro-
therapy is generating a great interest of both  researchers 
and pharmaceutical companies alike. The recent US 
FDA approval of talimogene laherparapvec (T-VEC, an 
 engineered herpes simplex virus-1 expressing GM-CSF), 
for the treatment of melanoma has given the field a much 
needed boost. As safety and efficacy data start to accu-
mulate the process of licensing new OVs will get easier. 
We anticipate other cytokine- and chemokine-armed 
viruses to enter clinical practice within the next few 
years. In addition, combining OVs with immune check-
point therapies, monoclonal antibodies and CAR-T ther-
apies will be an area of major research interest in the near 
future. Combining immune checkpoint antibodies with 
other immune-stimulating agents such as conventional 
drugs, targeted agents and most of all OVs, may increase 
the tumor types and individual patient profiles in which 
a durable clinical benefit can be achieved. OVs are finally 
being recognized for their ability to stimulate antitumor 
immunity, and with anti-CTLA-4 and anti-PD-1 agents 
on the market, OVs may finally have met their perfect 
match. It has never been a more promising era for cancer 
immunotherapy and personalized medicine.
We believe at the current rate of development it 
will not be long before OVs are part of routine clinical 
 practice.
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Executive summary
•฀ Pancreatic cancer is one of the most aggressive human cancers, without effective therapies.
•฀ Tumor-targeted oncolytic viruses is a new class of cancer therapeutic agents.
•฀ Oncolytic Vaccinia virus (VV) has distinctive features that make it ideal for treatment of pancreatic cancer.
•฀ The antitumor efficacy of oncolytic VV can be further improved by modification of viral genes and arming the 
virus with therapeutic genes.
•฀ Combination of oncolytic VV with other cancer therapies could be the future for treatment of pancreatic 
cancer.
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